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Cancers	  of	  the	  upper	  gastrointestinal	  tract	  present	  at	  an	  advanced	  stage	  and	  carry	  a	  
poor	  prognosis.	   	  Oesophageal	  and	  gastric	  tumours	  have	  a	  rich	  stroma	  composed	  of	  
vascular	   cells,	   immune	   cells,	   and	  myofibroblasts,	   which	   promotes	   tumour	   growth,	  
invasion	  and	  metastasis.	  In	  addition,	  mesenchymal	  stromal	  cells	  (MSCs)	  are	  recruited	  
from	   the	   bone	  marrow	   to	   the	   tumour	   stroma;	   the	  mechanisms	   underpinning	   this	  
have	   not	   yet	   been	   defined.	   	   Extracellular	   proteases	   play	   a	   role	   in	   cell	   migration,	  
invasion,	  and	  cell	  signalling	  and	  are	  known	  to	  influence	  cancer	  growth	  in	  conflicting	  
ways.	   	  Myofibroblasts	   present	   in	   normal	   tissue	   differ	   from	   those	   found	   in	   cancer.	  	  
Cancer-­‐associated	   myofibroblasts	   (CAMs)	   are	   known	   to	   modulate	   extracellular	  
protease	  activity	  by	  secreting	  plasminogen	  activator	  inhibitor-­‐1	  (PAI-­‐1),	  an	  inhibitor	  
of	   the	   serine	   protease	   urokinase	   plasminogen	   activator,	   and	   matrix	  
metalloproteinases	   (MMPs).	   	   This	   investigation	   studies	   the	   role	   of	   PAI-­‐1	   in	   gastric	  
cancer	   and	   assesses	   the	   contribution	   of	   myofibroblast-­‐derived	   MMPs	   to	   tumour	  
growth.	  	  Finally,	  the	  role	  of	  chemerin	  in	  recruiting	  MSCs	  has	  been	  investigated.	  
	  
The	   expression	   of	   PAI-­‐1	   in	   myofibroblasts	   was	   found	   to	   be	   higher	   than	   in	   gastric	  
cancer	  cells.	  	  Overexpression	  of	  PAI-­‐1	  in	  gastric	  cancer	  cells	  resulted	  in	  decreased	  cell	  
adhesion	  and	  decreased	  tumour	  growth	  in	  an	  in	  vivo	  subcutaneous	  xenograft	  model	  
of	  gastric	  tumour	  growth.	  	  	  
	  
	  The	  addition	  of	  gastric	  CAMs	  potentiated	  the	  growth	  of	  gastric	  cancer	  subcutaneous	  
xenografts.	   	   This	   was	   not	   accounted	   for	   by	   differences	   in	   cell	   proliferation	   rate,	  
apoptosis	  or	  final	  stromal	  content.	  	  Xenografts	  containing	  CAMs	  suppress	  the	  growth	  
of	   a	   contralateral	   xenograft	  without	  CAMs,	  demonstrating	   that	   a	   long-­‐range	   signal	  
can	  be	  generated	  as	  a	  result	  of	  stromal-­‐epithelial	  interactions.	  
	  
MMP	   and	   cathepsin	   activity	   was	   compared	   between	   xenografts	   containing	  
myofibroblasts	   to	   those	  without.	   	  MMP	  activity	   is	   increased	   in	   xenografts	   injected	  
with	   CAMs,	   compared	   to	   those	   injected	   with	   myofibroblasts	   taken	   from	   normal	  
stomach	   or	   those	   with	   gastric	   cancer	   cells	   alone.	   	   In	   an	   organotypic	   co-­‐culture	  
system,	  MMP	  inhibition	  resulted	  in	  a	  decrease	  in	  gastric	  cancer	  cell	  invasion.	  
	  
The	   injection	   of	   fluorescently	   labelled	  MSCs	   injected	   resulted	   in	   homing	   of	   these	  
cells	   to	   subcutaneous	   oesophageal	   tumours	   containing	   CAMs.	   	  Antagonism	   at	   the	  
ChemR23	  receptor	  inhibited	  this	  MSC	  homing	  to	  oesophageal	  xenografts	  containing	  
CAMs.	  	  	  
	  
This	   work	   emphasises	   the	   importance	   of	   assessing	   the	   contribution	   of	   specific	  
proteases	   and	   their	   inhibitors	   in	   gastric	   cancer.	   The	   stroma	   is	   an	   important	  
contributor	   to	   extracellular	   protease	   activity	   and	   myofibroblasts	   contribute	   both	  
proteases	   and	   their	   inhibitors	   to	   the	   tumour	   microenvironment,	   resulting	   in	   the	  
modulation	  of	  tumour	  growth	  and	  cell	  adhesion.	  	  MSCs	  are	  recruited	  to	  oesophageal	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CHAPTER	  1:	  INTRODUCTION	  	  
1.1	  Homeostasis	  and	  microenvironments	  
	  
In	  1865,	  Claude	  Bernard	  introduced	  the	  concept	  that	  the	  body	  maintains	  its	  internal	  
environment	  in	  a	  stable	  state	  (1).	  	  This	  was	  later	  defined	  as	  homeostasis,	  the	  ability	  
to	  maintain	   internal	   constancy	  under	   a	   variety	  of	   external	   conditions,	   for	   example	  
the	   maintenance	   of	   a	   steady	   internal	   temperature	   in	   spite	   of	   external	   variations.	  	  
Signals	   between	   neighbouring	   cells	   (‘paracrine’	   signals)	   or	   between	   organs	  
(‘endocrine’	   signals)	   form	   a	   network	   of	   communication	   which	   enables	   cells	   of	  
differing	   types	   and	   organs	   with	   differing	   functions	   to	   co-­‐operate	   in	   maintaining	  
homeostasis.	  	  Characterisation	  of	  the	  nature	  of	  the	  signals	  maintaining	  homeostasis	  
began	   with	   the	   identification	   of	   the	   first	   hormone,	   secretin,	   which	   increases	  
pancreatic	   secretion	   in	   response	   to	   increased	   acid	   in	   the	   duodenum	   in	   1902	   (2).	  	  
Since	  then,	  many	  paracrine	  and	  endocrine	  signalling	  molecules,	  their	  corresponding	  
receptors	  and	  intracellular	  signalling	  pathways	  have	  been	  identified,	  and	  their	  role	  in	  
controlling	  cell	  growth	  determined.	  	  	  
	  
In	  epithelia,	  the	  balance	  of	  cell	  proliferation	  and	  cell	  death,	  particularly	  in	  response	  
to	  damage,	  involves	  interactions	  with	  underlying	  mesenchymal	  cells.	  	  This	  process	  is	  
subverted	  in	  many	  common	  cancers	  (breast,	  prostate,	  colon,	  stomach)	  characterised	  
by	   uncontrolled	   cell	   proliferation,	   invasion	   and	   metastasis	   and	   disruption	   to	   the	  
homeostatic	  mechanisms	  controlling	  these	  processes.	  	  Solid	  tumours	  are	  composed	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of	  the	  parenchyma	  (the	  neoplastic	  cells)	  and	  the	  stroma,	  the	  supportive	  network	  of	  
connective	   tissue	   and	   cells	   surrounding	   epithelial	   cells.	   These	   cells	   are	   capable	   of	  
preventing	  cancer	  initiation	  by	  suppressing	  uncontrolled	  cell	  growth.	  	  Once	  a	  tumour	  
develops,	   the	   stroma	   can	   function	   to	   support	   tumour	   growth,	   invasion	   and	  
metastasis.	  	  This	  thesis	  focuses	  on	  studies	  of	  the	  effect	  of	  stromal	  myofibroblasts	  on	  
tumour	  growth	   in	  gastric	  cancer,	  and	  the	  contribution	  of	  extracellular	  proteases	  to	  
stromal-­‐epithelial	  signalling.	  
	  
1.2	  The	  cancer	  microevironment	  
	  
In	  1889,	  Paget	  noticed	  that	  breast	  cancer	  preferentially	  metastasised	  to	  specific	  sites	  
independent	   of	   the	   anatomy,	   vascular	   supply	   and	   lymphatic	   drainage.	   	   He	  
hypothesised	   that	   some	   tissues	   provided	   a	   favourable	   microenvironment	   for	  
metastatic	  growth,	  an	  appropriate	   ‘soil’	   for	  where	   the	  cancer	   ‘seeds’	  establish	  and	  
grow	   (3).	   This	   first	   evidence	   of	   how	   a	  microenvironment	   supports	   cell	   growth	   has	  
since	   been	   extended	   to	   include	   events	   at	   the	   primary	   site	   (4),	   where	   cancer	   cells	  
alter	   the	  behaviour	  of	   local	  stromal	  cells	  and	  vice	  versa,	  as	  well	  as	  recruiting	  other	  
cell	  types.	  
	  
In	   normal	   tissue	   there	   is	   a	   tight	   balance	  between	   cell	   proliferation	   and	   cell	   death,	  
mediated	  by	  intercellular	  communication.	  	  Proteins	  such	  as	  integrins,	  E-­‐cadherin	  and	  
laminin	  facilitate	  cell-­‐cell	  and	  cell-­‐extracellular	  matrix	  (ECM)	  interactions	  in	  epithelia,	  
creating	   a	   stable	   tissue	   structure	   and	   preventing	   neoplastic	   transformation	   (5).	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Berenblum	   noted	   in	   1949	   that	   the	   skin	   suppresses	   damage	   caused	   by	   topical	  
carcinogens,	   resulting	   in	   fewer	   tumours	   than	   expected	   after	   application	   of	   two	  
carcinogenic	   agents	   (6).	   	   The	   addition	   of	   multipotent	   malignant	   teratocarcinoma	  
cells	   to	   a	   mouse	   blastocyst	   results	   in	   the	   development	   of	   normal	   mosaic	   mice,	  
showing	   that	   the	   embryonic	   microenvironment	   is	   capable	   of	   reprogramming	   the	  
malignant	  cells	  to	  a	  non-­‐malignant	  state	  (7).	  
	  
In	   cancer,	   the	  microenvironment	   is	   altered	   by	   signals	   from	   tumour	   cells,	   changing	  
the	  behaviour	  of	  surrounding	  cells	  and	  recruiting	  further	  cell	  types.	  	  The	  number	  and	  
variety	   of	   cells	   present	   is	   similar	   to	   the	   temporary	   stromal	   reaction	   observed	   in	  
response	  to	   inflammation,	  and	  such	  a	  comparison	  has	   labelled	  cancer	  as	  a	   ‘wound	  
that	  does	  not	  heal’	  (8).	  	  Indeed,	  when	  colon	  cancer	  cells	  are	  transplanted	  into	  wound	  
granulation	   tissue,	   they	   show	   evidence	   of	   invasion	   ( 9 ).	   	   The	   cancer	  
microenvironment	   is	   formed	   by	   the	   stroma,	   the	   cancer	   cells	   and	   the	   network	   of	  
signalling	  molecules	  between	  these.	  	  
	  
1.2.1	  Components	  of	  the	  cancer	  stroma	  
In	   their	   updated	   review	   on	   the	   hallmarks	   of	   cancer,	   Hanahan	   and	   Weinberg	  
emphasised	  the	  contribution	  of	  stromal	  cell	  types	  to	  the	  tumour	  microenvironment	  
and	   the	   importance	   of	   studying	   stromal	   cell	   types	   as	   well	   as	   the	   neoplastic	   cells	  
themselves	   (10).	   	   It	   is	   clear	   that	   during	   the	  process	   of	   tumorigenesis,	   signals	   from	  
stromal	  cells	  aid	  the	  tumour	  to	  secure	  a	  blood	  supply	  for	  the	  tumour	  and	  acquire	  the	  
ability	  to	  invade	  and	  metastasise	  (11).	  	  Tumours	  from	  different	  tissues	  of	  origin	  vary	  
	  	   	   14	  
in	   the	   amount	   and	   type	   of	   stroma	   they	   contain,	   for	   instance	   pancreatic	   tumours	  
have	   a	   higher	   stromal	   content	   than	   other	   tumours	   and	   breast	   cancer	   stroma	   is	  
particularly	   rich	   in	   fibroblasts.	   The	   stroma	   is	   composed	   of	   immune	   cells,	   vascular	  
cells,	   the	  ECM,	  cancer-­‐associated	  fibroblasts	   (CAFs)	  and	  mesenchymal	  stromal	  cells	  
(MSCs)	  (Figure	  1.1).	  	  CAFs	  and	  MSCs	  will	  be	  discussed	  in	  detail	  in	  the	  next	  sections.	  	  	  













Figure	   1.1	   Components	   of	   the	   cellular	   microenvironment.	   	   In	   normal	   epithelial	  
tissues,	   the	   cross-­‐talk	  between	   tissue	   fibroblasts	   and	  epithelial	   cells	   contributes	   to	  
the	  maintenance	  of	  normal	  tissue	  architecture.	  	  In	  chronic	  inflammation,	  fibroblasts	  
increase	   and	   an	   immune	   reaction	   develops,	   changing	   the	   nature	   of	   the	   cell-­‐cell	  
communication.	  	  Finally	  in	  cancer,	  myofibroblasts	  with	  an	  	  ‘activated’	  phenotype	  are	  
present,	  as	  well	  as	   immune	  cells	  and	  endothelial	  cells.	   	  Stromal-­‐epithelial	  signalling	  
still	  takes	  place	  and	  the	  result	  of	  these	  signals	  is	  the	  promotion	  of	  cancer	  growth.	  	  In	  
the	   normal	   gut,	   small	   numbers	   of	   subepithelial	   myofibroblasts	   are	   found	   and	   in	  
tumours	  of	  the	  gastro-­‐intestinal	  tract	  their	  numbers	  increase.	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1.2.1.1	  Immune	  cells	  
Cells	   from	   the	   immune	   system,	  many	   of	  which	   originate	   in	   the	   bone	  marrow,	   are	  
recruited	   to	   tumours	   and	   secrete	   many	   signalling	   molecules,	   contributing	   to	   the	  
paracrine	  signals	  in	  the	  tumour	  microenvironment.	  	  These	  cells	  were	  initially	  thought	  
to	  attempt	   to	   suppress	   cancer	  growth,	  but	   it	   is	  now	  known	   that	  neutrophils,	  mast	  
cells,	  B	  and	  T	  lymphocytes	  and	  macrophages	  all	  stimulate	  cell	  proliferation,	  invasion	  
and	  metastasis	  (12,13).	   	  The	  pattern	  of	   immune	  cell	   infiltration	  resembles	  that	  of	  a	  
wound	  or	  area	  of	  inflammation.	  
	  
1.2.1.2	  Vascular	  cells	  
A	   growing	   tumour	   requires	   a	   blood	   supply,	   as	   the	   capacity	   of	   interstitial	   fluid	   for	  
oxygen	  diffusion	  is	  limited	  (14).	  	  The	  formation	  of	  blood	  vessels	  is	  a	  dynamic	  process	  
adapting	   to	   changes	   in	   tissue	  oxygen	  demand.	   	   Endothelial	   cells	   form	   the	  walls	   of	  
blood	   vessels	   and	  pericytes	   secrete	   vascular	   basement	  membrane;	   both	   cell	   types	  
play	  an	  important	  role	  in	  angiogenesis.	  	  Lymphatic	  cells	  are	  also	  recruited	  and	  form	  a	  
drainage	   system	   connecting	   to	   the	   local	   lymphatic	   supply,	   facilitating	   lymph	   node	  
metastasis	  (15).	  	  A	  variety	  of	  cancer	  cell	  and	  stromal	  signals	  stimulate	  angiogenesis.	  
	  
1.2.1.3	  ECM	  
The	  ECM	  is	  composed	  of	  fibrillar	  proteins,	  glycoproteins	  and	  proteoglycans	  (16).	   	  A	  
large	  component	  is	  collagen.	  	  It	  provides	  structural	  support	  and	  adhesion	  for	  cells	  as	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well	  as	  acting	  as	  a	  reservoir	  of	  biologically	  active	  molecules.	   	  Different	  tissues	  have	  
differing	   ECMs,	   providing	   contextual	   information	   to	   cells,	   aiding	   their	   ability	   to	  
respond	   to	  extracellular	   signals	   (17).	   	   The	  ECM	   is	   a	  dynamic	   structure,	   undergoing	  
constant	  synthesis	  and	  degradation	  appropriate	  to	  the	  tissue’s	  circumstances.	  	  	  
	  
Tumour-­‐associated	  ECM	  differs	  from	  that	  of	  the	  pre-­‐existing	  stroma	  in	  normal	  tissue	  
(18).	   	   In	   cancer,	   vascular	   cells	   and	   fibroblasts	   synthesis	   ECM	   proteins	   (19).	   	   ECM	  
remodelling	   takes	  place	  at	   the	   invasive	   front	  of	   a	   tumour,	  where	  protease	  activity	  




1.3.1	  Distribution	  and	  definition	  
Myofibroblasts	   are	   an	   important	   stromal	   cell	   type	   usually	   found	   rarely	   in	   normal	  
tissues	   (except	   the	   gut)	   but	   commonly	   in	   many	   tumours.	   	   Gabbiani	   et	   al	   first	  
identified	   myofibroblasts	   in	   tissues	   undergoing	   wound	   healing	   (21).	   These	   cells	  
resembled	  fibroblasts	  but	  possessed	  contractile	  elements,	  making	  them	  able	  to	  play	  
a	   role	   in	   scar	   contraction.	   	   These	   smooth	  muscle-­‐like	   cells	  were	   then	   identified	  on	  
the	   basis	   of	   alpha-­‐smooth	   muscle	   actin	   (α-­‐SMA)	   expression	   within	   the	   stroma	   of	  
breast	  cancers	   (22).	   	  Since	  then,	  myofibroblasts	  have	  been	   identified	   in	  many	  solid	  
tumours	   and	   their	   presence	   in	   large	   numbers,	   a	   ‘desmoplastic	   stroma’,	   confers	   a	  
poor	  prognosis	  (23,24).	  Although	  in	  most	  normal	  tissues	  very	  few	  myofibroblasts	  are	  
present,	   the	   normal	   gut	   contains	   a	   well-­‐defined	   population	   of	   subepithelial	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myofibroblasts	  (25).	  	  Gastric	  tumours	  are	  known	  to	  contain	  myofibroblasts	  (26),	  and	  
high	  myofibroblast	  content	  is	  associated	  with	  a	  poor	  prognosis	  (27).	  	  	  
	  
There	  is	  no	  specific	  immunohistochemical	  marker	  for	  myofibroblasts,	  although	  many	  
have	  been	  proposed.	  α-­‐SMA,	  although	  not	  exclusively	  expressed	  by	  myofibroblasts,	  
remains	   an	   important	   marker	   (28).	   	   Other	   markers	   include	   tenascin-­‐C	   (29),	   NG2	  
chondroitin	   suphate	   proteoglycan	   (30),	   podoplanin	   (31)	   and	   fibroblast-­‐activated	  
protein	   (32),	   as	   well	   as	   markers	   of	   mesenchymal	   cells	   such	   as	   vimentin	   (33).	  	  
Myofibroblasts	  need	  also	  be	  negative	  for	  markers	  defining	  other	  cell	  types,	  such	  as	  
epithelial	   cells	   (pancytokeratin).	   In	   2008	   DeWever	   et	   al	   proposed	   that	   a	  
myofibroblast	  be	  defined	  on	  the	  basis	  of	  α-­‐SMA	  expression	   in	  combination	  with	  at	  
least	  three	  other	  markers	  (34).	  	  The	  present	  work	  identifies	  gastric	  myofibroblasts	  on	  
the	   basis	   of	   α-­‐SMA	   and	   vimentin	   positivity,	   in	   combination	   with	   desmin	   and	  
cytokeratin	   negativity.	   	  Where	   these	   criteria	   have	   not	   been	   rigorously	   fulfilled	   the	  
term	  cancer-­‐associated	  fibroblast	  (CAF)	  will	  be	  used	  instead.	  
	  
1.3.2	  Origin	  of	  myofibroblasts	  
Myofibroblasts	   in	   wound	   healing	   are	   thought	   to	   arise	   from	   differentiation	   of	  
fibroblasts	   found	   in	  normal	   tissue	   (35).	   	   In	   renal	   fibrosis	   (such	  as	  occurs	   in	   chronic	  
hypertension)	   myofibroblasts	   originate	   both	   from	   transdifferentiation	   of	   tissue	  
fibroblasts	  and	   to	  a	   lesser	  extent	   from	  bone	  marrow-­‐derived	  cells	   (36).	   	   In	   cancer,	  
however,	   the	   origin	   of	   myofibroblasts	   remains	   unclear.	   	   Some	   evidence	   suggests	  
myofibroblasts	  arise	  from	  the	  transdifferentiation	  of	  fibroblasts	  (37),	  as	  well	  as	  from	  
MSCs.	  	  Others	  have	  suggested	  that	  epithelial-­‐mesenchymal	  transition	  (EMT)	  occurs,	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making	   the	   cancer	   cells	   the	   source	   of	   myofibroblasts	   ( 38 ).	   	   In	   the	   pancreas,	  
adipocytes,	   stellate	   cells	   and	   pericytes	   have	   all	   been	   proposed	   as	   precursors	   of	  
myofibroblasts	  (39).	  	  In	  gastric	  cancer,	  evidence	  is	  accumulating	  that	  MSCs	  from	  the	  
bone	   marrow	   are	   recruited	   to	   tumours	   and	   contribute	   to	   the	   myofibroblast	  
population	   (40,41).	   	   However,	   recent	   findings	   suggest	   that	  H.	   pylori	   infection	   can	  
cause	   the	   differentiation	   of	   fibroblasts	   into	   myofibroblasts	   (42).	   	   Many	   of	   the	  
findings	  support	  the	  notion	  that	  myofibroblasts	  arise	  from	  a	  variety	  of	  sources,	  and	  
that	   the	   myofibroblasts	   in	   a	   tumour	   comprise	   a	   heterogeneous	   population	   of	  
myofibroblast	  subtypes.	  
	  
1.3.3	  Role	  of	  myofibroblasts	  in	  promoting	  cancer	  growth	  
In	  vitro	  studies	  have	  demonstrated	  that	  in	  gastric	  cancer	  CAFs	  promote	  and	  support	  
tumour	   growth.	   	   Myofibroblasts	   from	   gastric	   cancers	   exhibit	   higher	   rates	   of	  
proliferation	   and	  migration	   than	  myofibroblasts	   taken	   from	   normal	   stomach	   (43).	  	  
Conditioned	  media	  (CM)	  from	  gastric	  CAFs	  or	  myofibroblasts	  increases	  the	  migration	  
and	   invasion	   of	   gastric	   cancer	   cells	   (43, 44 ),	   in	   comparison	   to	   CM	   from	  
fibroblasts/myofibroblasts	   taken	   from	   normal	   stomach	   ( 45 ).	   	   CM	   from	   CAFs	  
harvested	   from	   the	   cancer-­‐normal	  mucosa	   interface	   increased	   the	   proliferation	   of	  
cancer	  cells	  (46).	  	  	  
	  
In	   vivo	   xenograft	   co-­‐injection	   studies	   using	   CAFs	   or	  myofibroblasts	   in	   combination	  
with	   cancer	   cells	   have	   demonstrated	   the	   role	   of	   these	   cells	   in	   promoting	   tumour	  
growth.	  	  Olumi	  et	  al	  showed	  in	  prostate	  cancer	  that	  CAFs	  potentiated	  the	  growth	  of	  
both	  prostate	  cancer	  cells	  and	  when	  mixed	  with	  non-­‐tumorigenic	  prostatic	  epithelial	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cells,	  they	  caused	  their	  transformation	  and	  created	  in	  vivo	  tumours	  (47).	  	  Orimo	  et	  al	  
showed	   that	   in	   breast	   cancer,	   the	   growth	   of	   cancer	   cells	   was	   enhanced	   by	   the	  
addition	   of	   CAFs	   but	   not	   by	   fibroblasts	   harvested	   from	   normal	   breast	   tissue	   (48).	  	  
Similar	  findings	  were	  obtained	  in	  studies	  in	  gastric	  cancer	  (43).	  
	  
CAFs/myofibroblasts	  promote	  tumour	  growth	  by	  exerting	  an	  effect	  on	  a	  wide	  range	  
of	   processes	   involved	   in	   the	   generation,	   maintenance,	   invasion	   and	  metastasis	   of	  
many	   tumours.	   	   Studies	   in	   a	   mouse	   model	   of	   gastric	   cancer	   and	   in	   oesophageal	  
cancer	  have	  shown	  that	  myofibroblasts	  stimulate	  angiogenesis	  (49,50).	   	  These	  cells	  
are	  capable	  of	  transforming	  epithelial	  cells,	  stimulating	  them	  to	  produce	  xenografts	  
in	  vivo	  where	  previously	  they	  did	  not	  (47).	  	  They	  stimulate	  the	  proliferation	  of	  cancer	  
cells,	   as	   demonstrated	   in	   squamous	   cells	   from	   oral	   cancer	   (51),	   and	   they	   can	   be	  
instrumental	  in	  instigating	  metastasis	  in	  colon	  cancer	  (52).	  	  They	  are	  involved	  in	  the	  
suppression	   of	   the	   host-­‐mediated	   immune	   response	   to	   a	   tumour	   (32).	   	   CAFs	   also	  
promote	   tumour	   growth	   by	   remodelling	   the	   ECM	   into	   a	   more	   permissive	  
environment	  for	  tumour	  growth	  (53).	  
	  
1.3.4	  Genetics	  of	  myofibroblasts	  
Although	   early	   studies	   indicated	   that	   the	   stromal	   cells	   within	   tumours	   harboured	  
genetic	  mutations	   (54),	   these	  were	   based	   on	   paraffin-­‐embedded	   tissue	   or	   did	   not	  
isolate	  CAFs	  from	  other	  stromal	  components.	  	  Since	  then,	  one	  study	  failed	  to	  detect	  
any	  substantial	  genetic	  alterations	  in	  CAFs	  (55)	  and	  another	  investigated	  pancreatic	  
CAFs	  and	  found	  them	  to	  have	  normal	  allelotypes	  (56).	   	  In	  breast	  cancer,	  CAFs	  were	  
shown	  to	  only	  rarely	  exhibit	  mutations	  in	  the	  p53	  gene	  (57).	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Evidence	   from	   gene	   expression	   studies	   shows	   that	   in	   gastric	   cancer	   the	   tumour	  
stroma	   exhibits	   a	   distinctive	   expression	   profile	   compared	  with	   the	   stroma	  of	   non-­‐
malignant	   gastric	  mucosa	   (58).	   	   The	   differences	   in	   gene	   expression	   are	   unlikely	   to	  
arise	   from	   somatic	   genetic	   mutations,	   but	   may	   occur	   as	   a	   result	   of	   epigenetic	  
phenomena,	  such	  as	  changes	  in	  DNA	  methylation	  in	  the	  promoter	  region	  of	  a	  gene.	  	  
Myofibroblasts	   from	  gastric	  cancer	  patients	  exhibit	  global	  hypomethylation,	   similar	  
to	  the	  finding	  of	  hypomethylation	  in	  the	  epithelial	  cells	  of	  many	  carcinomas	  (59).	  	  In	  
pancreatic	   CAFs,	   however,	   few	   genes	   are	   reactivated	   after	   treatment	   with	   a	   DNA	  
methylation	  inhibitor,	  suggesting	  that	  there	  are	  few	  alterations	  in	  DNA	  methylation	  
in	  these	  cells	  (60).	  	  	  
	  
1.4	  Mesenchymal	  Stromal	  Cells	  (MSCs)	  
	  
Although	  many	   of	   the	   bone	  marrow-­‐derived	   cells	   found	   in	   tumours	   belong	   to	   the	  
immune	   system,	   recent	   evidence	   shows	   that	   another	   type	   of	   mesenchymal	   cell	  
populates	   tumours.	   	   Xenograft	   experiments	   using	   a	   variety	   of	   cancer	   cells	   have	  
shown	  that	  some	  CAFs	  in	  the	  tumours	  are	  derived	  from	  MSCs,	  and	  that	  the	  presence	  
of	  these	  cells	  stimulates	  xenograft	  growth	  (61).	  	  In	  gastric	  cancer,	  the	  CAFs	  resemble	  
the	  myofibroblasts	  found	  in	  normal	  gastric	  mucosa	  in	  the	  markers	  they	  express,	  but	  
their	   biological	   behaviour	   is	   different.	   	   An	   experiment	   examining	   the	   fate	   of	   bone	  
marrow-­‐derived	   cells	   in	   patients	   with	   gastric	   cancer	   who	   previously	   received	   a	  
gender-­‐mismatched	   bone	   marrow	   transplant	   showed	   that	   bone	   marrow-­‐derived	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cells	   contribute	   to	   the	   stroma	   in	   gastric	   cancer	   (62 ).	   	   In	   a	   mouse	   model	   of	  
inflammation-­‐induced	  gastric	  cancer,	   it	  was	   thought	   that	  20%	  of	  gastric	  CAFs	  were	  
derived	  from	  the	  mesenchymal	  stromal	  cells	  in	  the	  bone	  marrow	  (41).	  	  	  
	  
A	   population	   of	   spindle	   shaped	   clonogenic	   cells	   was	   first	   isolated	   from	   the	   bone	  
marrow	  by	  Friedenstein	   in	  1971	  (63).	   	  Owing	  to	  their	  capacity	   for	  self-­‐renewal	  and	  
multipotency	  these	  cells	  were	  termed	  mesenchymal	  stem	  cells	  (64).	  	  It	  is	  now	  known	  
that	   these	   cells	   actually	   comprise	   a	   mixed	   population,	   only	   a	   small	   proportion	   of	  
which	   is	   self-­‐renewing	   and	   multipotent,	   and	   the	   nomenclature	   was	   adjusted	   to	  
mesenchymal	  stromal	  cells	  (MSCs)	  (65).	  	  These	  cells	  have	  mainly	  been	  isolated	  from	  
the	   adult	   bone	  marrow	   (distinguishing	   them	   from	  embryonic	   stem	   cells),	   but	   they	  
are	  also	   released	   into	   the	  circulation	  and	   recruited	   to	   tissues	  undergoing	   repair	  or	  
renewal	   (66).	   	   Their	   physiological	   role	   in	   the	   bone	   marrow	   appears	   to	   be	   in	   the	  
maintenance	  of	  the	  haematopoietic	  stem	  cell	  niche,	  responsible	   for	  generating	  the	  
precursors	  of	  the	  cells	  which	  circulate	  in	  the	  blood	  (67).	  
	  
There	  is	  no	  single	  defining	  characteristic	  or	  marker	  of	  an	  MSC.	  	  In	  2006,	  a	  consensus	  
was	  reached	  regarding	  the	  features	  which	  define	  a	  multipotent	  MSC.	  	  The	  cells	  must	  
be	  plastic-­‐adherent	  in	  culture.	  	  Expression	  of	  the	  surface	  markers	  CD105,	  CD73	  and	  
CD90	   and	   absence	   of	   CD45,	   CD34,	   CD14,	   CD11b,	   CD79α,	   CD19	   and	   HLA-­‐DR	   are	  
necessary.	   	   Finally,	   the	   cells	   must	   show	   capacity	   to	   differentiate	   into	   osteoblasts,	  
adipocytes	   and	   chondroblasts	   in	   vitro	   (68).	   	   These	   criteria	   are	   however	   difficult	   to	  
fulfil	  owing	  to	  variations	  in	  MSCs	  from	  different	  tissues	  of	  origin	  and	  from	  different	  
species.	   	  More	   recent	   attempts	   at	   defining	  MSCs	   have	   included	   features	   from	   the	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transcriptome,	   secretome	  and	  proteome	   (69).	   	  The	   term	  mesenchymal	   stem	  cell	   is	  
now	   considered	   to	   only	   apply	   to	   those	   cells	   with	   a	   capacity	   for	   self-­‐renewal	   and	  
differentiation	  characteristics	  compatible	  with	  a	  multipotent	  state.	  
	  
1.5	  Stromal-­‐epithelial	  signals	  
	  
In	  cancer,	   the	  characterisation	  of	   intracellular	  signalling	  cascades	  within	  the	  cancer	  
cells	  has	   increased	  dramatically,	   increasing	   the	  development	  of	   therapies	   targeting	  
these	  processes.	  	  	  The	  paracrine	  heterotypic	  interactions	  occurring	  between	  stromal	  
cells	  and	  epithelial	  cells	  remain	  poorly	  defined,	  leaving	  a	  gap	  in	  the	  understanding	  of	  
extracellular	  processes,	  a	  potential	  source	  of	  therapeutic	  targets.	  	  Some	  examples	  of	  




Chemerin	   is	   a	   protein	   first	   identified	   as	   upregulated	   in	   psoriatic	   skin	   (70).	   	   It	   is	  
expressed	   in	  placenta,	   liver	  and	  adipose	  tissue.	   	   It	   is	   released	  as	  pro-­‐chemerin	   into	  
the	  circulation	  and	  is	  activated	  locally	  by	  proteolysis	  (71).	  	  Its	  binding	  to	  a	  G-­‐protein	  
coupled	  receptor	  known	  as	  ChemR23	  is	  known	  to	  cause	  an	  increase	  in	   intracellular	  
calcium	  (72)	  and	  cause	  ERK1/2	  phosphorylation	  (73).	  	  This	  receptor	  is	  homologous	  to	  
other	   chemoattractant	   receptors,	   raising	   suspicion	   that	   chemerin	   might	   act	   as	   a	  
chemoattractant.	  	  Chemerin-­‐mediated	  chemotaxis	  has	  been	  identified	  in	  leucocytes	  
expressing	  ChemR23	  (74).	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Chemerin	  was	  thought	  to	  play	  a	  role	  in	  inflammation	  (75)	  and	  increased	  circulating	  
chemerin	  is	  also	  found	  in	  obesity	  (76).	  	  Chemerin	  is	  overexpressed	  in	  oral	  squamous	  
cell	  carcinomas	  (77).	  	  In	  melanoma,	  however,	  chemerin	  acts	  as	  a	  chemoattractant	  to	  
natural	  killer	  (NK)	  cells,	  resulting	  in	  tumour	  suppression	  (78).	  	  The	  role	  of	  this	  poorly	  
characterised	  molecule	   in	   long	   range	  stromal	   signalling	  will	  be	  discussed	   further	   in	  
Chapter	  6.	  	  	  



















Figure	   1.2	   Stromal-­‐epithelial	   signals	   and	   their	   effects.	   CAFs	   secrete	   stroma	   cell-­‐
derived	  factor-­‐1	  (SDF-­‐1),	  which	  acts	  on	  tumour	  cells	  to	   increase	  growth	  (48).	   	  CAFs	  
also	   secrete	   vascular	   endothelial	   growth	   factor	   (VEGF),	   which	   acts	   on	   endothelial	  
cells	  and	  cancer	  cells,	   increasing	  angiogenesis	   (79).	   	  Cells	   from	  the	   immune	  system	  
secrete	  a	  variety	  of	  chemokines,	  cytokines	  and	  growth	   factors,	   including	   IL-­‐6,	   IL-­‐11	  
and	   TNFα.	   	   These	   promote	   tumour	   growth	   in	   a	   variety	   of	   ways.	   	   The	   release	   of	  
reactive	  oxygen	  species	  from	  these	  cells	  increases	  the	  likelihood	  of	  mutations	  in	  the	  
cancer	   cells,	   accelerating	   the	   tumour’s	   adaptation	   to	   the	   changing	  
microenvironment	  (80).	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1.7	  Extracellular	  proteases	  
	  
Extracellular	  proteases	  are	  enzymes	  released	  into	  the	  extracellular	  milieu	  capable	  of	  
degrading	   other	   proteins.	   	   They	   have	   the	   effect	   of	   remodelling	   the	   ECM,	   the	  
degradation	   of	   which	   is	   necessary	   in	   aiding	   tumour	   cells	   to	   migrate,	   invade	   and	  
metastasise.	  	  Proteolysis	  also	  releases	  and	  activates	  growth	  factors,	  chemokines	  and	  
cytokines,	   making	   extracellular	   proteases	   key	   players	   in	   the	   tumour	  
microenvironment.	  
	  
There	  are	  570	  proteases	  known	  in	  humans,	  involved	  in	  diverse	  processes	  (81).	  	  There	  
are	   six	   families	   of	   proteases:	   metallo-­‐,	   serine,	   aspartate,	   threonine,	   cysteine	   and	  
glutamic,	   named	   according	   to	   the	   component	   of	   their	   active	   site.	   	   The	   three	  
extracellular	   systems	   relevant	   to	   this	   investigation	   are	   the	   urokinase	   plasminogen	  
activator	  (uPA)	  system	  (a	  family	  of	  serine	  proteases),	  the	  matrix	  metalloproteinases	  
(MMPs),	  and	  cathepsins	  (a	  family	  of	  cysteine	  proteases).	  
	  
1.7.1	  uPA	  system	  
	  
The	  uPA	  system	  is	  an	  important	  extracellular	  proteolytic	  system.	  	  uPA	  is	  activated	  on	  
binding	   to	   the	   uPA	   receptor	   (uPAR),	   a	   cell	   membrane-­‐anchored	   protein,	   which	  
means	   that	   proteolytic	   activity	   is	   localised	   to	   the	   cell	   membrane	   (82).	   	   Upon	  
activation	  uPA	  cleaves	  plasminogen	  to	  produce	  plasmin,	  a	  powerful	  protease	  with	  an	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important	  role	  in	  fibrinolysis.	   	  In	  tumours,	  however,	  the	  ability	  of	  plasmin	  to	  cleave	  
proteins	  in	  the	  ECM	  releases	  cytokines	  and	  growth	  factors	  and	  is	  a	  driver	  of	  tumour	  
growth.	  	  Plasminogen	  activator-­‐inhibitor-­‐1	  (PAI-­‐1)	  functions	  as	  the	  main	  inhibitor	  of	  
uPA	  by	  binding	  to	  the	  uPA-­‐uPAR	  complex,	  resulting	  in	  its	  internalisation	  by	  the	  cell	  in	  
a	  low-­‐density	  lipoprotein	  (LDL)	  dependent	  manner	  (83)	  (Figure	  1.3).	  
	  
PAI-­‐1	   is	  a	  52kDa	  glycoprotein	   first	  characterized	   in	  bovine	  endothelial	  cells	   (84).	   	   It	  
forms	  part	  of	  the	  uPA	  system	  by	  acting	  as	  the	  main	  physiological	  inhibitor	  of	  uPA.	  	  It	  
circulates	  in	  plasma,	  is	  stored	  in	  platelets	  and	  is	  expressed	  in	  a	  variety	  of	  cell	  types	  
including	   endothelial	   cells,	   fibroblasts	   and	   hepatocytes	   (85).	   	   PAI-­‐1	   can	   exist	   in	   an	  
active	  (inhibiting	  proteolysis)	  state	  or	  a	  latent	  state	  (86).	  	  Circulating	  PAI-­‐1	  is	  bound	  
to	  vitronectin.	  	  The	  mouse	  and	  human	  proteins	  share	  82%	  amino	  acid	  homology	  (87)	  
(88).	  	  Genetically	  modified	  mice	  lacking	  the	  PAI-­‐1	  gene	  develop	  to	  term	  and	  exhibit	  a	  
mild	   hyperfibrinolytic	   state	   (89).	   	   They	   also	   demonstrate	   increased	   haemorrhagic	  
gastric	   lesions	   in	   response	   to	  ethanol	  or	   indomethacin	   (90).	   In	  humans,	  PAI-­‐1	  may	  
make	   a	   more	   significant	   contribution	   to	   the	   prevention	   of	   clot	   degradation	   as	  
humans	  lacking	  PAI-­‐1	  exhibit	  episodes	  of	  haemorrhage	  (91).	  	  


























Figure	   1.3	   Interactions	   between	   uPA,	   uPAR	   and	   PAI-­‐1.	   uPA	   binds	   to	   the	   cell	  
membrane-­‐anchored	   uPAR,	   catalysing	   the	   conversion	   of	   plasminogen	   to	   plasmin.	  	  
PAI-­‐1	   inhibits	   this	   process,	   preventing	   plasmin	   activation	   and	   the	   consequent	  
proteolytic	   processes	  which	   contribute	   to	   tumour	   growth	   and	   invasion.	   	   uPAR	   can	  
orchestrate	   intracellular	   signalling	   through	   its	   interaction	   with	   cell	   membrane-­‐
spanning	  integrins,	  causing	  an	  increase	  in	  cell	  motility,	  invasiveness	  and	  epithelial-­‐to-­‐
mesenchymal	   transition	   (EMT).	   	   uPAR	   also	   interacts	   with	   vitronectin,	   providing	  
anchorage	  to	  the	  ECM.	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In	   addition	   to	   binding	   to	   uPA-­‐uPAR	   complexes,	   when	   unbound	   PAI-­‐1	   has	   a	   high	  
affinity	   for	   vitronectin,	   an	   ECM	   protein	   (92).	   	   Vitronectin	   mediates	   intracellular	  
signalling	   by	   interacting	   with	   cell	   membrane-­‐spanning	   integrins.	   	   PAI-­‐1	   competes	  
with	   integrins	   for	   binding	   to	   vitronectin	   and	   this	   is	   independent	   of	   its	   ability	   to	  
inhibit	   uPA	   (93).	   	   uPAR	   also	   interacts	  with	   vitronectin,	   enhancing	   cell	   adhesion	   by	  
creating	  a	  connection	  between	  a	  membrane-­‐anchored	  protein	  and	  the	  ECM.	  	  PAI-­‐1	  is	  
able	  to	  compete	  with	  uPAR	  for	  vitronectin	  binding	  (94)	  (Figure	  1.4).	  	  
	  
Although	   an	   extracellular	   molecule,	   secreted	   PAI-­‐1	   is	   capable	   of	   exerting	   an	  
influence	   on	   intracellular	   signalling,	   causing	   changes	   in	   cell	   adhesion	   and	  
proliferation.	   	   This	   effect	   seems	   to	   be	   unrelated	   to	   its	   role	   in	   the	   inhibition	   of	  
proteolysis.	   	   In	   fibroblasts	   PAI-­‐1	   inhibited	   insulin-­‐induced	   protein	   kinase	   B	  
phosphorylation	   (an	   intracellular	   process)	   by	   preventing	   the	   integrin-­‐vitronectin	  
interaction	  necessary	  for	  this.	   	  This	  resulted	  in	  decreased	  cell	  migration	  (95).	   	  PAI-­‐1	  
activated	  the	  intracellular	  JAK/STAT	  pathway	  in	  a	  variety	  of	  cells	  and	  this	  resulted	  in	  
increased	  cell	  migration.	  	  This	  effect	  was	  dependent	  on	  the	  presence	  of	  a	  functional	  
LDL	  receptor-­‐related	  protein	  (LRP)	  (96)	  (Figure	  1.4).	  	  
	  
Intracellular	  PAI-­‐1	  also	  affects	  cell	  behaviour.	  	  In	  pulmonary	  fibroblasts,	  intracellular	  
PAI-­‐1	  knockdown	  results	  in	  an	  increase	  in	  caspase-­‐3	  mRNA,	  showing	  that	  PAI-­‐1	  has	  a	  
role	  in	  the	  inhibition	  of	  apoptosis	  (97).	  	  	  
	  















Figure	  1.4	  Protease-­‐independent	  actions	  of	  PAI-­‐1.	  	  PAI-­‐1	  interacts	  with	  vitronectin,	  
preventing	   uPAR	   from	   binding	   and	   causing	   loss	   of	   anchorage	   to	   the	   ECM.	   	   PAI-­‐1	  
increases	   cell	   motility	   by	   stimulating	   intracellular	   signalling	   in	   an	   LDL-­‐dependent	  
manner.	  	  Binding	  of	  PAI-­‐1	  to	  the	  uPA-­‐uPAR	  complex	  stimulates	  mitogenesis	  through	  
an	  interaction	  with	  the	  LDL	  receptor.	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Based	   on	   its	   role	   in	   protease	   inhibition,	   it	   might	   be	   predicted	   that	   PAI-­‐1	   offers	   a	  
protective	   role	   in	   cancer,	   by	  preventing	   the	  degradation	  of	   the	  ECM	  necessary	   for	  
local	  tumour	  invasion	  and	  release	  of	  tumour	  cells	  into	  the	  circulation.	  	  Indeed,	  there	  
are	   in	   vitro	   data	   to	   suggest	   that	   this	   is	   the	   case.	   	   PAI-­‐1	   prevents	   uPA-­‐dependent	  
invasion	  of	   lung	   cancer	   cells	   into	  an	  amnion	   cell	  membrane	   (98).	   	   PAI-­‐1	  promoted	  
cell	  adhesion	  of	  human	  myogenic	  cells	  in	  a	  dose-­‐dependent	  manner	  (99).	  	  In	  vivo	  this	  
may	   also	   be	   the	   case,	   as	   a	   study	   using	   PAI-­‐1	   overexpressing	   fibrosarcoma	   cells	  
showed	  reduced	  metastasis	  formation	  from	  tumours	  overexpressing	  PAI-­‐1	  (100).	  	  	  
	  
However,	  many	   studies	  have	  described	  evidence	   that	   conflicts	  with	   these	   findings,	  
suggesting	   that	   PAI-­‐1	  may	   also	   promote	   tumour	   growth,	   invasion	   and	  metastasis.	  	  
For	   example,	   when	   PAI-­‐1	   is	   added	   to	   tumour	   cell	   cultures,	   it	   inhibits	   apoptosis,	  
showing	   that	   it	   contributes	   to	   cell	   survival	   in	   cancer	   (101).	   	   Evidence	   from	   clinical	  
samples	  of	  gastric	  cancer	  reveals	  that	  high	  PAI-­‐1	  expression	  is	  associated	  with	  a	  poor	  
prognosis	  (102,	  103,	  104).	  	  In	  an	  in	  vivo	  model	  of	  gastric	  cancer,	  knockdown	  of	  PAI-­‐1	  
decreased	   peritoneal	   metastases,	   showing	   that	   PAI-­‐1	   plays	   an	   important	   role	   in	  
tumour	  dissemination	  (105).	  
	  
1.7.2	  MMPs	  
MMPs	   are	   a	   family	   of	   24	   zinc	   binding	   endopeptidases	   either	   secreted	   as	   soluble	  
enzymes	  or	  bound	  to	  the	  cell	  membrane,	  first	  discovered	  by	  Gross	  and	  Lapiere	  (106).	  	  
Their	   shared	   structure	   consists	   of	   a	   prodomain,	   a	   catalytic	   domain	   and,	   usually,	   a	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haemopexin-­‐like	  domain	  (not	  present	  in	  MMP-­‐7),	  connected	  to	  the	  catalytic	  domain	  
by	  a	  hinge	  region	  (Figure	  1.5).	  	  Intracellularly,	  the	  protein	  has	  a	  preprodomain	  which	  
directs	   it	   to	   the	   endoplasmic	   reticulum	   for	   processing.	   	   The	   prodomain	   contains	   a	  
Cys	   residue	  which	   interacts	  with	   the	   zinc-­‐binding	  domain,	  maintaining	   the	   inactive	  
state.	  	  Cleavage	  of	  the	  prodomain	  separates	  the	  Cys	  residue	  from	  the	  active	  domain,	  
activating	   the	   enzyme.	   	   The	   catalytic	   domain	   contains	   the	   active	   site.	   	   The	  
haemopexin-­‐like	   domain	   mediates	   interaction	   with	   tissue	   inhibitors	   of	  
metalloproteinases	   (TIMPs),	   binds	   cell	   surface	   molecules	   and	   interacts	   with	  
substrate	   molecules.	   	   MMPs	   have	   a	   role	   in	   diverse	   processes	   including	  
embryogenesis	  (107),	  wound	  healing	  (108)	  and	  angiogenesis	  (109).	  	  MMP	  inhibition	  
occurs	  through	  TIMPs	  (110)	  and	  in	  plasma,	  MMPs	  are	  inhibited	  by	  α2-­‐macroglobulin	  
(111).	  















Figure	   1.5	   Structure	   of	   MMPs.	   	   MMPs	   share	   a	   common	   structure,	   with	   minor	  
modifications	  to	  this	  according	  to	  which	  class	  of	  MMP	  they	  are	  from.	  	  MMPs	  all	  have	  
a	  pre-­‐pro-­‐peptide	  which	  targets	  the	  protein	  to	  the	  endoplasmic	  reticulum	  for	  post-­‐
translational	  processing.	  	  After	  being	  secreted,	  cleavage	  of	  the	  prodomain	  results	  in	  
activation	  of	  the	  MMP	  as	  the	  Cys	  residue	  is	  separated	  from	  the	  active	  domain.	  	  The	  
catalytic	   domain’s	   active	   site	   contains	   a	   zinc	   ion.	   	   A	   hinge	   region	   connects	   the	  
catalytic	   domain	   to	   a	   haemopexin-­‐like	  domain,	  which	   is	   responsible	   for	   binding	   to	  
substrate	  molecules,	  TIMPs	  and	  cell-­‐surface	  receptors.	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Tumours	   often	   express	   a	   variety	   of	   MMPs	   which	   may	   activate	   each	   other	   and	  
together	  create	  a	  cascade	  of	  proteolytic	  activity	  	  (Figure	  1.6)	  or	  may	  individually	  play	  
roles	  in	  specific	  process.	  	  The	  earliest	  evidence	  suggested	  that	  MMPs,	  through	  their	  
ability	  to	  degrade	  ECM,	  aided	  tumour	   invasion	  and	  cell	  migration.	   	  Liotta	  et	  al	   first	  
showed	  that	  the	  metastatic	  potential	  of	  cancer	  cells	  was	  proportional	  to	  their	  ability	  
to	  degrade	  the	  basement	  membrane	  (112).	  	  Evidence	  from	  mouse	  models	  of	  breast	  
cancer	   confirmed	   that	   overexpression	   of	   MMPs	   caused	   tumours	   to	   develop	   and	  
invade	   (113,114,115).	   	   In	   gastric	   cancer,	  MMP-­‐7	   was	   shown	   to	   play	   a	   role	   in	   the	  
migration	  of	  cancer	  cells	  in	  vitro	  (116)	  and	  in	  vivo,	  MMP-­‐7	  deficient	  mice	  developed	  
fewer	  colonic	  tumours	  than	  their	  MMP-­‐7-­‐expressing	  counterparts	  (117).	  
	  
This	   prompted	   the	   rapid	   development	   of	   small	   molecule	   MMP	   inhibitors,	   which	  
although	   promising	   in	   in	   vitro	   assays,	   were	   not	   successful	   in	   clinical	   trials.	   	   This	  
failure	  was	  due	  to	  a	  variety	  of	  reasons.	  	  Some	  trials	  were	  discontinued	  due	  to	  severe	  
musculoskeletal	   side	   effects.	   	  Others	   noticed	   that	   patients	   in	   the	   treatment	   group	  
experienced	  poorer	  survival	  or	  an	  increase	  in	  metastases	  compared	  with	  those	  in	  the	  
placebo	  group	  (118).	  	  In	  gastric	  cancer,	  however,	  the	  results	  showed	  some	  promise	  
as	   the	   use	   of	   a	   MMP	   inhibitor	   increased	   the	   survival	   of	   patients	   with	   inoperable	  
disease	  (119).	  	  	  
	  
Further	   research	   into	  MMPs	  demonstrated	   that	   these	  proteins	   exert	  wider	   effects	  
than	  was	  previously	  thought,	  and	  that	  these	  may	  not	  necessarily	  involve	  proteolysis.	  	  
MMP-­‐9	  is	  capable	  of	  providing	  growth	  signals	  through	  its	  interaction	  with	  E-­‐Cadherin	  
and	   the	   epidermal	   growth	   factor	   receptor,	   leading	   to	   ovarian	   cancer	   metastasis	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(120).	   	  MMP-­‐7	   is	   capable	  of	  disrupting	  apoptosis	  by	  cleaving	   the	  Fas	   ligand	  on	   the	  
surface	   of	   cells,	   diminishing	   the	   effect	   of	   doxorubicin	   chemotherapy	   ( 121 ).	  	  
Furthermore,	   it	  has	  now	  been	  shown	  that	  MMP-­‐9	  can	  stimulate	  cell	  migration	   in	  a	  
proteolysis-­‐independent	  manner	  (122).	   	  MMP-­‐12	  exerts	  antimicrobial	  effects,	  again	  
through	  a	  mechanism	  which	  is	  independent	  of	  proteolysis	  (123).	  	  This	  shows	  that	  the	  
role	  MMPs	  extends	  beyond	  ECM	  degradation	  and	  that	  some	  effects	  are	  not	  due	  to	  
proteolysis.	  	  
	  
1.7.2.1	  MMPs	  in	  stroma	  
The	  majority	  of	  MMPs	  are	  not	  usually	  secreted	  in	  healthy	  tissue,	  with	  the	  exception	  
of	   MMP-­‐7,	   which	   is	   expressed	   constitutively	   in	   most	   epithelia	   ( 124 ).	   	   MMP	  
expression	  typically	  increases	  in	  response	  to	  injury,	  disease	  or	  inflammation.	  
	  
It	   is	  clear	  that	  MMPs	  play	  an	  important	  role	   in	  the	  extracellular	  milieu	  and	  there	   is	  
abundant	   evidence	   showing	   that	   the	   stroma	   is	   an	   important	   source	   of	   MMPs.	  	  
Fibroblasts	   in	   particular	   have	  been	   shown	   to	   secrete	   a	   variety	   of	  MMPs,	   including	  
MMP-­‐1	   (125)	   and	  MMP-­‐3	   (115).	   	   The	   production	   of	   MMPs	   by	   fibroblasts	   can	   be	  
stimulated	   by	   paracrine	   signals	   from	   cancer	   cells,	   highlighting	   the	   importance	   of	  
reciprocal	  interaction	  in	  this	  system	  (126).	  	  Tumour-­‐associated	  macrophages	  are	  also	  
implicated	  in	  MMP	  production	  (127).	  	  Mast	  cell	  degranulation	  results	  in	  the	  release	  
of	  proteases	  (128)	  and	  when	  this	  process	  is	  inhibited,	  this	  results	  in	  the	  inhibition	  of	  
tumour	  growth	  (129).	  	  	  Neutrophils	  are	  thought	  to	  be	  the	  primary	  source	  of	  MMP-­‐8	  
(130).	  	  Vascular	  cells	  such	  as	  endothelial	  cells	  and	  pericytes	  are	  not	  implicated	  in	  the	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production	   of	   MMPs	   but	   MMPs	   nevertheless	   contribute	   to	   the	   control	   of	  
angiogenesis,	  as	   the	  cleavage	  of	  pro-­‐	  or	  anti-­‐angiogenic	   factors	  by	   these	  proteases	  
can	  result	  in	  their	  activation	  or	  degradation	  (131).	  	  	  
	  
The	  impact	  of	  stromal	  MMPs	  is	  demonstrated	  in	  breast	  cancer,	  where	  the	  presence	  
of	   microinvasion	   in	   ductal	   carcinoma	   in	   situ	   samples	   is	   associated	   with	   MMP-­‐13	  
expression	  in	  stromal	  fibroblasts	  (132).	  	  In	  xenograft	  studies,	  the	  tumour-­‐promoting	  
effect	   of	   fibroblasts	   can	   be	   diminished	   by	   the	   inhibition	   of	   MMPs,	   either	   by	   the	  
addition	  of	  TIMPs	  or	  the	  administration	  of	  synthetic	  MMP	  inhibitors	  (133).	  
	  
1.7.2.2	  MMPs	  in	  gastric	  cancer	  
In	   gastric	   cancer,	   expression	   of	   various	   MMPs	   has	   been	   associated	   with	   poor	  
prognosis,	  advanced	  cancer	  stage	  and	  short	  survival.	  	  MMP-­‐9	  protein	  expression	  by	  
immunohistochemistry	   and	   mRNA	   expression	   by	   qPCR	   is	   correlated	   with	   short	  
survival	   (134,135).	   	   MMP-­‐9	   increases	   gastric	   cancer	   cell	   invasion	   in	   response	   to	  
gastrin	  stimulation	  (136).	   	  MMP-­‐1	  expression	  is	  correlated	  with	  lymph	  node	  spread	  
(137),	  with	  poor	  prognosis	  and	  presence	  of	  metastases	  (138).	  	  MMP-­‐7	  has	  also	  been	  
proposed	  as	  an	  independent	  prognostic	  marker	  in	  gastric	  cancer	  (139).	  	  	  
	  
It	  is	  now	  known	  that	  in	  gastric	  cancer,	  MMPs	  are	  expressed	  both	  by	  cancer	  cells	  and	  
by	   stromal	   cells.	   	  MMP-­‐7	   is	   unusual	   in	   that	   it	   is	   expressed	   by	   gastric	   cancer	   cells	  
(140).	  	  Ohtani	  et	  al	  showed	  that	  in	  colon	  and	  gastric	  cancer,	  MMP-­‐1	  was	  expressed	  
on	  the	  surface	  of	  stromal	  cells	  such	  as	  macrophages	  and	  fibroblasts	  (141).	  	  MMP-­‐2	  is	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expressed	  by	  fibroblasts	  in	  gastric	  cancer	  (142).	  	  	  	  Stromal	  MMP	  expression	  may	  play	  
a	   role	   in	   stromal-­‐epithelial	   signalling,	   enabling	   intercellular	   communication	   within	  
the	   tumour.	   	  Higher	  concentrations	  of	   serum	  MMP-­‐9	  are	  associated	  with	  a	  denser	  
stromal	   reaction	   in	   the	  primary	   tumour,	  which	   is	  associated	  with	  a	  poor	  prognosis	  
(143).	  	  MMP-­‐1	  expression	  in	  gastric	  fibroblasts	  can	  be	  induced	  by	  treatment	  with	  CM	  
from	   cancer	   cells,	   showing	   that	  MMP	  expression	   is	   regulated	  by	   stromal-­‐epithelial	  
interactions	   ( 144 ).	   	   MMP-­‐7	   expression	   by	   gastric	   cancer	   cells	   stimulates	  
myofibroblast	  proliferation	  (145).	  
	  
One	   of	   the	   major	   risk	   factors	   for	   the	   development	   of	   gastric	   cancer	   is	   H.	   pylori	  
infection	   (see	   below).	   	   This	   infection	   has	   been	   shown	   to	   stimulate	   expression	   of	  
MMPs	   in	   the	   stomach	   (116,146).	   	   The	   increase	   in	   MMP-­‐7	   in	   H.	   pylori	   infection	  
stimulates	   myofibroblast	   proliferation,	   demonstrating	   that	   stromal	   changes	   may	  
even	  precede	  the	  development	  of	  neoplasia	  (147).	  	  
	  
It	   is	   clear	   that	  MMPs	   are	   involved	   in	   tumour	   progression	   owing	   to	   their	   ability	   to	  
facilitate	   ECM	   degradation.	   	   In	   gastric	   cancer,	   it	   appears	   that	   MMP	   expression	   is	  
correlated	  with	  advanced	  tumour	  stage	  and	  short	  survival.	  	  Stromal	  MMP	  expression	  
has	  been	  demonstrated	  although	  the	  effect	  of	  stromal-­‐derived	  MMPs	  remains	  to	  be	  
determined	   in	  gastric	  cancer.	   	  With	   increasing	  evidence	  that	  MMPs	  are	  cancer	  and	  
situation	  specific,	  it	  will	  be	  interesting	  to	  see	  which	  MMPs	  are	  particularly	  important	  
in	  gastric	  cancer.	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1.7.2.2	  Imaging	  MMPs	  
Many	  of	  the	  clinical	  trials	  assessing	  MMP	  inhibitors	  failed	  to	  demonstrate	  an	  effect	  
on	  tumour	  burden,	  which	  was	  assessed	  using	  conventional	  imaging	  modalities	  such	  
as	  computed	  tomography.	   	  MMP	   inhibitors	  are	  cytostatic	  agents,	   so	  a	   reduction	   in	  
tumour	  volume	  may	  not	  necessarily	  result	  although	  the	  activity	  of	  the	  tumour	  could	  
have	   changed	   significantly.	   	   There	   is	   therefore	   a	   need	   for	   alternative	  methods	   of	  
assessing	   tumour	   burden.	   	   The	   use	   of	   conventional	   clinical	   imaging	   techniques	   in	  
combination	  with	  the	  development	  of	  new	  MMP-­‐sensing	  probes	  has	  shown	  promise.	  	  
The	   first	   fluorogenic	   MMP	   substrate	   was	   used	   in	   2001	   by	   Bremer	   et	   al	   (148).	  	  
Positron	  emission	  tomography	  has	  also	  been	  used	  in	  the	  detection	  of	  MMP	  activity	  
(149).	  	  A	  gadolinium-­‐related	  MMP-­‐sensitive	  probe	  has	  been	  developed	  for	  use	  with	  
magnetic	  resonance	  imaging	  (150).	  	  With	  increasing	  resolution,	  these	  techniques	  will	  
enable	   the	   assessment	   of	   biochemical	   processes	   within	   the	   tumour,	   allowing	   the	  
effect	  of	  new	  drug	  compounds	  to	  be	  measured.	  
	  
1.7.3	  Cathepsins	  
Cathepsins	  are	  a	  family	  of	  11	  proteins,	  all	  with	  a	  conserved	  active	  site	  composed	  of	  
histidine	   and	   cysteine	   residues	   (151).	   	   They	   are	   synthesised	   as	   inactive	   precursors	  
and	  are	  activated	  in	  the	  acidic	  environment	  of	  the	  lysosome.	  	  Historically,	  their	  role	  
was	  thought	  to	  be	  in	  the	  terminal	  degradation	  of	  proteins	  within	  the	  lysosome	  but	  
more	   recently	   they	   have	   been	   implicated	   in	   a	   larger	   variety	   of	   intracellular	   and	  
extracellular	  processes.	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Cathepsin	  expression	  in	  many	  tumours	  correlates	  with	  a	  poor	  prognosis	  (152).	  	  In	  the	  
RIP1-­‐Tag-­‐2	   mouse	   model	   of	   pancreatic	   cancer	   many	   of	   the	   cathepsins	   are	  
upregulated	   in	   the	   tumours	   (153).	   	   In	   humans,	   cathepsin	   E	   is	   expressed	   in	   the	  
stomach	  and	   in	   signet	  cell	   carcinomas	   (154).	   	  Cathepsin	  B	  activity	   is	   increased	   in	  a	  
genetically	   engineered	  mouse	  model	   of	   gastric	   cancer	   (155).	   	   Proteomic	  work	   has	  
identified	  that	  cathepsin	  S	  is	  upregulated	  in	  gastric	  cancer	  cell	  lines	  and	  knockdown	  
of	  this	  protein	  results	  in	  decreased	  gastric	  cancer	  cell	  migration	  and	  invasion	  (156).	  	  	  	  
	  
These	  extracellular	  protease	  systems	  interact	  with	  one	  another	  by	  cleaving	  members	  
of	   another	   family	   of	   enzymes	   (Figure	   1.6).	   	   For	   instance,	   plasmin	   stimulates	   the	  
activation	  of	  MMP-­‐3	  (157).	  	  uPA	  is	  implicated	  in	  the	  activation	  of	  MMP-­‐9	  (158)	  and	  
interacts	  with	  cathepsin	  B	   (159).	   	   Extracellular	  protease	   systems	  are	  key	  players	   in	  
the	  network	  of	  stromal-­‐epithelial	  signals	  and	  investigation	  of	  these	  will	  shed	  insight	  
into	  the	  most	  important	  paracrine	  signals	  in	  gastric	  cancer.	  















Figure	  1.6	  Interactions	  between	  extracellular	  protease	  systems.	  	  The	  MMPs	  form	  a	  
cascade	  of	  extracellular	  protease	  activity	  by	  mutual	  activation.	  	  The	  uPA	  system	  plays	  
a	   central	   role	   in	   the	   enhancement	   of	   proteolysis	   as	   uPA	   activates	   MMP-­‐9	   and	  
cathepsin	  B,	  and	  plasmin	  activates	  MMP-­‐3.	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1.5	  The	  stomach	  
	  
The	   stomach	   is	   structurally	   divided	   into	   five	   areas	   (Figure	   1.7A).	   	   The	  majority	   of	  
gastric	  cancers	  occur	   in	   the	  corpus	  and	  antrum.	   	  The	  stomach	  wall	   is	  composed	  of	  
four	   layers	   (Figure	  1.7B).	   	  The	   level	  of	   invasion	  of	   the	  primary	   tumour	   through	  the	  
wall	  of	  the	  stomach	  is	  used	  in	  the	  staging	  of	  gastric	  cancer	  (Table	  1.1).	  
	  
The	   gastric	   epithelium	   secretes	   enzymes,	   acid	   and	  hormones	   involved	   in	   digestion	  
and	  protection	  against	   infection.	   	  The	  secretion	  of	  proteolytic	  enzymes	  and	   lipases	  
commences	  the	  process	  of	  digestion.	  	  The	  digestive	  enzymes	  in	  the	  stomach	  function	  
optimally	   at	   low	   pH.	   The	   secretion	   of	   acid	   by	   the	   gastric	   epithelium	   creates	   an	  
environment	   hostile	   to	   pathogens,	   enabling	   the	   stomach	   to	   protect	   against	   food-­‐
borne	  pathogens.	  The	  production	  of	  a	  mucous	  layer	  protects	  the	  gastric	  epithelium	  
from	   the	   acidic	   stomach	   contents.	   	   The	   gastric	   epithelium	   is	   also	   capable	   of	  
absorbing	  water	  and	  ethanol.	   	  The	  secretion	  of	   intrinsic	   factor	   is	  necessary	   for	   the	  
absorption	  of	  vitamin	  B12.	  	  The	  gastric	  epithelium	  has	  invaginations	  known	  as	  gastric	  
pits	   and	   at	   the	   base	   of	   these	   the	   gastric	   glands	   produce	   the	   acid,	   enzymes	   and	  
hormones	  crucial	  to	  the	  normal	  functioning	  of	  the	  stomach	  (Figure	  1.8).	  
	  
It	  was	  thought	  that	  the	  gastric	  epithelium	  was	  renewed	  by	  a	  population	  of	  stem	  cells	  
located	   in	   the	   isthmus	   of	   gastric	   glands	   (160).	   	   Recent	   evidence	   suggests	   that	  
another	  population	  of	  cells	  located	  in	  the	  base	  of	  gastric	  glands	  is	  capable	  of	  acting	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as	   a	   reserve	   of	   stem	   cells	   increasing	   epithelial	   cell	   renewal	   in	   response	   to	   tissue	  
damage	  	  (Figure	  1.8)	  (161).	  	  It	  is	  thought	  that	  dysregulation	  of	  stem	  cell	  renewal	  is	  an	  
important	   contributing	   factor	   in	   the	   development	   of	   gastric	   cancer	   and	   stem	   cells	  
may	  represent	  a	  therapeutic	  target	  (162).	  
	  






















Figure	  1.7	  The	  Stomach.	  A,	  The	  five	  regions	  of	  the	  stomach:	  fundus,	  corpus,	  antrum,	  
cardia	   and	   pylorus.	   	   B,	   Layers	   of	   the	   stomach	   wall	   from	   inner	   to	   outer:	   mucosa,	  
submucosa,	  muscularis	  propria	  (containing	  circular,	  oblique	  and	  longitudinal	  muscle)	  
and	  serosa	  (which	  is	  continuous	  with	  the	  visceral	  peritoneum).	  
	  
















Figure	  1.8.	  Schematic	  illustrating	  a	  gastric	  pit	  and	  gland	  with	  the	  cell	  types	  involved	  
in	   gastric	   epithelial	   function.	   	   The	   epithelium	   of	   the	   fundus	   and	   corpus	   of	   the	  
stomach	  has	  invaginations	  known	  as	  gastric	  pits.	  	  Gastric	  pits	  are	  lined	  with	  mucous	  
cells,	  which	  secrete	  the	  protective	  layer	  of	  bicarbonate-­‐rich	  mucus	  which	  covers	  the	  
gastric	  epithelium.	  	  The	  base	  of	  gastric	  pits	  opens	  into	  gastric	  glands,	  which	  contain	  
cells	  responsible	  for	  the	  secretion	  of	  gastric	  enzymes	  and	  acid	  and	  for	  renewal	  of	  the	  
epithelium.	  	  Parietal	  cells	  secrete	  hydrochloric	  acid	  and	  intrinsic	  factor	  (necessary	  for	  
the	  absorption	  of	  vitamin	  B12	  in	  the	  terminal	  ileum).	  	  Chief	  cells	  secrete	  pepsinogen	  
which	   is	   converted	   to	   pepsin	   (an	   important	   digestive	   enzyme)	   in	   the	   presence	   of	  
hydrochloric	   acid.	   	   G-­‐cells	   secrete	   gastrin,	   which	   acts	   on	   neuroendocrine	   cells	   to	  
stimulate	  histamine	  release,	  which	  acts	  on	  parietal	  cells	  to	  increase	  acid	  production.	  	  
Gastrin	   also	   stimulates	   gastric	   motility.	   	   Neuroendocrine	   cells	   also	   secrete	   other	  
hormones	  such	  as	  serotonin.	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1.6	  Gastric	  cancer	  
	  
1.6.1	  Epidemiology	  of	  gastric	  cancer	  
In	  the	  UK,	  the	  incidence	  of	  gastric	  adenocarcinoma	  is	  16	  per	  100,000	  for	  men	  and	  8	  
per	  100,000	  for	  women.	   	   It	   is	  the	  ninth	  most	  commonly	  diagnosed	  cancer	   in	  males	  
and	   the	   fourteenth	   most	   common	   in	   females	   (163).	   	   Tumours	   of	   the	   corpus	   and	  
antrum	  are	  decreasing	  but	  adenocarcinomas	  of	  the	  gastric	  cardia	  are	   increasing,	   in	  
parallel	  with	  the	  increase	  in	  these	  tumours	  in	  the	  distal	  oesophagus	  (164).	  	  The	  five-­‐
year	   survival	   rate	   for	   gastric	   cancer	  was	   reported	   to	  be	  17%	   in	  2011,	  which	   is	   low	  
when	  compared	  to	  survival	  from	  other	  cancers	  such	  as	  breast	  and	  colon	  (165).	  
	  
Worldwide	   there	   are	   geographical	   variations	   in	   the	   incidence	   of	   gastric	   cancer.	  	  
These	   seem	   to	   be	   related	   to	   the	   variation	   in	   the	   incidence	   of	   risk	   factors	   for	   the	  
disease,	  diet	  and	  H.	  pylori	  infection.	  	  The	  highest	  incidence	  occurs	  in	  Eastern	  Asia	  at	  
42	  per	  100,000	  and	  the	  lowest	  in	  Southern	  Africa	  at	  2	  per	  100,000	  (166).	   	  Stomach	  
cancer	  is	  the	  second	  commonest	  cause	  of	  cancer-­‐related	  death	  worldwide	  (167).	  
	  
1.6.2	  Classification	  of	  gastric	  cancer	  
Gastric	  adenocarcinoma	  represents	  more	  than	  95%	  of	  malignant	  stomach	  tumours,	  
the	   rest	   being	   accounted	   for	   mostly	   by	   lymphomas	   and	   leiomyosarcomas.	  	  
Histological	  classification	  of	  these	  tumours	  is	  based	  on	  Lauren’s	  classification,	  where	  
the	   two	  main	   subtypes	   are	   intestinal	   or	   diffuse	   (168).	   	   The	   intestinal	   type	   is	  more	  
frequently	  associated	  with	  H.	  pylori	  infection,	  while	  the	  diffuse	  type	  affects	  females	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and	  young	  patients	  more	  frequently.	  	  The	  TNM	  (tumour,	  nodes,	  metastasis)	  staging	  
system	  is	  used	  to	  assess	  the	  extent	  of	  the	  primary	  tumour’s	  local	  invasion,	  its	  spread	  
to	  lymph	  nodes	  and	  the	  burden	  of	  metastatic	  disease	  (Table	  1.1).	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Primary	  tumour	  (T)	   T0:	  	  	  no	  evidence	  of	  primary	  tumour	  
T1:	  	  tumour	  invades	  lamina	  propria	  or	  muscularis	  mucosa	  
(T1a)	  or	  submucosa	  (T1b)	  
T2:	  	  	  tumour	  invades	  muscularis	  propria	  
T3:	   tumour	   penetrates	   subserosal	   connective	   tissues	  
without	  invasion	  of	  serosa	  
T4:	   	   tumour	   invades	   serosa	   (T4a)	   or	   adjacent	   structures	  
(T4b)	  
Lymph	  node	  status	  (N)	   N0:	  no	  metastasis	  to	  lymph	  nodes	  
N1:	  metastasis	  in	  1-­‐2	  regional	  lymph	  nodes	  
N2:	  metastasis	  in	  3-­‐6	  regional	  lymph	  nodes	  
N3:	  metastasis	  in	  7	  or	  more	  regional	  lymph	  nodes	  
Metastasis	  (M)	   M0:	  no	  distant	  metastasis	  
M1:	  distant	  metastasis	  
	  
Table	   1.1	   TNM	   staging	   system	   for	   gastric	   cancer	   showing	   the	   staging	   of	   disease	  
based	   on	   the	   extent	   of	   the	   primary	   tumour,	   the	   spread	   to	   lymph	   nodes	   and	   any	  
metastatic	  disease	  (169).	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1.6.3	  Management	  of	  gastric	  cancer	  
The	  only	  curative	  procedure	  for	  gastric	  cancer	  is	  surgical	  resection,	  involving	  either	  a	  
total	   or	   partial	   gastrectomy.	   	   This	   is	   sometimes	   combined	   with	   adjuvant	   or	   neo-­‐
adjuvant	  chemotherapy	  (170).	   	  Surgery	  is	  most	  successful	   if	  the	  tumour	  is	  confined	  
to	  the	  mucosa	  or	  submucosa,	  but	  only	  a	  small	  percentage	  of	  tumours	  are	  still	  at	  this	  
early	   stage	   at	   the	   time	   of	   diagnosis.	   	   More	   than	   50%	   of	   patients	   have	   locally	  
advanced	  or	  metastatic	  disease	  at	  presentation	  (171).	  	  In	  this	  setting,	  chemotherapy	  
and	  radiotherapy	  are	  used	  to	  prolong	  survival	  by	  months	  or	  in	  the	  palliative	  setting,	  
to	  alleviate	  symptoms	  of	  metastatic	  disease	  or	  from	  local	  recurrence	  (172).	  
	  
1.6.4	  Aetiology	  of	  gastric	  cancer	  
Correa	  et	  al	  proposed	  in	  1975	  that	  chronic	  inflammation	  of	  the	  gastric	  mucosa	  led	  to	  
gastric	   atrophy,	   causing	   intestinal	   metaplasia	   and	   eventually	   leading	   to	   neoplasia	  
over	  decades	  (173).	  	  Until	  the	  discovery	  of	  H.	  pylori	  by	  Marshall	  and	  Warren	  in	  1984	  
(174),	  the	  cause	  of	  gastric	  inflammation	  was	  thought	  to	  be	  environmental.	  	  It	  is	  now	  
known	   that	   H.	   pylori	   infection	   increases	   the	   risk	   of	   gastric	   cancer	   (175).	   	   Other	  
patients	   at	   risk	   of	   gastric	   cancer	   include	   those	   who	   have	   undergone	   a	   partial	  
gastrectomy	   or	   vagotomy	   and	   those	   with	   chronic	   atrophic	   gastritis	   (176).	   	   This	   is	  
thought	   to	   be	   related	   to	   chronic	   inflammation	   and	   hypochlorhydria.	   	   Like	   many	  
other	  cancers,	  the	  incidence	  of	  gastric	  cancer	  increases	  with	  age	  (162).	  	  A	  diet	  rich	  in	  
preserved	  or	  pickled	  foods	  was	  thought	  to	  be	  associated	  with	  a	  higher	  risk	  of	  gastric	  
cancer	  due	   to	   their	  high	  nitrosamine	  content.	   	  Recent	  evidence	   suggests	   that	  high	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dietary	  nitrates	  and	  nitrites	  may	  not	  necessarily	  cause	  gastric	  cancer	  (177).	  	  Cigarette	  
smoking	  increases	  the	  risk	  of	  developing	  gastric	  cancer	  by	  nearly	  two-­‐fold	  (178).	  
	  
In	   some	   cancers,	   a	   multi-­‐step	   sequence	   of	   carcinogenesis	   has	   been	   characterised	  
involving	   the	   accumulation	   of	   genetic	   lesions	   resulting	   in	   phenotypic	   changes,	   for	  
example	  the	  adenoma-­‐carcinoma	  sequence	  in	  colon	  cancer	  (179).	  	  In	  gastric	  cancer,	  
however,	  there	  is	  histopathological	  and	  molecular	  heterogeneity	  that	  precludes	  the	  
identification	  of	  a	   common	  sequence	   (180).	   	   Loss	  of	  expression	  of	   certain	  genes	   is	  
associated	  with	  gastric	  cancer.	  	  Germ-­‐line	  mutations	  in	  the	  CDH1	  gene	  (encoding	  E-­‐
Cadherin)	  predispose	  to	  a	  hereditary	  form	  of	  gastric	  cancer	  (181).	  	  Loss	  of	  expression	  
of	   the	   transcription	   factor	   RUNX3	   in	   gastric	   cancer	   cells	   is	   associated	  with	   gastric	  
cancer	   formation	   and	   progression	   (182).	   	  Mutations	   of	   p53,	   an	   event	   common	   to	  
many	  cancers,	  occur	  in	  up	  to	  70%	  of	  gastric	  cancers,	  with	  a	  wide	  distribution	  of	  these	  
mutations	  throughout	  the	  gene	  (183).	  
	  
1.6.4.1	  H.	  pylori	  
H.	   pylori	   is	   a	   gram-­‐negative	   bacillus	   which	   chronically	   infects	   the	   gastric	   mucosa.	  	  
Infection	   increases	   the	   risk	   of	   developing	   gastric	   cancer	   (176).	   	   It	   is	   a	   genetically	  
diverse	   organism,	   and	   infection	   with	   strains	   positive	   for	   the	   CagA	   pathogenicity	  
island	  are	  particularly	  associated	  with	  higher	  grades	  of	  inflammation	  and	  the	  highest	  
risk	   of	   cancer	   (184).	   	   H.	   pylori	   activates	   Wnt	   signalling	   in	   gastric	   epithelial	   cells,	  
causing	  cell	  cycle	  disruption	  (185).	  	  Infection	  activates	  stromal	  fibroblasts,	  increasing	  
the	  myofibroblast	  content	  in	  the	  stomach	  wall	  (42,	  147).	  	  Increased	  epithelial	  MMP-­‐7	  
expression	  in	  H.	  pylori	  may	  contribute	  to	  epithelial	  cell	  proliferation	  by	  increasing	  the	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availability	  of	  myofibroblast-­‐derived	  growth	  factors	  (147).	  	  H.	  pylori	  stimulates	  PAI-­‐1,	  
uPA	   and	   uPAR	   expression	   in	   gastric	   epithelial	   cells,	   stimulating	   epithelial	   cell	  
proliferation	  (186).	  
	  
1.6.5	  Mouse	  models	  of	  gastric	  cancer	  
In	  gastric	  cancer,	  the	  use	  of	  mice	  as	  model	  organisms	  requires	  caution,	  as	  there	  are	  
important	  differences	  in	  gastric	  anatomy	  between	  mice	  and	  humans.	   	  For	  instance,	  
the	  mouse	   fundus	   is	   lined	  with	   squamous	  epithelium	   rather	   than	   glandular.	   	  Mice	  
rarely	  spontaneously	  develop	  gastric	  cancer,	  so	  early	  models	  attempted	  to	  increase	  
the	  likelihood	  of	  a	  cancer	  developing	  by	  administering	  chemical	  carcinogens	  such	  as	  
nitrosamines	   (187).	   	   With	   the	   discovery	   of	   H.	   pylori	   and	   its	   effect	   on	   gastric	  
carcinogenesis,	   the	   focus	   shifted	   to	   mimicking	   the	   effects	   of	   this	   bacterium	   on	  
gastric	   mucosa.	   	   Few	   strains	   of	  Helicobacter	   infect	   the	   mouse	   stomach,	   with	   the	  
notable	   exception	  of	  H.	   felis,	  where	   infection	   results	   in	   a	   similar	   progression	   from	  
inflammation,	  to	  atrophy,	  metaplasia,	  dysplasia	  and	  finally	  neoplasia	  as	  is	  seen	  in	  H.	  
pylori	   infection	  in	  humans	  (188).	  	  However,	  H.	  felis	   lacks	  the	  cagA	  gene	  responsible	  
for	   causing	  ulcers	   in	   humans,	   so	   the	  mechanisms	  by	  which	   it	   causes	   inflammation	  
are	  almost	  certainly	  different	  from	  those	  in	  humans.	  	  
	  
Genetically	   engineered	   mice	   have	   struggled	   to	   replicate	   human	   gastric	   cancer.	  	  
Gastric	  cancer	  is	  a	  genetically	  heterogeneous	  disease,	  making	  it	  difficult	  to	  replicate	  
the	   disease	   by	   mutating	   one	   or	   two	   genes.	   	   Early	   genetically	   engineered	   models	  
mutated	  genes	  not	  known	  to	  be	  associated	  with	  gastric	  cancer,	  such	  as	  the	  SV40	  T	  
antigen	  (189),	  and	  the	  resulting	  lesions	  did	  not	  follow	  the	  sequence	  of	  development	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commonly	   observed	   in	   gastric	   cancer.	   	   INS-­‐GAS	  mice	   (where	   the	   insulin	   promoter	  
has	   been	   inserted	   upstream	   of	   the	   coding	   region	   for	   gastrin	   leading	   to	  
hypergastrinaemia	   due	   to	   expression	   in	   pancreatic	   β-­‐cells)	   develop	   gastritis	   and	  
metaplasia	   which	   is	   accelerated	   by	  H.	   felis	   infection	   (190).	   	   The	   H/K-­‐ATPase-­‐IL-­‐1β	  
mouse	  (over-­‐expressing	  IL-­‐1β	  in	  the	  stomach)	  also	  mimics	  human	  gastric	  cancer,	  and	  
IL-­‐1β	  mutations	  have	  been	  identified	  in	  gastric	  cancers	  (191).	  
	  
Genetically	   engineered	  mouse	  models	   have	   the	   advantage	   of	  working	   in	   a	   system	  
with	  an	  intact	  host	  response	  including	  the	  immune	  reaction.	   	  However,	  as	  they	  are	  
developed	   from	   a	   single	   genetic	   lesion	   they	   fail	   to	   replicate	   the	   complexity	   and	  
variety	  of	  lesions	  in	  gastric	  cancer.	  
	  
Human	   cells	   taken	   from	   gastric	   cancers	   can	   be	   used	   in	  mouse	  models	   if	   they	   are	  
injected	   into	   strains	   of	  mice	   lacking	   in	   components	   of	   the	   immune	   system.	   	  Nude	  
athymic	   mice	   are	   lacking	   in	   mature	   T	   cells,	   but	   retain	   B	   cells,	   dendritic	   cells	   and	  
granulocytes.	  	  They	  have	  increased	  natural	  killer	  cells	  and	  macrophages.	  	  NOD/SCID	  
mice	  are	  more	  profoundly	  immunodeficient	  and	  lack	  both	  B	  and	  T	  cells.	  	  	  
	  
Injection	  of	  cells	  subcutaneously	   is	  quick,	   technically	  simple	  and	  results	   in	   tumours	  
which	  are	  easy	  to	  monitor.	  	  However,	  the	  subcutaneous	  tissue	  will	  not	  fully	  replicate	  
the	   characteristics	   of	   the	   tissue	   of	   origin.	   	   Orthotopic	   implantation	   of	   tumours	   is	  
more	  invasive,	  time-­‐consuming	  and	  technically	  challenging.	  	  Often	  the	  site	  is	  difficult	  
to	  monitor	  without	  the	  use	  of	  in	  vivo	  imaging.	  	  These	  tumours	  mirror	  the	  behaviour	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of	  the	  original	  tumour	  more	  accurately	  and	  in	  many	  cases	  an	  orthotopic	  model	  is	  the	  
only	  way	  to	  replicate	  the	  pattern	  of	  metastasis	  seen	  in	  the	  human	  disease.	  
	  
Xenografts	  created	  with	  the	  use	  of	  human	  cell	  lines	  show	  a	  poor	  correlation	  with	  the	  
response	   to	   therapy	   of	   the	   primary	   disease	   (192).	   	   The	   use	   of	   primary	   cells	   in	  
xenograft	  experiments	   increases	   the	   correlation	  between	   the	   xenograft’s	   response	  
to	   therapy	   and	   that	   of	   the	   primary	   tumour	   (193).	   	   In	   vivo	   modelling	   of	   stromal-­‐
epithelial	  interactions	  will	  be	  discussed	  in	  the	  next	  section.	  
	  
1.8	  Modelling	  stromal-­‐epithelial	  interactions	  
	  
The	  first	  insights	  in	  the	  investigation	  of	  stromal-­‐epithelial	  interactions	  came	  from	  the	  
field	   of	   developmental	   biology,	   where	   reciprocal	   signalling	   between	   mesenchyme	  
(which	   later	  becomes	   stroma	   in	   the	  adult)	   and	  epithelium	   results	   in	   the	  activation	  
differentiation	   programs	   and	   the	   development	   of	   tissues	   and	   organs.	   	   An	   early	  
example	  of	  this	  was	  the	  finding	  that	  stromal-­‐epithelial	  interactions	  were	  necessary	  in	  
directing	  the	  morphogenesis	  of	  the	  male	  or	  female	  urogenital	  system	  in	  response	  to	  
sex	  hormones	  (194).	  	  The	  cancer	  stroma	  is	  composed	  of	  cells	  of	  mesenchymal	  origin,	  
and	  similarities	  in	  behaviour	  were	  noted	  between	  the	  mesenchyme	  in	  development	  
and	  the	  stroma	  in	  cancer	  (195).	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1.8.1	  In	  vitro	  models	  
Since	  the	  first	  attempts	  at	  cell	  culture	  in	  the	  nineteenth	  century	  	  (196)	  this	  technique	  
has	   become	   established	   as	   the	   fastest	   and	   easiest	   way	   to	   study	   cell	   behaviour.	  	  
Primary	   cells	   (those	  harvested	   from	   tissues	  or	  organs)	  undergo	   senescence	  after	   a	  
few	   passages,	   limiting	   their	   long-­‐term	   use.	   	   This	   can	   be	   circumvented	   by	  
immortalisation	   of	   the	   cells	   using	   viruses.	   	   The	   present	   investigation	   used	  MKN45	  
cells,	   which	   are	   derived	   from	   a	   poorly	   differentiated	   metastatic	   gastric	  
adenocarcinoma	   (197).	   	  AGS	  cells	  were	  also	  used;	   these	  are	  derived	   from	  a	  gastric	  
adenocarcinoma	   (198).	   	  Although	  normal	   fibroblast	   cell	   lines	  exist,	   they	  are	  not	  of	  
gastric	   origin	   so	   this	   study	   used	   primary	   gastric	   myofibroblasts	   harvested	   from	  
gastric	  adenocarcinoma	  tissue.	  	  	  
	  
Defining	   the	   signals	   between	   stromal	   and	   epithelial	   cells	   begins	   with	   the	  
examination	  of	  the	  range	  of	  secreted	  proteins	  in	  the	  medium	  of	  cells.	  	  Studying	  the	  
response	   of	   cells	   to	   treatment	   with	   conditioned	   media	   from	   another	   cell	   type	   is	  
useful	   in	   determining	   the	   effect	   of	   stromal-­‐epithelial	   interactions.	   	   However,	   two-­‐
dimensional	  cell	  monolayers	  do	  not	  accurately	  replicate	  in	  vivo	  cell	  morphology	  and	  
this	  system	  does	  not	  allow	  the	  study	  of	  short-­‐range	  or	  short-­‐lived	  signals,	  for	  which	  
direct	  cell-­‐cell	  contact	  may	  be	  necessary.	  	  
	  
Organotypic	   cultures	   are	   three-­‐dimensional	   co-­‐culture	   systems	  where	   cells	   are	   re-­‐
aggregated	   into	   an	   organ-­‐appropriate	   architectural	   arrangement	   and	   embedded	  
within	   a	   synthetic	   basement	   membrane.	   	   There	   is	   evidence	   to	   show	   that	   matrix	  
attachment	  is	  necessary	  for	  the	  maintenance	  of	  cell	  differentiation	  and	  cell	  polarity	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(199).	   	  These	  systems	  were	  first	  developed	  in	  the	  1980s	  (200)	  and	  are	  now	  used	  to	  
assess	   the	   response	   to	   drug	   treatment	   (201).	   	   It	   is	   important	   to	   remember	   that	  
although	   good	   in	   vitro	   models	   of	   tumorigenic	   processes	   (proliferation,	   invasion,	  
migration)	   do	   exist,	   some	   aspects	   of	   tumorigenesis	   such	   as	   metastasis	   cannot	   be	  
modelled	  in	  vitro.	  
	  
1.8.2	  In	  vivo	  models	  
In	  vivo	  modelling	  of	   stromal-­‐epithelial	   interactions	  poses	  a	  particular	  challenge.	   	   In	  
genetically	  modified	  models	  of	  gastric	  cancer	  the	  stroma	  arises	  from	  the	  host	  mouse.	  	  
Comparison	   of	   any	   stromal	   reaction	   therefore	   relies	   on	   similarities	   between	   the	  
mouse	  immune	  response,	  vasculature	  and	  recruitment	  of	  myofibroblasts	  and	  those	  
of	   humans.	   	   Additionally,	   the	   use	   of	   genetically	   modified	   mice	   has	   proven	  
challenging	  owing	  to	   the	   lack	  of	  organ-­‐specific	  promoters	  allowing	  the	  targeting	  of	  
stromal	  genes.	  	  The	  role	  of	  the	  stromal	  TGF-­‐	  type	  II	  receptor	  was	  however	  elucidated	  
by	  creating	  a	  conditional	  knockout	  in	  mouse	  fibroblasts	  (202).	  	  In	  xenograft	  models,	  
stromal	   cells	   can	   be	   co-­‐injected	   with	   the	   cancer	   cells	   (48),	   enabling	   a	   degree	   of	  
control	  over	  stromal	  composition.	  	  The	  use	  of	  immunocompromised	  animals	  for	  this	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1.9	  In	  vivo	  imaging	  	  
	  
1.9.1	  History	  of	  imaging	  
For	  many	   years	  microscopy	  has	   provided	   a	   foundation	   for	  much	  of	   cell	   and	   tissue	  
biology.	   	   However,	   conventional	   microscopy	   is	   limited	   by	   a	   visualisation	   depth	   of	  
10μm,	  necessitating	  sectioning	  prior	  to	  examination.	  	  Transparent	  organisms	  such	  as	  
C.	   elegans	   or	  monolayers	   of	   cells	   can	   be	   inspected	  whilst	   alive,	   and	   consequently	  
have	  become	  popular	  model	  systems.	   	  The	  reason	  for	  the	   limited	  depth	  of	  focus	   is	  
the	   high	   light	   scattering	   seen	   in	   the	   visible,	   UV	   and	   near	   infra-­‐red	   parts	   of	   the	  
electromagnetic	   spectrum	   as	   photons	   are	   most	   able	   to	   interact	   with	   cellular	  
components	  at	  these	  wavelengths	  (203).	  	  Light	  scattering	  creates	  image	  blur,	  and	  the	  
more	   scattering	   events	   occur,	   the	   poorer	   the	   image	   quality.	   	   Confocal	  microscopy	  
partially	  overcomes	  this	  problem,	  and	  extends	  the	  depth	  of	  imaging	  to	  hundreds	  of	  
μm	   in	   some	   tissues.	   	   It	   achieves	   this	   by	   taking	   into	   account	   the	   average	   angle	   by	  
which	  photons	  are	  scattered	  and	  calculates	  the	  distance	  a	  photon	  travels	  before	  its	  
direction	  of	  travel	  is	  no	  longer	  related	  to	  its	  original	  direction	  of	  travel	  (204).	  
	  
The	  need	  for	  thin	  sections	  of	  tissue	  had	  largely	  precluded	  the	  use	  of	  microscopy	  in	  
live	   animals	   until	   laser	   scanning	   confocal	   microscopy	   and	   two-­‐photon	  microscopy	  
reduced	  light	  scattering	  further,	  enabling	  the	  visualisation	  of	  virtual	  tissue	  sections	  in	  
intact	   tissues.	   	   This	   allowed	   microscopy	   to	   be	   used	   in	   vivo	   in	   an	   unperturbed	  
environment,	  with	   tissue	  penetration	  reaching	  up	  to	  a	   few	  mm.	   	  These	   techniques	  
have	   been	   used	   to	   examine	   the	   activity	   of	   fluorescent	   proteins,	   probes	   and	   dyes	  
(205).	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Imaging	  deeper	  than	  a	  few	  mm	  in	  tissue	  required	  further	  approaches	  to	  reduce	  light	  
scattering.	   	   Tissues	   can	   be	   treated	   with	   chemicals	   to	   minimize	   the	   scattering	   of	  
photons,	   but	   this	   is	   toxic	   to	   cells	   and	   therefore	   only	   appropriate	   for	   post-­‐mortem	  
examination	   (206).	   	  The	  reduction	   in	  scattering	  does,	  however,	  make	   it	  possible	   to	  
image	   specimens	   by	   measuring	   the	   transillumination	   of	   light	   through	   them	   and	  
processing	   of	   these	   data	   using	   3D	   reconstruction	   algorithms	   to	   create	   3D	   images.	  	  
This	  is	  known	  as	  optical	  tomography.	  
	  
1.9.2	  Fluorescence	  Molecular	  Tomography	  (FMT)	  
Improvements	  in	  imaging	  methods	  which	  account	  for	  photon	  diffusion	  beyond	  a	  few	  
mm	   in	   combination	   with	   the	   development	   of	   optical	   reporters	   of	   biological	  
processes	   have	   allowed	   the	   visualisation	   of	   deeper	   tissues	   and	  whole	   organs.	   	   At	  
these	  depths,	   light	  in	  the	  visual	  spectrum	  is	  absorbed	  by	  melanin	  and	  haemoglobin	  
and	   there	   is	   a	  high	  degree	  of	  photon	   scattering.	   	  Beyond	  wavelengths	   longer	   than	  
1100nm,	   however,	   light	   absorption	   by	  water	   precludes	   adequate	   signal	   detection.	  	  
This	  makes	  the	  most	  favourable	  window	  for	  animal	  tissue	  imaging	  between	  600	  and	  
1000nm.	   	  Fluorescence	  molecular	  tomography	  (FMT)	  combines	  optical	  tomography	  
with	  fluorescence,	  taking	  advantage	  of	  the	  low	  light	  scattering	  and	  tissue	  absorption	  
experienced	   in	   the	   600-­‐800nm	   range.	   	   It	   uses	   data	   obtained	   from	   the	   optical	  
illumination	  of	  a	  specimen	  over	  many	  different	  angles	  and	  combines	  this	  to	  build	  a	  
quantitative	  3D	  representation	  of	  the	  fluorescence	  from	  a	  reporter,	  illuminating	  the	  
surface	   using	   point	   light	   sources	   and	   different	   mathematical	   models	   of	   photon	  
behaviour	   than	   optical	   tomography	   (207 )	   (Figure	   1.9).	   This	   technique	   permits	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imaging	   of	   biological	   processes	   such	   as	   protease	   activity	   through	   the	   use	   of	  
activatable	  fluorochromes.	  	  These	  injectable	  molecules	  mimic	  the	  protease	  substrate	  
and	   upon	   cleavage	   by	   the	   enzyme	   of	   interest,	   emit	   light	   in	   the	   near	   infra-­‐red	  
spectrum	  (208).	  	  In	  order	  to	  improve	  the	  resolution	  of	  FMT,	  data	  obtained	  from	  this	  
technique	   can	   be	   combined	   with	   more	   detailed	   anatomical	   information	   from	   a	  
different	   imaging	  modality,	   such	   as	   computed	   tomography	   (CT)	   (209)	   or	  magnetic	  
resonance	  imaging	  (MRI)	  (210).	  	  	  
















Figure	   1.9	   FMT	   imaging.	   	   The	   anaesthetised	  mouse	   is	   immobilised	   in	   the	   imaging	  
cassette.	  	  Light	  is	  directed	  at	  the	  animal	  from	  different	  projections	  and	  the	  signal	  is	  
detected	  by	   the	  charge-­‐coupled	  device	   (CCD)	  camera	   from	  multiple	  points.	   	  Paired	  
absorption	   and	   fluorescence	   acquisition	   data	   are	   normalised	   according	   to	  
algorithmic	  models	  of	  photon	  transport	  in	  tissue.	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The	   appeal	   of	   harnessing	   red-­‐shifted	   fluorescent	   proteins	   for	   in	   vivo	   imaging	   applications	  
has	  led	  to	  intense	  research	  into	  the	  development	  of	  more	  intensely	  fluorescent	  proteins	  in	  
the	   far-­‐red	   range.	   	   This	   has	   proved	   to	   be	   challenging,	   due	   to	   difficulties	   with	   poor	   light	  
intensity,	  insufficiently	  red-­‐shifted	  emission	  spectra	  and	  detrimental	  effects	  on	  cell	  viability	  
following	   transfection.	   	   Using	   site-­‐directed	   and	   random	   mutagenesis,	   proteins	   such	   as	  
mCherry	  and	  mPlum	  have	  been	  altered	  further	  to	  shift	  their	  excitation	  and	  emission	  peaks	  
beyond	   600nm	   (211).	   	   E2-­‐Crimson	   was	   created	   in	   this	   manner	   from	   the	   red	   fluorescent	  
protein	  dsRed	  Express2	  (212).	  	  	  
	  
The	  main	  advantage	  of	  FMT	  is	  its	  ability	  to	  detect	  fluorescent	  reporters	  of	  cellular	  processes	  
and	  track	  fluorescent	  cells	  at	  a	  variety	  of	  wavelengths,	  enabling	  the	  visualization	  of	  multiple	  
processes	  simultaneously.	  	  Other	  imaging	  modalities,	  such	  as	  CT	  and	  MRI,	  do	  not	  have	  such	  
varied	  reporters	  and	  are	  limited	  to	  reporting	  anatomical	  features.	  	  Combined	  with	  positron	  
emission	   tomography	   (PET)	   CT	   can	   highlight	   areas	   of	   high	   glucose	   uptake	   using	   the	  
radiotracer	  fluorodeoxyglucose.	  	  MRI	  can	  also	  estimate	  local	  blood	  flow,	  which	  in	  the	  brain	  
can	  highlight	  areas	  of	  activity.	  These	  represent	  the	  only	  visualisations	  of	  cellular	  processes	  in	  
widespread	   clinical	   use.	   	   Emerging	   clinical	   applications	   of	   FMT	   include	   mapping	   the	  
lymphatic	  spread	  of	  tumours,	  accurate	   identification	  of	  tumour	  margins	  and	  as	  an	  adjunct	  
to	  endoscopic	  or	  radiological	  imaging	  to	  improve	  the	  diagnostic	  yield	  (213).	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1.10	  Overview	  of	  the	  present	  study	  
	  
This	   investigation	   focuses	  on	   the	   role	  of	  myofibroblasts	   in	   gastric	   cancer.	   	   These	   cells	   are	  
known	   to	  produce	  PAI-­‐1	   (214),	   an	   inhibitor	  of	   the	   serine	  protease	  urokinase	  plasminogen	  
activator	   (uPA),	   as	   well	   as	   MMPs	   (215).	   	   	   An	   in	   vivo	   subcutaneous	   xenograft	   model	   of	  
stroma-­‐stimulated	   tumour	   growth	   has	   been	   developed	   together	   with	   an	   in	   vitro	   3D	  
organotypic	  culture	  modelling	  myofibroblast-­‐stimulated	  cancer	  cell	  invasion;	  together	  these	  
were	  used	  to	  assess	  the	  contribution	  of	  extracellular	  proteases.	  	  Finally,	  the	  recruitment	  of	  
MSCs	   to	   oesophageal	   xenografts	   was	   assessed	   and	   the	   role	   that	   chemerin-­‐ChemR23	  
signalling	  plays	  in	  this	  process	  was	  studied	  using	  a	  ChemR23	  antagonist.	  
	  
1.11	  Aims	  	  
1.	   To	   characterise	   the	   expression	   of	   PAI-­‐1	   in	   gastric	   cancer	   cells	   and	  myofibroblasts	   and	  
create	  cancer	  cells	  overexpressing	  PAI-­‐1	  
2.	   To	   create	   an	   in	   vivo	   model	   of	   stromal-­‐epithelial	   signalling,	   and	   characterise	   the	  
contribution	  of	  myofibroblasts	  to	  tumour	  growth.	  
3.	  To	  compare	  MMP	  and	  cathepsin	  activity	  in	  xenografts	  containing	  myofibroblasts	  to	  those	  
without.	  
4.	   To	   assess	   the	   effect	   of	   a	   ChemR23	   antagonist	   on	   recruitment	   of	  MSCs	   to	   oesophageal	  
xenografts	  containing	  myofibroblasts.	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2.1.1	  Cell	  culture	  
AGS	   and	  MKN45	   gastric	   cancer	   cell	   lines	  were	   obtained	   from	   the	   American	   Type	   Culture	  
Collection	   (Manassas,	   VA,	   USA)	   and	   RIKEN	   (Tsukuba,	   Ibaraki,	   Japan)	   respectively.	   	   OE21	  
oesophageal	   squamous	   carcinoma	   cells	   were	   from	   American	   Type	   Culture	   Collection.	  	  
Human	   MSCs	   were	   from	   Lonza	   (Castleford,	   UK).	   	   Dulbecco’s	   Modified	   Eagle’s	   Medium	  
(DMEM),	   antibiotic-­‐antimycotic	   solution,	   non-­‐essential	   amino	   acid	   solution,	   penicillin-­‐
streptomycin	   solution,	   erythrosin	   B	   and	   trypsin-­‐EDTA	   0.25%	   were	   obtained	   from	   Sigma	  
(Poole,	  UK).	  	  The	  MycoAlertTM	  Kit	  was	  purchased	  from	  Lonza.	  Fetal	  bovine	  serum	  (FBS)	  was	  




Male	   6-­‐week	   old	   nude	   mice	   (BALB/c	   nu/nu)	   were	   purchased	   from	   Charles	   River	  
(Wilmington,	  MA,	  USA).	   	  Heparin	  sodium	  1000units/1ml	  vial	  was	  obtained	   from	  the	  Royal	  
Liverpool	  Hospital.	  	  Isoflurane	  for	  general	  anaesthesia	  was	  from	  O’Neill	  Medicalia	  (Liverpool,	  
UK).	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2.1.3	  Fluorescence	  molecular	  tomography	  
ProSense	   750	   FASTTM,	   Cat	   B	   750	   FASTTM	   and	  MMPSense	   750	   FASTTM	  were	   obtained	   from	  
Perkin	  Elmer	  (Cambridge,	  UK).	  CellVue®	  Claret	  and	  PKH67	  green	  fluorescent	  cell	  linker	  mini-­‐
kits	  were	  purchased	  from	  Sigma.	   	   	  E2-­‐Crimson	  plasmid	  was	  from	  Clontech	  (Saint-­‐Germain-­‐
en-­‐Laye,	  France).	  	  CCX832	  in	  corn	  oil	  and	  vehicle	  were	  gifts	  from	  ChemoCentryx	  (Mountain	  
View,	  CA,	  USA).	  	  	  
	  
2.1.4	  Immunofluorescence	  
Bovine	   serum	   albumin	   (BSA)	   and	   donkey	   serum	   were	   obtained	   from	   Jackson	   Immuno	  
Research	   Laboratories	   (Suffolk,	   UK).	   Vectashield	   with	   or	   without	   4',6-­‐diamidino-­‐2-­‐
phenylindole	   (DAPI)	   was	   purchased	   from	   Vector	   laboratories	   (Peterborough,	   UK).	  	  	  
Novocastra	   mouse	   monoclonal	   anti-­‐human	   vimentin	   intermediate	   filament	   antibody	   was	  
from	   Leica	   Biosystems	   (Newcastle-­‐upon-­‐Tyne,	   UK).	   	   Guinea	   pig	   polyclonal	   anti-­‐vimentin	  
antibody	  was	   from	   Fitzgerald	   Industries	   (North	   Acton,	  MA,	   USA).	   	   NaCl	   and	   HEPES	   (4-­‐(2-­‐
hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	   acid)	   were	   from	   Sigma.	   	   Triton-­‐X-­‐100	   was	  
obtained	   from	   Sigma.	   	   Paraformaldehyde	   (PFA)	   was	   from	   Agar	   Scientific	   (Stansted,	   UK).	  	  
Cryo-­‐M-­‐Bed	  and	  Cryospray	  were	  obtained	   from	  VWR	   Jencons	   (Lutterworth,	  UK).	   	   Thermo	  
scientific	   microscope	   slides	   with	   polysine	   adhesion	   and	   cork	   discs	   were	   purchased	   from	  
Fisher	  Scientific	  (Loughborough,	  UK).	  	  Sucrose	  was	  purchased	  from	  Sigma.	  
	  
2.1.5	  EdU	  
The	  EdU	  Click-­‐It®	  kit	  was	  purchased	  from	  Invitrogen.	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2.1.6	  Adhesion	  assays	  
PBS	   containing	   CaCl2/MgCl2	   was	   purchased	   from	   Invitrogen.	   	   Crystal	   violet,	   H2SO4	   and	  
NaH2PO4	  were	  from	  Sigma.	  	  Human	  vitronectin	  from	  human	  plasma	  was	  obtained	  from	  BD	  
Biosciences	  (San	  Jose,	  CA,	  USA).	  
	  
2.1.7	  Transfection	  of	  MKN45	  cells	  
TransFastTM	   transfection	   reagent	   cationic	   lipid	  was	  obtained	   from	  Promega	   (Madison,	  WI,	  
USA).	  	  Calbiochem	  G418	  sulphate	  was	  purchased	  from	  Merck	  KGaA	  (Darmstadt,	  Germany).	  	  
Human	   PAI-­‐1	   overexpressing	   plasmid	   was	   a	   gift	   from	   Prof.	   Rod	   Dimaline,	   University	   of	  
Liverpool.	  	  Cloning	  cylinders	  were	  from	  Sigma.	  
	  
2.1.8	  Scratch	  migration	  assays	  
Calbiochem	  recombinant	  human	  mutant	  plasminogen	  activator	  inhibitor-­‐1	  was	  from	  Merck	  
KGaA.	  
	  
2.1.9	  Boyden	  chamber	  migration	  assays	  
BD	  Control	  Cell	  Culture	  Inserts	  were	  purchased	  from	  BD	  Biosciences.	  	  Diff-­‐Quick	  staining	  kit	  
was	  obtained	  from	  Dade	  Behring	  Inc.	  (Glasgow,	  DE,	  USA).	  
	  
2.1.10	  PAI-­‐1	  ELISA	  
The	  Imubind	  Tissue	  PAI-­‐1	  ELISA	  kit	  was	  purchased	  from	  American	  Diagnostica	  (Stamford,	  CT,	  
USA).	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2.1.11	  RNA	  extraction,	  reverse	  transcription	  and	  qPCR	  
The	  RNase-­‐Free	  DNase	   set	   and	   the	   RNeasy	  Mini	   Kit	  were	   from	  Qiagen	   (Manchester,	  UK).	  	  
Precision	  2x	  real	  time	  PCR	  master	  mix	  with	  or	  without	  SYBRgreen	  was	  from	  PrimerDesign,	  
(Southampton,	  UK).	  	  RNAsin,	  dNTPs,	  oligoDT	  and	  AMV	  reverse	  transcriptase	  were	  obtained	  
from	  Promega.	  	  Primers	  and	  probes	  were	  obtained	  from	  Eurogentec	  (Liege,	  Belgium).	  
	  
2.1.11	  Organotypic	  co-­‐cultures	  	  
Collagen	   Type	   1	   Rat	   Tail	   extracted	   from	   rat	   tail	   tendons	   was	   obtained	   from	   Millipore	  
(Billerica,	  MA,	  USA).	   	   BD	  MatrigelTM	  Basement	  Membrane	  Matrix	  was	  purchased	   from	  BD	  
Biosciences.	  	  Stainless	  steel	  mesh	  was	  purchased	  from	  Bracon	  (Etchingham,	  UK).	  	  Gauze	  was	  
a	  gift	   from	  Jag	  Dhanda,	  University	  of	  Liverpool,	  UK.	   	  Glutaraldehyde	  25%,	  10	  x	  DMEM	  and	  
NaOH	  were	  obtained	   from	  Sigma.	   	  Calbiochem	  MMP-­‐2	   Inhibitor	   I	  and	  MMP-­‐3	   Inhibitor	   IV	  
were	  from	  Millipore.	  
	  
2.1.11	  Luciferase	  promoter-­‐reporter	  assays	  
A	  Dual-­‐Luciferase®	  Reporter	  Assay	  System	  was	  purchased	  from	  Promega.	  	  PMA	  (phorbol	  12-­‐
myristate-­‐13-­‐acetate)	  was	  from	  Sigma.	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2.2	  Methods	  	  
2.2.1	  Culture	  of	  gastric	  cancer	  cell	  lines	  
MKN45	  and	  AGS	  cells	  were	   cultured	   in	  DMEM	  containing	  10%	  v/v	  FBS,	  2%	  v/v	  Antibiotic-­‐
Antimycotic,	  1%	  v/v	  Penicillin-­‐Streptomycin	  in	  5%	  CO2	  at	  37°C.	  	  Medium	  was	  changed	  every	  
48-­‐60	  h.	   	  At	   confluence,	   cells	  were	  washed	   in	  PBS	   twice	   and	   trypsinised	  using	  0.25%	  w/v	  
trypsin-­‐EDTA	  until	   they	  were	   fully	   detached	   (4-­‐8	  min).	   	   Viable	   cells	  were	   counted	  using	   a	  
haemocytometer	  by	  preparing	  a	  50:50	  mixture	  of	  cell	  suspension	  and	  Erythrosin	  B.	  	  
	  
Media	   were	   tested	   for	   mycoplasma	   using	   the	   Lonza	   MycoAlertTM	   kit	   according	   to	   the	  
maufacturer’s	  instructions	  and	  found	  to	  be	  negative.	  
	  
Conditioned	  medium	  (CM)	  was	  prepared	  by	  plating	  1.5	  x	  106	  cells	  in	  a	  75cm2	  flask.	  	  After	  24	  
h,	  cells	  were	  washed	  twice	  in	  PBS,	  15ml	  of	  serum-­‐free	  (SF)	  medium	  was	  added,	  collected	  24	  
h	  later	  and	  centrifuged.	  	  Supernatants	  were	  either	  used	  immediately	  or	  frozen	  at	  -­‐80°C	  for	  
use	  in	  subsequent	  experiments.	  
	  
OE21	  and	  MSC	  cell	  lines	  were	  maintained	  and	  harvested	  by	  J.	  Dinesh	  Kumar.	  	  	  
	  
2.2.2	  Primary	  gastric	  myofibroblasts	  	  
Human	   gastric	   myofibroblasts	   were	   derived	   from	   samples	   obtained	   peri-­‐operatively	   at	  
resection	  of	  12	  gastric	  tumours	  at	  the	  Department	  Surgery,	  University	  of	  Szeged,	  Hungary.	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Patients	  were	   aged	   39-­‐84	   and	   64%	  were	  male.	   	   Tissue	  was	   taken	   from	   the	   tumour	   itself	  
(from	  which	  CAMs	  were	  derived)	  and	  adjacent	  normal	  tissue	  located	  at	  least	  5cm	  from	  the	  
tumour	   margin	   (from	   which	   ATMs	   were	   derived).	   	   Data	   on	   patient	   demographics,	   TNM	  
staging,	  tumour	  classification	  and	  patient	  survival	  are	  detailed	  in	  Table	  2.1.	  	  Myofibroblasts	  
were	   also	   derived	   from	   deceased	   transplant	   donors	   with	   no	   gastric	   pathology	   (NTMs).	  	  
Immunohistochemical	   staining	   revealed	   spindle-­‐shaped	   α-­‐SMA	   positive	   cells	   and	   the	  
morphology,	  architecture	  and	  number	  of	  these	  had	  been	  scored.	  	  All	  tumours	  had	  increased	  
numbers	   of	   myofibroblasts	   and	   distorted	   architecture.	   Myofibroblasts	   were	   prepared	   as	  
previously	   described	   (43).	   	   This	   work	   was	   approved	   by	   the	   Ethics	   Committee	   of	   the	  
University	  of	  Szeged,	  Hungary.	  	  	  
	  
Both	  native	  (in	  situ)	  and	  cultured	  myofibroblasts	  were	  positive	  for	  α-­‐SMA	  and	  vimentin	  and	  
negative	  for	  desmin	  and	  cytokeratin.	  Myofibroblasts	  were	  used	  from	  passages	  3	  to	  12	  in	  in	  
vitro	  assays;	  for	  in	  vivo	  work	  myofibroblasts	  were	  used	  from	  passages	  3	  to	  7.	  
	  
Primary	   gastric	   myofibroblasts	   were	   cultured	   in	   DMEM	   containing	   10%	   v/v	   FBS,	   2%	   v/v	  
Antibiotic-­‐Antimycotic,	  1%	  v/v	  Penicillin-­‐Streptomycin	  and	  1%	  non-­‐essential	  amino	  acids	  in	  
5%	  CO2	  at	  37°C.	  	  Medium	  was	  changed	  every	  48-­‐60	  h.	  	  At	  confluence	  cells	  were	  washed	  in	  
PBS	  twice	  and	  trypsinised	  using	  0.25%	  w/v	  trypsin-­‐EDTA	  until	  cells	  were	  fully	  detached	  (5-­‐10	  
minutes).	   	   Cells	   were	   counted	   using	   a	   haemocytometer.	   CM	   from	   myofibroblasts	   was	  
prepared	  in	  the	  same	  manner	  as	  for	  AGS	  and	  MKN45	  cells	  as	  detailed	  above.	  
	  
Oesophageal	  CAMs	  were	  derived	  from	  samples	  obtained	  peri-­‐operatively	  at	  resection	  of	  4	  
squamous	  carcinoma	  at	   the	  Department	  Surgery,	  University	  of	  Szeged,	  Hungary	  and	  were	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prepared	  as	  previously	  described	  (43).	  	  Myofibroblasts	  were	  maintained	  and	  harvested	  by	  J.	  
Dinesh	  Kumar.	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2.2.3	  Cell	  preparation	  for	  xenograft	  experiments	  
Cells	  were	  cultured	  as	  described	  above.	  	  After	  trypsinisation,	  cells	  were	  centrifuged	  and	  re-­‐
suspended	   in	  10ml	  PBS.	   	  Viable	   cells	  were	   counted	  using	  a	  haemocytometer	  and	  aliquots	  
(containing	   the	   appropriate	   cell	   number)	   prepared	   for	   injection.	   	   If	   cells	   were	   to	   be	   co-­‐
injected	  (e.g.	  MKN45	  cells	  +	  myofibroblasts)	  they	  were	  mixed	  at	  this	  stage.	   	  Aliquots	  were	  
then	  centrifuged	  for	  7	  min	  at	  800	  xg	  and	  re-­‐suspended	  in	  an	  appropriate	  volume	  of	  PBS,	  so	  
that	  an	  injection	  corresponded	  to	  100μl	  of	  cell	  suspension.	  
	  
MSCs	  were	  labelled	  separately	  with	  CellVue®	  Claret	  Fluorescent	  Cell	  Linker	  and	  with	  PKH67	  
Green	  Fluorescent	  Cell	   Linker	   kit.	   	   They	  underwent	   fluorescence-­‐activated	   cell	   sorting.	   	   In	  
preparation	   for	   IV	   injection,	   cells	  were	   trypsinised	   and	   counted.	   	   Aliquots	  were	   prepared	  
such	   that	  7.5	  x	  105	  CellVue®	  Claret-­‐labelled	  cells	  and	  7.5	  x	  105	  PKH67	  Green-­‐labelled	  cells	  
were	  combined	  and	  re-­‐suspended	  in	  100μl	  of	  PBS,	  which	  was	  injected	  IV	  into	  the	  mice.	  	  This	  
work	  was	  performed	  by	  J.	  Dinesh	  Kumar.	  	  	  
	  
2.2.4	  Xenograft	  studies	  in	  nude	  mice	  
Male	   6-­‐week	   old	   nude	   mice	   (BALB/c	   nu/nu,	   Charles	   River,	   Wilmington,	   MA)	   were	  
acclimatized	   for	   1	   week	   prior	   to	   subcutaneous	   injection	   of	   cancer	   cells	   with	   or	   without	  
primary	  human	  gastric	  or	  oesophageal	  myofibroblasts,	  suspended	  in	  0.1ml	  PBS.	  	  For	  gastric	  
cancer	   experiments,	   1	   x	   105	  MKN45	   cells,	  with	   or	  without	   5	   x	   104	   gastric	  myofibroblasts,	  
were	  used	  unless	  otherwise	  indicated.	   	  For	  oesophageal	  cancer	  experiments,	  1	  x	  106	  OE21	  
cells	  with	  or	  without	  5	   x	  105	  oesophageal	  myofibroblasts	  were	  used.	   	   Following	   injection,	  
the	   weight	   and	   general	   condition	   of	   the	   mice	   were	   monitored	   daily.	   	   Tumours	   were	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measured	   in	   two	   dimensions	   three	   times	   per	   week	   using	   external	   callipers.	   	   Estimated	  
tumour	   volumes	   were	   determined	   using	   the	   two	   longest	   measurements	   of	   these	   in	   the	  
modified	  ellipsoid	  formula	  	  
	  
Tumour	  volume	  =	  ½(ab2)	  
where	  a	  =	  longest	  diameter	  and	  b	  =	  shortest	  diameter.	  
	  
Animals	   were	   culled	   using	   a	   Schedule	   1	   method	   once	   the	  mean	   diameter	   of	   the	   tumour	  
reached	  1.2	  cm,	  or	  alternatively	  if	  there	  were	  any	  signs	  of	  tumour	  ulceration	  or	  if	  the	  animal	  
lost	   more	   than	   20%	   of	   its	   body	   weight,	   in	   accordance	   with	   guidelines	   from	   the	   British	  
Journal	  of	  Cancer	  (216).	  	  	  
	  
Post-­‐mortem,	  the	  tumours	  were	  dissected	  and	  fixed	  in	  4%	  w/v	  PFA	  in	  PBS	  for	  1	  h.	  	  Tumours	  
were	   then	  halved	   and	  one	  half	   transferred	   to	   20%	  w/v	   sucrose	   in	   PBS	   after	  which	   it	  was	  
embedded	   in	  Cryo-­‐M-­‐Bed	  and	  frozen	  onto	  cork	  discs	  using	  Cryospray;	  sections	   (5	   -­‐	  10μm)	  
were	   cut	   on	   a	   cryostat	   and	   mounted	   using	   Vectashield	   containing	   DAPI	   for	   direct	  
visualisation.	   	   The	   remaining	   slides	  were	   stained	  by	   immunofluorescence	  or	   using	   EdU	  as	  
detailed	  below.	  After	  24	  h	  the	  other	  half	  of	  the	  tumour	  was	  transferred	  to	  70%	  v/v	  ethanol	  
and	   processed	   into	   paraffin	   blocks	   by	   the	  Department	   of	   Pathology,	   School	   of	   Veterinary	  
Science,	  University	  of	  Liverpool.	  	  	  
	  
2.2.5	  Fluorescence	  molecular	  tomography	  (FMT)	  
All	  FMT	  and	  IV	  tail	  vein	  injections	  were	  carried	  out	  under	  general	  anaesthesia.	   	  Mice	  were	  
placed	   in	   a	   box	   filled	   with	   oxygen	   and	   an	   increasing	   concentration	   of	   isoflurane.	   	   At	   a	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respiratory	   rate	   of	   60-­‐100/min	   isoflurane	   was	   decreased	   to	   maintenance	   levels	   and	   the	  
mouse	   transferred	   to	   an	   imaging	   cassette.	   	   Oxygen	   and	   isoflurane	  were	   delivered	   to	   the	  
mouse	   during	   FMT	   imaging,	   which	   lasted	   2-­‐4	   min/mouse.	   	   For	   IV	   tail	   vein	   injections	  
anaesthesia	  was	   administered	   through	   a	   nose	   cone.	   	  Mice	  were	   allowed	   to	   recover	   on	   a	  
heat	  pad	  until	  moving	  independently	  when	  they	  were	  transferred	  to	  their	  cages.	  	  
	  
a) Identification	  of	  E2-­‐C	  labelled	  cells	  
Validation	  of	  E2-­‐C-­‐labelled	  MKN45	  cells	  was	  performed	  by	  imaging	  100μl	  droplets	  of	  MKN45	  
E2-­‐C	   and	   MKN45	   cells	   of	   varying	   concentrations	   suspended	   in	   PBS	   and	   comparing	   to	  
droplets	  containing	  PBS	  only.	  
	  
Subcutaneous	  xenografts	  containing	  MKN45E2-­‐C	  cells	  were	  established	  as	  described	  above.	  	  
When	   a	   mouse	   was	   approaching	   an	   endpoint	   (mean	   diameter	   >1.2cm,	   early	   signs	   of	  
ulceration,	  weight	  loss	  approaching	  >20%	  of	  starting	  weight),	  FMT	  imaging	  at	  635nm	  under	  
GA	  was	  carried	  out.	  
	  
b) MSC	  homing	  assay	  
Subcutaneous	   xenografts	   were	   established	   as	   described	   above.	   	   When	   a	   mouse	   was	  
approaching	   an	   endpoint	   (mean	   diameter	   >1.2cm,	   early	   signs	   of	   ulceration,	   weight	   loss	  
approaching	   >20%	   of	   starting	   weight),	   baseline	   FMT	   imaging	   at	   680nm	   under	   GA	   was	  
carried	  out.	  	  Animals	  received	  a	  subcutaneous	  injection	  of	  125μl	  CCX832	  (2mg/ml)	  or	  vehicle	  
24	   h	   prior	   to	   and	   at	   the	   time	  of	   IV	  MSC	   injection.	   	   Tail	   vein	   injections	   of	   7.5	   x	   105	  MSCs	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labelled	   with	   CellVue®	   Claret	   Fluorescent	   Cell	   Linker	   kit	   combined	   with	   7.5	   x	   105	   MSCs	  
labelled	  with	  PK67	  Green	  Fluorescent	  Cell	  Linker	  kit	  (cells	  were	  labelled	  and	  selected	  by	  flow	  
cytometry	  or	  by	   fluorescence	  microscopy	  by	   J.	  Dinesh	  Kumar)	  were	  performed	  under	  GA.	  	  
FMT	  imaging	  at	  680nm	  under	  GA	  was	  then	  carried	  out	  at	  6	  and	  24	  h	  post	  injection..	  	  Animals	  
were	  culled	  24	  h	  post	  injection	  and	  tissue	  processed	  as	  described	  above.	  	  The	  images	  were	  
processed	   using	   TrueQuant	   software.	   	   PKH67-­‐labelled	   cells	   were	   identified	   in	   frozen	  
sections	  using	  the	  FITC	  filter	  on	  a	  Zeiss	  Axioplan-­‐2	  microscope	  (Zeiss	  vision,	  Welwyn	  Garden	  
City,	  UK).	  
	  
c)	  Quantification	  of	  MMPSense	  750	  FASTTM,	  ProSense	  750	  FASTTM	  and	  CatB	  750	  FASTTM	  
activity	  
Subcutaneous	   xenografts	   were	   established	   as	   described	   above.	   	   When	   a	   mouse	   was	  
approaching	   an	   endpoint	   (mean	   diameter	   >1.2cm,	   early	   signs	   of	   ulceration,	   weight	   loss	  
approaching	   >20%	   of	   starting	   weight),	   baseline	   FMT	   imaging	   at	   750nm	   under	   GA	   was	  
carried	   out.	   	  MMPSense	   750	   FASTTM,	   ProSense	   750	   FASTTM,	   and	   CatB	   750	   FASTTM	   (100μl)	  
were	  injected	  IV	  (tail	  vein),	  and	  after	  6	  and	  24	  h	  further	  FMT	  imaging	  at	  750nm	  was	  carried	  
out	   under	   GA	   and	   the	   animal	   then	   culled.	   	   Images	   were	   processed	   using	   TrueQuant	  
software.	  
	  
2.2.6	  Immunofluorescence	  	  
a) Tissue	  sections	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Frozen	  sections	  were	  thawed	  by	  immersion	  in	  distilled	  water	  for	  30	  seconds.	  	  Sections	  were	  
transferred	   to	   50%	   v/v	   ethanol	   for	   10	  min	   followed	  by	   75%	   v/v	   ethanol	   for	   10	  min.	   	   The	  
ethanol	  was	  rinsed	  off	  by	  repeated	  immersion	  in	  distilled	  water.	  	  Sections	  were	  covered	  in	  
10%	   v/v	   donkey	   serum	   in	   PBS	   for	   30	  min	   at	   room	   temperature	   to	   decrease	   non-­‐specific	  
binding	  of	   the	  secondary	  antibody.	   	  This	  was	  then	  removed	  and	  the	  sections	   incubated	   in	  
primary	  antibody	  (Table	  2.1)	  diluted	  in	  1%	  w/v	  BSA	  in	  PBS	  overnight	  at	  4°C	  in	  a	  humidified	  
chamber.	   	   The	   sections	  were	   then	  washed	   sequentially	  with	   0.14M	  NaCl,	   0.5M	  NaCl	   and	  
0.14M	   NaCl	   for	   5	  min	   each.	   	   Sections	   were	   then	   incubated	   in	   an	   appropriate	   secondary	  
antibody	   (Table	   2.1)	   diluted	   in	   10mM	  HEPES	   at	   room	   temperature	   in	   darkness.	   	   This	  was	  
washed	   off	   with	   3	   5	  min	   PBS	  washes.	   	   Slides	  were	  mounted	  with	   Vectashield	   containing	  
DAPI.	  
	  
b) Cultured	  cells	  
MKN45,	  MKN45	  E2-­‐C	  cells	  and	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  (1	  x	  104	  per	  well)	  were	  plated	  onto	  
coverslips	  in	  24-­‐well	  plates	  in	  FM.	  	  24	  h	  later	  they	  were	  washed	  twice	  in	  PBS	  and	  fixed	  for	  30	  
min	   in	  4%w/v	  PFA	   in	  PBS.	   	  Cells	  were	   then	  washed	  4	   times	   in	  PBS.	   	  Permeabilisation	  was	  
carried	  out	  by	  incubating	  cells	  in	  0.3%w/v	  BSA	  0.2%v/v	  Triton	  X-­‐100	  in	  PBS	  (PBT)	  for	  30	  min.	  	  
Cells	  were	  then	  washed	  twice	  in	  PBS	  and	  incubated	  in	  5%w/v	  BSA	  in	  PBS	  for	  30	  min.	  	  Cells	  
were	  washed	  twice	  in	  PBS	  and	  blocked	  in	  10%v/v	  donkey	  serum	  for	  30	  min.	  	  After	  washing	  
twice	   in	   PBS	   cells	   were	   incubated	   in	   primary	   antibody	   (Table	   2.2)	   diluted	   in	   PBS	   at	   4°C	  
overnight	   in	   a	   humidified	   chamber.	   	   Cells	  were	   then	  washed	   sequentially	   in	   0.14M,	  0.5M	  
and	  0.14M	  NaCl	  for	  10	  min	  each	  and	  incubated	  in	  secondary	  antibody	  (Table	  2.2)	  diluted	  in	  
10mM	  HEPES	  for	  1	  h	  at	  room	  temperature	   in	  the	  dark.	   	  Cells	  were	  washed	  3	  times	   in	  PBS	  
and	  coverslips	  were	  mounted	  in	  Vectashield	  containing	  DAPI.	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1/400	   Jackson,	   PA,	  
USA	  
	  
Table	  2.2	  Primary	  and	  secondary	  antibodies	  used	  for	  immunofluorescence	  experiments	  on	  
frozen	  tissue	  sections	  and	  on	  cultured	  cells.	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2.2.7	  EdU	  cell	  proliferation	  assay	  
a) Cultured	  cells	  
MKN45,	  MKN45E2-­‐C	  cells	  and	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  (1	  x	  105)	  were	  plated	  on	  coverslips	  in	  
24-­‐well	  plates	  in	  FM.	  	  After	  allowing	  them	  to	  adhere	  overnight,	  the	  cells	  were	  washed	  in	  PBS	  
3	   times	   and	   incubated	   in	   SF	  medium.	   	   Cells	  were	  washed	   in	   PBS	   24	   h	   later	   and	   fresh	   SF	  
medium	  was	   added.	   	   After	   24	   h,	   EdU	  was	   added	   to	   a	   final	   concentration	   of	   10μM.	   	   Two	  
hours	  following	  EdU	  addition	  cells	  were	  fixed	  in	  4%	  w/v	  PFA	  in	  PBS	  for	  30	  min,	  washed	  twice	  
with	   3%	   w/v	   BSA	   in	   PBS	   and	   then	   twice	   in	   PBS.	   	   Permeabilisation	   was	   carried	   out	   by	  
incubating	  cells	  in	  0.5%	  v/v	  Triton	  X-­‐100	  in	  PBS	  for	  20	  min.	  	  Cells	  were	  then	  washed	  twice	  in	  
3%	  w/v	  BSA	   in	  PBS,	   incubated	   for	  30	  min	   in	   the	  dark	  with	  Click-­‐ItTM	   reaction	   cocktail	   and	  
washed	   with	   3%	   w/v	   BSA	   in	   PBS	   followed	   by	   PBS.	   	   DNA	   staining	   was	   carried	   out	   by	  
incubating	  cells	   in	  2μg/ml	  Hoechst	  33342	   in	  PBS	   for	  30	  min	   in	   the	  dark.	  Finally	   cells	  were	  
washed	  twice	  in	  PBS	  and	  coverslips	  were	  mounted	  with	  Vectashield.	  	  EdU	  positive	  nuclei	  in	  
5	  fields	  were	  quantified	  as	  a	  proportion	  of	  the	  total	  number	  of	  nuclei	  and	  the	  mean	  taken.	  
Cells	   were	   visualized	   with	   a	   Zeiss	   Axiovert	   microscope	   and	   images	   acquired	   with	   a	  
Hamamatsu	  480-­‐80	  CCD	  camera	  with	  Axioplan	  software.	  
	  
b) In	  vivo	  
One	   hour	   prior	   to	   sacrifice	  mice	   received	   an	   IP	   injection	   of	   0.2ml	   EdU	   (2	  mg/ml	   in	   PBS;	  
equivalent	   to	   400μg/mouse).	   	   Tissues	   were	   processed	   post-­‐mortem	   as	   described	   above.	  	  
Frozen	  tumour	  sections	  were	  thawed	  by	  immersion	  in	  distilled	  water	  for	  30	  sec.	   	  Click-­‐ItTM	  
reaction	  cocktail	  was	  applied	   to	  sections	  and	  they	  were	   incubated	   in	   the	  dark	   for	  30	  min.	  	  
Sections	  were	  then	  washed	  3	  times	  in	  PBS	  and	  mounted	  with	  Vectashield	  containing	  DAPI.	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2.2.8	  Adhesion	  assays	  
MKN45,	  MKN45	   E2-­‐C	   cells	   and	  MKN45	   E2-­‐C	   PAI-­‐1	   cells	   (1	   x	   105	   per	  well)	   were	   plated	   in	  
quadruplicate	  on	  24	  well	  plates	   in	  FM.	   	  After	  45	  min	  at	  37°C,	  5%	  CO2	  cells	  were	  washed	  3	  
times	  with	  PBS	  containing	  CaCl2/MgCl2	  and	  stained	  using	  0.2%	  w/v	  crystal	  violet	  in	  50%	  v/v	  
ethanol	   for	  5	  min	  on	  a	   shaker.	   	  Cells	  were	  solubilized	  by	   incubation	   in	  a	  50:50	  mixture	  of	  
0.1M	  NaH2PO4,	  pH4.5	  and	  ethanol	  for	  5	  min	  on	  a	  shaker	  at	  room	  temperature	  and	  100μl	  of	  
the	  solution	  transferred	  to	  a	  96-­‐well	  plate	  for	  determination	  of	  absorbance	  at	  550nm	  using	  
a	  Spectracount	  (Packard,	  CT,	  USA)	  plate	  reader.	   	  Blank	  controls	  (no	  cells)	  were	  subtracted.	  	  
The	  mean	  absorbance	  at	  550nm	  was	  reported.	  	  Assays	  were	  also	  performed	  on	  vitronectin-­‐
coated	  plates.	   	  These	  were	  prepared	  by	  making	  a	  250ng/ml	   solution	  of	  vitronectin	   in	  PBS	  
and	   adding	   0.25ml	   of	   this	   to	   each	   well	   of	   a	   24-­‐well	   plate.	   	   After	   90	  min	   the	   wells	   were	  
washed	  in	  PBS	  twice	  and	  the	  plate	  stored	  at	  4°C	  until	  required.	  
	  
2.2.9	  Transfection	  of	  MKN45	  cells	  with	  vectors	  for	  hPAI-­‐1	  and	  E2-­‐Crimson	  (E2-­‐C)	  
MKN45	   cells	   (3	   x	   106	   per	   10cm	  dish)	  were	   allowed	   to	   adhere	   overnight.	  DNA	   (15μg)	  was	  
vortexed	   with	   5ml	   warmed	   SF	   medium.	   	   For	   cells	   co-­‐transfected	   with	   E2-­‐C	   and	   PAI-­‐1	  
encoding	   vectors	   the	   DNA	   sample	   was	   composed	   of	   50%	   E2-­‐C	   and	   50%	   PAI-­‐1	   DNA.	  	  
TransFastTM	   (45μl)	  was	  added	   to	   the	  SF	  medium-­‐DNA	  mixture	  and	  vortexed.	   	  The	  mixture	  
was	   left	   at	   room	   temperature	   for	   15	   min.	   	   FM	   was	   removed	   from	   the	   cells	   and	   the	   SF	  
medium-­‐DNA-­‐TransFastTM	  mixture	  added.	  	  The	  dish	  was	  incubated	  at	  37°C,	  5%	  CO2	  for	  1	  h.	  	  
FM	  (5	  ml)	  containing	  20%	  FBS	  was	  then	  added.	   	  After	  48	  h	  the	  medium	  was	  removed	  and	  
replaced	  with	  FM	  containing	  1.5mg/ml	  G418	  (selection	  medium).	   	  This	  was	  replaced	  every	  
48-­‐72	  h	  until	  colonies	  appeared.	  	  Fluorescent	  colonies	  were	  marked	  following	  examination	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of	  the	  cells	  under	  the	  Texas	  red	  (TXR)	  filter	  on	  a	  Leica	  DMIRE2	  microscope	  (Leica	  Microcsope	  
Systems	  GmbH,	  Wetzlar,	  Germany)	  and	  images	  captured	  with	  a	  Hamamatsu	  Orca	  ER	  camera	  
(Hamamatsu	  photonics,	  Hamamatsu	  City,	  Japan).	   	  Colonies	  were	  then	  cloned	  using	  cloning	  
cylinders.	   	   The	   colonies	  were	  washed	   twice	   in	   PBS	   and	   cloning	   cylinders	   placed	   over	   the	  
marks.	  	  Trypsin-­‐EDTA	  (50μl,	  0.25%	  v/v)	  was	  added	  to	  each	  cylinder	  and	  the	  plate	  incubated	  
at	   37°C,	   5%	   CO2	   for	   10	   min.	   	   FM	   (200μl)	   was	   added	   to	   each	   cylinder	   and	   the	   contents	  
transferred	   to	   a	   5cm	   diameter	   dish	   filled	  with	   5ml	   selection	  medium.	   	   This	  was	   replaced	  
every	  48-­‐72	  h	  until	  colonies	  appeared.	  	  Once	  again,	  red	  colonies	  were	  marked	  and	  cloned	  as	  
described	   above.	   	   The	   procedure	   was	   repeated	   until	   all	   colonies	   growing	   in	   the	   5cm	  
diameter	  plate	  appeared	  red.	   	  At	   this	  point,	   colonies	  were	  allowed	  to	  grow	  to	  confluence	  
and	  cultured	  in	  selection	  medium	  for	  5	  passages	  (Figure	  2.1).	  	  Flasks	  of	  cells	  were	  regularly	  
examined	  under	  the	  microscope	  and	  cells	  validated	   in	  the	  FMT	  equipment	  as	  described	   in	  
2.2.5b.	   	  qPCR	  was	  performed	  on	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  to	  assess	  PAI-­‐1	  mRNA	  expression	  	  
(see	  2.2.13-­‐15).	  	  Immunofluorescent	  staining	  for	  PAI-­‐1	  was	  carried	  out	  on	  MKN45	  E2-­‐C	  PAI-­‐1	  
cells	  (see	  2.2.6b).	  	  
	  










Figure	  2.1.	  Schematic	  of	   the	  process	  of	  creating	  stably	  transfected	  MKN45	  cells.	   	  MKN45	  
cells	  were	   transfected	  with	   an	   E2-­‐C	  plasmid	   alone	  or	   in	   combination	  with	   a	   human	  PAI-­‐1	  
overexpressing	  plasmid.	  	  Transfected	  cells	  were	  selected	  for	  using	  FM	  containing	  G418	  and	  
emerging	   colonies	   visualised	   under	   a	   TXR	   filter.	   	   Further	   rounds	   of	   subcloning	   took	   place	  
until	  a	  uniform	  population	  of	  cells	  had	  developed.	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2.2.10	  Scratch	  migration	  assays	  
MKN45,	  MKN45	  E2-­‐C	  cells	  and	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	   (1.5	  x	  106	  per	  well)	  were	  grown	  to	  
confluence	  in	  6-­‐well	  plates.	  	  The	  medium	  was	  removed	  and	  a	  vertical	  scratch	  wound	  made	  
in	  the	  cell	  monolayer	  using	  a	  10μl	  pipette	  tip.	  	  Wells	  were	  then	  washed	  3	  times	  with	  PBS	  and	  
SF	  medium	  containing	  50nM	  human	  recombinant	  PAI-­‐1	  was	  added.	  	  Baseline	  images	  at	  fixed	  
points	  along	  the	  scratch	  were	  acquired.	  	  The	  cells	  were	  then	  incubated	  at	  37°C,	  5%	  CO2	  for	  
16	  h.	  	  For	  MKN45	  cells,	  the	  distance	  across	  the	  wound	  was	  measured	  at	  10	  fixed	  points	  at	  
time	  0	  and	  after	  16	  h.	  	  Assays	  were	  performed	  in	  triplicate	  and	  the	  mean	  result	  calculated.	  
	  
2.2.11	  Boyden	  chamber	  migration	  assays	  
BD	  Control	  Cell	  Culture	  inserts	  and	  companion	  plates	  were	  used	  (BD	  Biosciences).	  	  These	  are	  
composed	  of	   inserts	  with	  a	  base	  made	  of	  a	  membrane	  with	  8μm	  pores	  and	  a	  companion	  
plate	  where	   putative	  modulators	   of	   cell	  migration	   can	   be	   added.	   	   The	   inserts	  were	   filled	  
with	   a	   suspension	   of	   2.5	   x	   104	   AGS	   or	   CAM14	   cells	   in	   SF	   medium.	   	   The	   wells	   in	   the	  
companion	   plate	  were	   filled	  with	   0.75ml	   SF	  medium	  with	   or	  without	   the	   treatment	   (e.g.	  
50nM	  recombinant	  human	  PAI-­‐1).	  	  The	  inserts	  were	  then	  transferred	  onto	  the	  wells	  of	  the	  
companion	  plate	  (Figure	  2.2).	  	  This	  was	  incubated	  for	  22	  h	  at	  37°C,	  5%	  CO2.	  	  Non-­‐migrated	  
cells	  were	  scrubbed	  off	  with	  a	  cotton-­‐tipped	  swab.	  	  Migrated	  cells	  were	  then	  stained	  using	  
Diff-­‐QuikTM.	  	  The	  inserts	  were	  transferred	  sequentially	  through	  the	  staining	  solutions	  every	  2	  
min	  and	  then	  rinsed	  in	  distilled	  water.	  	  Once	  dry,	  the	  membrane	  was	  excised	  and	  mounted	  
on	   immersion	   oil.	   	   Migrating	   cells	   were	   counted	   at	   x	   10	   magnification	   in	   5	   fields	   per	  
membrane	  and	  the	  mean	  calculated.	  








Figure	  2.2.	  Schematic	  of	  Boyden	  chamber	  migration	  assay.	  AGS	  cells	  were	  seeded	  onto	  a	  
membrane	  with	  8μm	  pores.	  	  Putative	  chemoattractants	  (e.g.	  PAI-­‐1)	  were	  added	  to	  the	  wells	  
in	   the	   companion	   plate	   and	   the	   number	   of	   cells	   which	  migrated	   through	   the	   pores	   was	  
compared	  to	  the	  SF	  control.	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2.2.12	  PAI-­‐1	  ELISA	  
Imubind	  Tissue	  PAI-­‐1	  ELISA	  kits	  (American	  Diagnostica)	  were	  used	  to	  assay	  PAI-­‐1	  in	  CM.	  	  PAI-­‐
1	  standard,	  control	  or	  sample	  (100	  µl)	  was	  added	  to	  wells	  in	  the	  precoated	  microtest	  strips	  
and	   incubated	   overnight	   at	   4°C	   in	   a	   humidified	   chamber.	   	  Wells	  were	  washed	   4	   times	   in	  
wash	   buffer	   and	   then	   incubated	   with	   100μl	   of	   detection	   antibody	   for	   1	   h	   at	   room	  
temperature.	  	  Wells	  were	  washed	  4	  times	  with	  wash	  buffer	  and	  then	  incubated	  with	  100μl	  
of	  diluted	  enzyme	  conjugate	  for	  1	  h	  at	  room	  temperature,	  washed	  with	  wash	  buffer	  4	  times	  
and	   then	   incubated	   for	   20	   min	   after	   the	   addition	   of	   100μl	   of	   substrate	   solution.	   	   The	  
enzymatic	  reaction	  was	  stopped	  by	  the	  addition	  of	  50μl	  0.5N	  H2SO4	  and	  the	  absorbance	  at	  
450nm	  read	  on	  a	  Spectracount	  plate	   reader	   (Packard).	   	  Background	  signal	  was	  subtracted	  
from	   the	   sample	   values.	   	   Samples	   were	   assayed	   in	   duplicate	   and	   the	   mean	   taken.	   	   A	  
standard	   curve	   was	   generated	   using	   recombinant	   PAI-­‐1	   and	   the	   concentration	   in	   the	  
samples	  determined	  by	  reference	  to	  this.	  
	  
2.2.13	  RNA	  extraction	  for	  qPCR	  
Cancer	  cells	  or	  CAMs	  (1.5	  x	  106)	  were	  plated	  in	  10cm	  diameter	  dishes	  and	  incubated	  at	  37°C,	  
5%	  CO2.	  Cells	  were	  then	  trypsinised,	  counted	  and	  RNA	  extracted	  after	  24	  h	  treatment	  with	  
SF	   medium	   or	   CM.	   	   RNA	   extraction	   was	   performed	   using	   the	   Qiagen	   RNeasy	   Mini	   kit	  
according	   to	   the	   manufacturer’s	   instructions,	   with	   the	   lysate	   homogenized	   by	   passage	  
through	  a	  blunt	  20G	  needle	  at	  least	  5	  times.	  	  On-­‐column	  DNase	  digestion	  was	  performed	  to	  
eliminate	   contamination	   by	   genomic	   DNA.	   	   RNA	   yield	   was	   quantified	   on	   a	   NanoDrop	  
spectrophotometer	  (Labtech,	  Uckfield,	  UK).	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2.2.14	  Reverse	  transcription	  for	  qPCR	  
All	  cDNAs	  were	  prepared	  using	  4μg	  RNA.	   	  RNA	  was	  combined	  with	  oligoDT	  and	  heated	  to	  
70°C	  for	  5	  min	  to	  achieve	  RNA/primer	  annealing.	  	  	  The	  RNA/primer	  mixture	  was	  combined	  
with	  AMV	  reverse	  transcriptase,	  RNAsin	  and	  dNTPs	  in	  AMV	  buffer	  and	  incubated	  at	  42°C	  for	  
1	  h.	  	  	  
	  
2.2.15	  qPCR	  for	  hPAI-­‐1	  
Real	  time	  PCR	  was	  carried	  out	  in	  an	  ABI7500	  thermocycler	  (Applied	  Biosystems,	  Warrington,	  
UK).	   	  For	  PAI-­‐1	  Precision	  FAST	  2x	  real	  time	  PCR	  master	  mix	  with	  SYBRgreen	  was	  used.	  	  For	  
GAPDH	  (the	  reference	  gene)	  Precision	  FAST	  2x	  real	  time	  PCR	  master	  mix	  was	  used	  with	  5’-­‐
FAM,	   3’-­‐TAMRA	  double	   dye	   probes.	   	   	   Primers	   and	   intron-­‐spanning	   probes	  were	   designed	  
using	   Primer	   Express	   v3.0	   software	   (Applied	   Biosystems,	   Warrington,	   UK)	   by	   Prof	   Rod	  
Dimaline	  (Table	  2.3).	  	  
	  
All	  assays	  included	  a	  no	  template	  control	  and	  a	  standard	  curve,	  which	  was	  developed	  using	  
serial	  dilutions	  of	  cDNA	  template	  corresponding	  to	  the	  relevant	  gene	  amplicon,	  ligated	  into	  
pGEM-­‐T	  Easy	  (Promega).	  	  For	  all	  assays	  the	  correlation	  coefficient	  of	  the	  slope	  of	  standard	  
curve	  was	   greater	   than	   0.97	   and	   the	   PCR	   amplification	   efficiency	  was	   between	   90–110%	  
(calculated	  from	  the	  log-­‐linear	  part	  of	  the	  standard	  curve	  as	  being	  between	  -­‐3.6	  and	  -­‐3.1).	  	  
For	  PAI-­‐1	  assays	  the	  dissociation	  curve	  was	  examined	  and	  found	  to	  contain	  a	  single	  narrow	  
peak.	   	  Each	  sample	  was	  assayed	   in	   triplicate	  and	  PAI-­‐1	  mRNA	  abundance	  was	  determined	  
based	  on	  expression	  relative	  to	  GAPDH.	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Primer/Probe	   Sequence	  
hGAPDH	  probe	   CGT	  CGC	  CAG	  CCG	  AGC	  CAC	  A	  
hGAPDH	  forward	   GCT	  CCT	  CCT	  GTT	  CGA	  CAG	  TCA	  
hGAPDH	  reverse	   ACC	  TTC	  CCC	  ATG	  GTG	  TCT	  GA	  
hPAI	  1	  probe	   AGT	  TCA	  ACT	  ATA	  CTG	  AGT	  TCA	  CCA	  CGC	  CCG	  
hPAI	  1	  forward	   TGC	  CCA	  TGA	  TGG	  CTC	  AGA	  
hPAI	  1	  reverse	   GCA	  GTT	  CCA	  GGA	  TGT	  CGT	  AGT	  AAT	  G	  
	  
Table	   2.3.	   Primers	   and	   probes	   used	   in	   qPCR	   experiments.	   	   PAI-­‐1	   and	   GAPDH	   (as	   the	  
reference	  gene)	  were	  assayed.	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2.2.16	  Organotypic	  co-­‐cultures	  
The	  protocol	  was	  adapted	  from	  a	  previously	  described	  organotypic	  co-­‐culture	  system	  (217).	  	  
Gels	  were	  prepared	  by	  mixing	  350μl	  MatrigelTM,	  350μl	  collagen,	  100μl	  10	  x	  DMEM	  solution,	  
100μl	  FBS	  and	  5	  x	  105	  myofibroblasts	  suspended	  in	  100μl	  FM,	  leading	  to	  a	  final	  gel	  volume	  
of	  1ml.	  	  Treatments	  were	  applied	  to	  the	  gel	  at	  appropriate	  concentrations.	  	  Reagents,	  tubes	  
and	  pipettes	  were	  cooled	  on	  ice	  to	  facilitate	  handling	  of	  the	  MatrigelTM	  and	  collagen.	   	  The	  
resulting	   1ml	   solutions	   were	   transferred	   to	   wells	   of	   a	   24-­‐well	   plate	   and	   allowed	   to	  
polymerise	  at	  37°C	  for	  30	  min.	  	  FM	  (1ml/well)	  was	  then	  added	  to	  the	  top	  and	  left	  overnight	  
at	  37°C.	  	  The	  next	  day,	  FM	  was	  aspirated	  and	  2	  x	  106	  MKN45	  cells	  suspended	  in	  100μl	  of	  FM	  
were	  added	  dropwise	  to	  the	  top	  of	  the	  gel,	  and	  the	  gel	   incubated	  overnight	  at	  37°C.	   	  The	  
following	   day	   gels	   were	   removed	   from	   the	   24-­‐well	   plate	   and	   transferred	   to	   the	   top	   of	  
collagen-­‐coated	  gauze	  squares	  resting	  on	  steel	  grids	  in	  6-­‐well	  plates.	  	  The	  steel	  grids	  allowed	  
the	  gel	  to	  sit	  5mm	  higher	  than	  the	  bottom	  of	  the	  well.	  	  FM	  (with	  treatments	  as	  appropriate)	  
was	   added	   to	   the	   bottom	  of	   the	  well	   until	   it	   reached	   the	   undersurface	   of	   the	   steel	   grid,	  
allowing	  the	  epithelial	   layer	   to	  remain	  at	  an	  air-­‐liquid	   interface	   (Figure	  2.3).	   	  Medium	  was	  
replaced	  every	  2	  days	  and	  the	  gels	  incubated	  at	  37°C	  throughout.	  	  After	  2	  weeks,	  gels	  were	  
bisected	  and	  fixed	   in	  4%	  PFA	  in	  PBS	  for	  24	  h.	   	  They	  were	  then	  transferred	  to	  70%	  ethanol	  
and	   embedded	   in	   paraffin	   for	   histology	   by	   the	   Department	   of	   Pathology,	   School	   of	  
Veterinary	  Science,	  University	  of	  Liverpool	  and	  the	  Department	  of	  Cellular	  Pathology,	  Royal	  
Liverpool	   University	   Hospital.	   	   Quantification	   of	   the	   invasive	   front	   of	   MKN45	   cells	   was	  
performed	  using	  ImageJ	  software.	  













Figure	   2.3.	   Schematic	   showing	   the	   process	   of	   creating	   the	   3-­‐D	   organotypic	   co-­‐culture	  
system.	   	  Myofibroblasts	   were	   seeded	   into	   a	  Matrigel/collagen	  matrix	   and	   left	   overnight.	  	  
MKN45	   cells	   were	   added	   to	   the	   top	   and	   left	   overnight.	   	   On	   day	   3,	   the	   gel	   culture	   was	  
transferred	   to	   an	   air-­‐liquid	   interface.	   	   This	   was	   achieved	   by	   placing	   the	   gel	   on	   top	   of	   a	  
collagen-­‐soaked	  gauze	  on	  a	   steel	  mesh	  platform.	   	   FM	  was	   then	  added	   to	   the	   level	  of	   the	  
gauze	  and	  replaced	  every	  48	  hours	  for	  2	  weeks.	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2.2.17	  Luciferase	  promoter-­‐reporter	  assays	  
A	  PAI-­‐1-­‐luciferase	  promoter-­‐reporter	  construct	  was	  generated	  using	  a	  4.5kb	  fragment	  of	  the	  
human	  PAI-­‐1	  promoter	  generated	  by	  PCR	  of	  human	  genomic	  DNA	  and	  cloned	  into	  the	  firefly	  
luciferase	  reporter	  construct	  pXP2	  as	  previously	  described	  (183).	  	  AGS	  cells	  (2	  x	  105	  per	  well)	  
were	   plated	   into	   wells	   of	   a	   6-­‐well	   plate	   in	   FM	   and	   allowed	   to	   adhere	   overnight.	   	   The	  
following	  day,	  cells	  were	  washed	  in	  PBS	  3	  times	  and	  cells	  were	  co-­‐transfected	  with	  PAI-­‐1-­‐luc	  
(0.25ng/well)	  and	  a	  constitutively	  active	  Renilla	  luciferase	  reporter	  (phRL-­‐SV40,	  0.5ng/well)	  
by	  TransFastTM	  (see	  2.2.9)	  in	  SF	  medium	  for	  1	  h.	  	  After	  transfection	  2ml	  of	  FM	  were	  added	  to	  
each	  well	  and	  24	  h	  later	  cells	  were	  washed	  3	  times	  in	  PBS.	  	  Cells	  were	  then	  incubated	  in	  SF	  
medium	  or	  CM	  for	  6	  h.	   	   SF	  medium	  containing	  100nM	  PMA,	  which	   is	  known	  to	  stimulate	  
PAI-­‐1	  expression	   (218),	  was	  used	  as	   a	  positive	   control	   (Figure	  2.4).	   	   Cells	  were	  washed	   in	  
PBS,	  500μl/well	  of	  lysis	  buffer	  was	  added	  and	  the	  plate	  was	  placed	  on	  a	  shaker	  for	  30	  min.	  
Lysates	  (20μl)	  were	  transferred	  to	  a	  tube	  and	  luciferase	  activity	  was	  measured	  using	  a	  dual	  
luciferase	   reporter	   assay	   on	   a	   Lumat	   LB9507	   luminometer	   (Berthold	   Technologies,	  
Redbourne,	   Herts,	   UK)	   according	   to	   the	   manufacturer’s	   instructions.	   	   Assays	   were	  
performed	  in	  duplicate	  and	  the	  mean	  result	  calculated.	   	  Results	  were	  normalized	  to	  Renilla	  
activity.	  

















Figure	   2.4.	  Schematic	   illustrating	   principle	   of	   the	   luciferase	   promoter-­‐reporter	   assay.	   	  A	  
plasmid	  encoding	  a	  region	  of	  the	  human	  PAI-­‐1	  promoter	  and	  luciferase	  was	  transfected	  into	  
AGS	   cells.	   	   These	   were	   then	   incubated	   with	   SF	   control,	   putative	   stimulators	   of	   PAI-­‐1	  
transcription	  (e.g.	  CM)	  and	  PMA	  as	  a	  positive	  control.	  	  If	  transcription	  factors	  bound	  to	  the	  
PAI-­‐1	  promoter,	  luciferase	  was	  transcribed	  and	  translated.	  	  Luciferase	  activity	  was	  measured	  
in	  a	  luminometer.	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2.2.18	  Statistics	  
Results	  are	  expressed	  as	  mean	  ±	  standard	  error	  of	   the	  mean	  (SE)	  unless	  otherwise	  
stated.	   	   Student’s	   t-­‐test	   and	   one-­‐way	   analysis	   of	   variance	   (ANOVA)	   were	   used	   to	  
determine	   the	   significance	   of	   results	   with	   significance	   defined	   as	   p=<0.05,	   unless	  
otherwise	   stated.	   	   Vertical	   lines	   represent	   SE	   and	   horizontal	   lines	   with	   asterisks	  
denote	   statistical	   significance	   unless	   otherwise	   stated.	   	   Graphs	   and	   statistics	  were	  
produced	  using	  GraphPad	  Prism	  version	  5.0	  software.	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Members	   of	   the	   uPA	   system	   are	   known	   to	   play	   a	   role	   in	   carcinogenesis	   and	  
frequently	   overexpression	   of	   these	   proteins	   is	   associated	   with	   a	   more	   invasive	  
phenotype	  and	  a	  poor	  prognosis	  (219).	  	  The	  role	  of	  PAI-­‐1,	  however,	  remains	  unclear	  
as	  it	  acts	  both	  as	  a	  promoter	  of	  carcinogenesis	  as	  well	  as	  a	  protective	  factor	  (220).	  	  In	  
gastric	   cancer,	   the	   role	   of	   PAI-­‐1	   also	   remains	   poorly	   defined	   although	   there	   is	  
evidence	  to	  show	  that	  PAI-­‐1	  is	  overexpressed	  (221).	  	  It	  is	  unclear	  whether	  high	  PAI-­‐1	  
expression	  in	  gastric	  cancer	  is	  stromal	  or	  epithelial	  and	  this	  study	  aims	  to	  define	  PAI-­‐
1	  expression	   in	   gastric	  myofibroblasts	   compared	  with	   two	  gastric	   cancer	   cell	   lines,	  
AGS	   and	  MKN45.	   	   The	   effect	   of	   PAI-­‐1	   overexpression	   on	   the	   in	   vitro	   and	   in	   vivo	  
behaviour	  of	  gastric	  cancer	  cells	  was	  then	  assessed	   in	  an	  effort	   to	  characterise	  the	  
role	  of	  PAI-­‐1	  in	  gastric	  cancer.	  	  	  
	  
Stromal-­‐epithelial	   signalling	   relies	   on	   the	   release	   of	   soluble	   mediators	   capable	   of	  
affecting	   the	   behaviour	   of	   neighbouring	   cells.	   	   The	   stimulus	   for	   increased	   PAI-­‐1	  
expression	  in	  stomach	  has	  not	  been	  demonstrated	  and	  this	  study	  has	  examined	  the	  
role	   of	   soluble	  mediators	   released	   from	  myofibroblasts	   and	   gastric	   cancer	   cells	   in	  
modulating	  PAI-­‐1	  expression.	  	  PAI-­‐1	  is	  a	  secreted	  molecule	  and	  is	  known	  to	  affect	  cell	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migration	   and	   invasion	   in	   vitro	   (222).	   	   This	   study	   examined	   the	   effect	   of	   PAI-­‐1	   on	  




1. To	   determine	   the	   relative	   abundance	   of	   PAI-­‐1	   in	   gastric	   cancer	   cells	   and	  
myofibroblasts.	  
2. To	   study	   the	   effect	   of	   soluble	   mediators	   produced	   by	   cancer	   cells	   or	  
myofibroblasts	  on	  PAI-­‐1	  expression.	  
3. To	  create	  fluorescently	  labelled,	  PAI-­‐1	  over-­‐expressing,	  MKN45	  cells	  in	  order	  
to	   examine	   the	   effect	   of	   PAI-­‐1	   over-­‐expression	   on	   cancer	   cell	   behaviour	   in	  
vitro	  and	  in	  vivo.	  




Cell	  culture	  was	  performed	  as	  detailed	  in	  2.2.1-­‐2.	  	  Boyden	  chamber	  migration	  assays	  
were	  described	  in	  2.2.11.	  	  Preparation	  of	  samples	  and	  qPCR	  was	  described	  in	  2.2.13-­‐
15.	   	   PAI-­‐1	   ELISA	   was	   carried	   out	   as	   outlined	   in	   2.2.12.	   	   Luciferase	   assays	   were	  
described	   in	   2.2.17.	   	   Transfection	   of	   MKN45	   cells	   was	   described	   in	   2.2.9.	  	  
Immunofluorescence	  was	  carried	  out	  as	  detailed	  in	  2.2.6b.	  	  Scratch	  migration	  assays	  
were	  performed	  as	  in	  2.2.10.	  	  EdU	  incorporation	  assays	  were	  performed	  as	  outlined	  
in	  2.2.7a.	  	  Cell	  adhesion	  assays	  were	  described	  in	  2.2.8.	  	  
	  
3.2.1	  PAI-­‐1	  ELISA	  
CM	   from	  CAM1,	  CAM11	  and	  CAM14	  was	  prepared	  as	  described	   in	  2.2.1	  using	  CM	  
from	   1.2	   x	   107	  MKN45	   cells	   in	   12ml	   SF	   medium	   and	   collected	   24	   h	   later.	   	   	   The	  
Imubind	   Tissue	   PAI-­‐1	   ELISA	   kit	   (American	   Diagnostica,	   Stamford,	   CT)	   was	   used	  
according	  to	  the	  manufacturer’s	  instructions.	  	  
	  
3.2.2	  Organotypic	  invasion	  assay	  
MKN45,	  MKN45	  E2-­‐C	  cells	  and	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  were	  added	  dropwise	  to	  the	  
top	  of	  gels	  seeded	  with	  CAM4	  on	  day	  2	  as	  described	  in	  2.2.16.	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3.2.3	  Subcutaneous	  xenografts	  
MKN45,	  MKN45	   E2-­‐C	   cells	   and	  MKN45	   E2-­‐C	   PAI-­‐1	   cells	   (5	   x	   105	   per	  mouse)	  were	  
injected	  subcutaneously	  in	  the	  left	  flank	  as	  described	  in	  2.2.4.	  	  




3.3.1	  Increased	  expression	  of	  PAI-­‐1	  in	  CAMs	  compared	  with	  cancer	  cells.	  	  
In	   order	   to	   establish	   the	   relative	   expression	   of	   PAI-­‐1	   in	   gastric	   cancer	   cells	   and	  
myofibroblasts,	   mRNA	   abundance	   was	   determined	   by	   qPCR	   and	   secreted	   PAI-­‐1	  
protein	  was	   quantified	   by	   ELISA	   of	   CM.	   	   Expression	   of	   PAI-­‐1	  mRNA	  was	   higher	   in	  
CAMs	   (CAM1,	   CAM11	   and	   CAM14)	   than	   in	   AGS	   cells	   (Figure	   3.1A).	  Moreover,	   the	  
concentration	   of	   PAI-­‐1	   in	  media	   from	   these	   CAMs	  was	   higher	   than	   in	  MKN45	   cell	  
media	  (Figure	  3.1B).	  	  	  
	  
To	   determine	   whether	   stromal-­‐epithelial	   interactions	   influenced	   PAI-­‐1	   expression,	  
CAMs	  (CAM1,	  CAM11	  and	  CAM14)	  were	  treated	  with	  CM	  from	  MKN45	  or	  AGS	  cells	  
and	  the	  effect	  on	  PAI-­‐1	  mRNA	  abundance	  was	  quantified	  by	  qPCR	  (Figure	  3.1C).	  	  PAI-­‐
1	  expression	   in	  CAMs	  did	  not	   change	   significantly	   in	   response	   to	  CM	   from	  MKN45	  
cells.	   	   Treatment	   with	   CM	   from	   AGS	   cells	   resulted	   in	   a	   1.3-­‐fold	   increase	   in	   PAI-­‐1	  
mRNA	   abundance,	   although	   this	   did	   not	   reach	   statistical	   significance.	   	   As	   an	  
alternative	   approach,	   the	   expression	   of	   a	   PAI-­‐1-­‐luc	   promoter	   reporter	   construct	  
transfected	   into	  AGS	  cells	  was	  examined.	   In	   transfected	  AGS	  cells	   treated	  with	  CM	  
from	  myofibroblasts	  (3	  NTMs	  or	  CAMs	  3,	  4,	  10,	  11	  and	  14)	  there	  appeared	  to	  be	  a	  
decrease	   in	   PAI-­‐1-­‐luc	   expression	   compared	   with	   control,	   but	   this	   did	   not	   achieve	  
statistical	  significance	  (Figure	  3.1D).	  	  These	  data	  suggest	  that	  soluble	  factors	  derived	  
from	  cancer	  cells	  or	  myofibroblasts	  do	  not	  affect	  PAI-­‐1	  transcription	  or	  expression.	  






































































































Figure	  3.1.	   Increased	  expression	  of	  PAI-­‐1	  in	  CAMs	  compared	  with	  cancer	  cells.	  	  A,	  
PAI-­‐1	  mRNA	  expression	  determined	  by	  qPCR	  and	  expressed	  relative	  to	  GAPDH	  mRNA	  
expression	   is	   elevated	   in	   CAMs	   (n=3	   independent	   lines)	   compared	   to	  AGS	   cells.	  B,	  
Higher	  concentrations	  of	  secreted	  PAI-­‐1	  assessed	  by	  ELISA	   in	  the	  medium	  of	  CAMs	  
(n=3	   independent	   lines)	   compared	   to	  MKN45	   cells,	   normalised	   to	   cell	   number.	   C,	  
PAI-­‐1	  mRNA	  expression	  in	  CAMs	  1,	  11	  and	  14	  is	  not	  significantly	  changed	  in	  response	  
to	   CM	   from	   gastric	   cancer	   cell	   lines.	   PAI-­‐1	   mRNA	   abundance	   relative	   to	   GAPDH	  
mRNA	   is	   expressed	   as	   a	   fold	   change	   compared	   to	   SF	   medium.	   	   D,	   PAI-­‐1-­‐luc	  
expression	   in	   AGS	   cells	   is	   unchanged	   in	   response	   to	   CM	   from	   NTMs	   (n=3	  
independent	   lines)	   and	   from	   CAMs	   (n=4	   independent	   lines).	   The	   mean	   of	   2-­‐3	  
experiments	  is	  shown.	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3.3.2	  PAI-­‐1	  suppresses	  migration	  of	  AGS	  cells	  and	  CAMs	  but	  stimulates	  migration	  of	  
NTMs.	  
In	   order	   to	   investigate	   the	   effect	   of	   PAI-­‐1	   on	   the	   migration	   of	   cancer	   cells	   and	  
myofibroblasts,	  PAI-­‐1	  was	  added	  to	  the	  bottom	  well	  in	  Boyden	  chamber	  assays.	  	  AGS	  
cells	   were	   used	   for	   these	   experiments,	   as	   MKN45	   cells	   do	   not	   exhibit	   transwell	  
migration	   in	   this	   type	   of	   assay.	   	   Addition	   of	   50nM	   of	   human	   recombinant	   PAI-­‐1	  
almost	  completely	  suppressed	  migration	  of	  AGS	  cells	   (Figure	  3.2A).	   	  Similarly	  PAI-­‐1	  
suppressed	   migration	   of	   CAM14	   cells,	   although	   in	   this	   case	   the	   reduction	   was	  
approximately	  50%	  of	  that	  in	  SF	  medium	  (Figure	  3.2B).	  However,	  when	  NTMs	  were	  
used	   in	   the	   assay,	   PAI-­‐1	   had	   the	   opposite	   effect,	   stimulating	   cell	  migration	   6-­‐fold	  
(Figure	  3.2C).	  	  	  

































































Figure	   3.2.	   PAI-­‐1	   suppresses	   migration	   of	   AGS	   cells	   and	   CAMs	   but	   stimulates	  
migration	  of	  NTMs.	  A,	  Recombinant	  human	  PAI-­‐1	  (50	  nM)	  suppresses	  cell	  migration	  
in	  AGS	   cells	   in	   a	  Boyden	  chamber	  assay	  expressed	   relative	   to	   control	   (SF	  medium:	  
mean	  ±	  SE,	  105	  ±	  7	  cells	  per	  field).	  B,	  PAI-­‐1	  suppresses	  cell	  migration	  in	  CAM14	  cells	  
in	   a	   Boyden	   chamber	   assay	   relative	   to	   control	   (119	   ±	   5	   cells	   per	   field).	   C,	   PAI-­‐1	  
stimulates	  migration	   of	  NTMs	   relative	   to	   SF	   control	   (196	   ±	   17	   cells	   per	   field).	   The	  
mean	  of	  3	  experiments	  is	  shown.	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3.3.3	  MKN45	  E2-­‐C	  cells	  can	  be	  visualised	  by	  fluorescence	  microscopy	  and	  using	  
FMT.	  
MKN45	   E2-­‐C	   cells	  were	   visualised	   in	   culture	   under	   a	   TRITC	   filter.	   	   The	   intensity	   of	  
fluorescence	  was	  heterogeneous	  within	  the	  cell	  population	  but	  the	  majority	  of	  cells	  
appeared	   red	   (Figure	   3.3A).	   	   Varying	   concentrations	   of	   cells	   were	   suspended	   in	  
droplets	  of	  PBS	  and	  these	  were	  visualised	  using	  FMT,	  in	  the	  635nm	  channel	  (Figure	  
3.3B).	   	   The	   droplet	   containing	   the	   highest	   number	   of	   cells	   exhibited	   the	   highest	  
fluorescence.	  	  Untransfected	  MKN45	  cells	  exhibited	  fluorescence	  comparable	  to	  PBS	  
containing	  no	  cells	  (data	  not	  shown).	  
	  
In	  vivo,	  xenografts	  composed	  of	  MKN45	  cells	  transfected	  with	  E2-­‐C	  (with	  or	  without	  
PAI-­‐1)	  were	  more	   fluorescent	   than	   those	   composed	  of	  MKN45	  cells	   alone	   (Figures	  
3.4	  and	  3.5).	   	  The	  15-­‐120-­‐fold	  increase	  in	  fluorescent	  signal	  due	  to	  the	  transfection	  
of	   E2-­‐C	   shows	   that	   it	   is	   possible	   to	   grow	   and	   quantify	   fluorescent	   xenografts.	   	   In	  
order	  to	  eliminate	  any	  changes	  in	  fluorescent	  signal	  owing	  to	  differences	  in	  tumour	  
size,	   animals	   were	   imaged	   when	   the	   tumours	   reached	   comparable	   sizes.	   	   No	  
significant	  difference	  was	  observed	  in	  tumour	  volume	  at	  the	  time	  of	  imaging	  in	  this	  
experiment	  (Figure	  3.4D),	  although	  differences	  in	  the	  rate	  of	  tumour	  growth	  due	  to	  
the	  overexpression	  of	  PAI-­‐1	  were	  observed	  as	  described	  in	  3.3.4.	  
















Figure	   3.3.	   MKN45	   E2-­‐C	   cells	   can	   be	   visualised	   by	   fluorescence	   microscopy	   and	  
using	   FMT.	  A,	  Representative	   images	  of	  MKN45	  E2-­‐C	  cells	   in	  culture	  viewed	  under	  
phase	   contrast	   microscopy	   (left)	   and	   under	   fluorescence	   microscopy	   (right).	   B,	  
Representative	   images	   of	   droplets	   of	   MKN45	   E2-­‐C	   cells	   imaged	   using	   FMT	  
demonstrates	   higher	   fluorescence	   in	   the	   droplet	   containing	   the	   highest	  
concentration	  of	  cells	  (arrow).	  






































Figure	  3.4.	  Xenografts	  composed	  of	  MKN45	  E2-­‐C	  cells	  fluoresce	  at	  635nm	  and	  this	  
is	   captured	   by	   FMT.	   A-­‐C,	   Representative	   FMT	   images	   at	   635	   nm	  of	   subcutaneous	  
xenografts	  composed	  of	  MKN45	  cells	  (A),	  MKN45	  E2-­‐C	  cells	  (B)	  and	  MKN45	  E2-­‐C	  PAI-­‐
1	   cells	   (C)	   demonstrating	   higher	   signal	   in	   the	   xenografts	   composed	   of	   cells	  
transfected	  with	  E2-­‐C.	  D,	  Tumours	  did	  not	  have	  significantly	  different	  volumes	  at	  the	  
time	   of	   imaging.	   	   Mean	   results	   from	   4-­‐5	   animals	   are	   shown;	   results	   were	   not	  
statistically	  significantly	  difference	  by	  one-­‐way	  ANOVA.	  	  






































































Figure	   3.5.	   Subcutaneous	   xenografts	   transfected	   with	   E2-­‐C	   cells	   fluoresce	   at	  
635nm.	  A,	  Quantification	  of	  FMT	  signal	  in	  MKN45	  E2-­‐C	  xenografts	  (right)	  relative	  to	  
MKN45	  xenografts	  (left).	  B,	  Quantification	  of	  FMT	  signal	  in	  MKN45	  xenografts	  (left)	  
compared	   to	  MKN45	  E2-­‐C	  PAI-­‐1	  xenografts	   (right).	   	  Mean	  results	   from	  4-­‐5	  animals	  
are	   shown;	   horizontal	   bars	   denote	   statistical	   significance	   at	   p<0.05	   by	   Mann-­‐
Whitney	  test.	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3.3.4	  Transfection	  of	  MKN45	  cells	  with	  a	  PAI-­‐1	  over-­‐expressing	  plasmid	  results	  in	  
higher	  PAI-­‐1	  expression	  
As	  MKN45	  cells	  normally	  express	   low	  amounts	  of	  PAI-­‐1	   the	  consequences	  of	  over-­‐
expressing	  PAI-­‐1	  were	  studied	  as	  a	  model	  for	  elucidating	  the	  role	  of	  PAI-­‐1	  expression	  
in	  gastric	  cancer	  cells.	  	  This	  approach	  made	  it	  possible	  to	  study	  MKN45	  cell	  function	  
in	   response	   to	   increased	   autocrine	   PAI-­‐1	   without	   the	   influence	   of	   other	   soluble	  
mediators	   secreted	   by	  myofibroblasts.	   	   Thus	  MKN45	   cells	   were	   stably	   transfected	  
with	   either	   the	   fluorescent	   protein	   E2-­‐C	   alone	   or	   in	   combination	   with	   PAI-­‐1.	  	  	  
Transfection	   with	   E2-­‐C	   enabled	   colonies	   composed	   of	   transfected	   cells	   to	   be	  
identified	   and	   selected	   under	   the	   microscope	   (and	   was	   also	   used	   as	   a	   marker	   in	  
subsequent	   xenograft	   studies).	   	   As	   expected,	   MKN45	   E2-­‐C	   PAI-­‐1	   cells	   exhibited	  
higher	   PAI-­‐1	  mRNA	   expression	   than	   their	  MKN45	   E2-­‐C	   counterparts	   (Figure	   3.6A).	  
Moreover,	   immunofluorescence	   for	  PAI-­‐1	   in	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  demonstrated	  
more	   intense	   fluorescence	   than	   either	   MKN45	   cells	   or	   MKN45	   E2-­‐C	   cells	   (Figure	  
3.6B).	  	  	  









































Figure	  3.6.	  Transfection	  of	  MKN45	  cells	  with	  a	  PAI-­‐1	  overexpressing	  plasmid	  results	  
in	   higher	   PAI-­‐1	   expression.	   A,	   PAI-­‐1	   mRNA	   expression	   is	   elevated	   in	   2	   separate	  
transfections	   (I	   and	   II)	   of	   human	   PAI-­‐1	   plasmid	   into	  MKN45	   cells.	   The	  mean	   of	   3	  
experiments	   is	   shown.	   B,	   Representative	   immunocytochemistry	   images	   showing	  
higher	  intensity	  PAI-­‐1	  staining	  in	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  (bottom	  row)	  compared	  to	  
control	  MKN45	  cells	   (top	  row)	  or	  MKN45	  E2-­‐C	  cells	   (middle	  row).	  Left	  panels	  show	  
nuclear	  staining	  with	  DAPI,	  centre	  panels	  show	  PAI-­‐1	  localisation	  using	  FITC-­‐labelled	  
secondary	  antibody,	  right	  panels	  show	  merged	  images.	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3.3.5	  Transfection	  with	  PAI-­‐1	  has	  no	  effect	  on	  cell	  migration.	  
The	   effect	   of	   PAI-­‐1	   overexpression	   on	   cell	   migration	   was	   assessed	   using	   scratch	  
migration	  assays	  (Figure	  3.7A).	   	  Comparison	  of	  MKN45	  E2-­‐C	  cells	  with	  MKN45	  E2-­‐C	  
PAI-­‐1	   cells	   showed	   no	   significant	   difference	   in	   migration	   in	   SF	   medium	   or	   in	   FM	  
(Figure	  3.7B).	  	  	  
	  
3.3.6	  Transfection	  with	  PAI-­‐1	  has	  no	  effect	  on	  cell	  proliferation.	  
The	   effect	   of	   PAI-­‐1	   overexpression	   on	   cell	   proliferation	   was	   examined	   using	   EdU	  
incorporation	  assays	  (Figure	  3.8A).	  	  Comparison	  of	  proliferation	  in	  MKN45	  E2-­‐C	  cells	  
with	  MKN45	  E2-­‐C	  PAI-­‐1	  cells	  showed	  no	  significant	  difference	  in	  proliferation	  (Figure	  
3.8B).	  
	  
3.3.7	  Transfection	  with	  PAI-­‐1	  decreases	  cell	  adhesion	  and	  this	  is	  inhibited	  by	  
vitronectin.	  
The	  effect	  of	  overexpression	  of	  PAI-­‐1	  in	  MKN45	  cells	  on	  cell	  adhesion	  was	  assessed	  
using	  an	  in	  vitro	  assay	  of	  cell	  adhesion.	  	  Transfection	  of	  PAI-­‐1	  resulted	  in	  decreased	  
cell	  adhesion	  (Figure	  3.9A).	  	  However,	  when	  the	  assay	  was	  performed	  on	  vitronectin-­‐
coated	   plates,	   PAI-­‐1	   overexpressing	   cells	   exhibited	   increased	   adherence	   (Figure	  
3.9B).	  	  
	  
3.3.8	  Transfection	  with	  PAI-­‐1	  has	  no	  effect	  on	  invasion	  in	  an	  organotypic	  assay.	  
In	  order	  to	  assess	  cell	  invasion	  in	  a	  system	  which	  reflects	  the	  three-­‐way	  interaction	  
of	  cancer	  cells,	  myofibroblasts	  and	  extracellular	  matrix	  which	  occurs	  in	  vivo,	  an	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organotypic	  co-­‐culture	  system	  was	  developed	  (see	  chapter	  5).	  	  Overexpression	  of	  
PAI-­‐1	  in	  MKN45	  cells	  did	  not	  affect	  invasion	  into	  the	  gel	  layer	  seeded	  with	  
myofibroblasts	  after	  2	  weeks	  (Figure	  3.10A).	  
























Figure	   3.7.	   Transfection	   with	   PAI-­‐1	   has	   no	   effect	   on	   cell	   migration.	   A,	  
Representative	   example	   illustrating	   the	   method	   for	   quantification	   of	   scratch	  
migration	  assays;	  the	  mean	  percentage	  scratch	  closure	  across	  10	  measurements	  of	  
scratch	  width	  (red	  arrows,	  5	  points	  shown)	  per	  well	  after	  48	  h	  was	  determined.	   	  B,	  
Cell	   migration	   in	   serum-­‐free	   media	   (SF)	   or	   in	   full	   media	   (FM)	   is	   not	   significantly	  
different	   in	   MKN45	   E2-­‐C	   cells	   (left)	   and	   MKN4545	   E2C	   PAI-­‐1	   cells	   (right)	   by	  
transfection	  with	  PAI-­‐1.	  The	  mean	  of	  3	  experiments	  is	  shown.	  
	  























Figure	   3.8.	   Transfection	   with	   PAI-­‐1	   has	   no	   effect	   on	   cell	   proliferation.	   A,	  
Representative	   images	   showing	   EdU	   incorporation;	   quantification	   is	   performed	   by	  
calculation	   of	   the	   percentage	   of	   EdU	   positive	   nuclei.	   B,	   Cell	   proliferation	   is	   not	  
significantly	  different	  in	  MKN45	  E2-­‐C	  cells	  (left)	  and	  MKN4545	  E2C	  PAI-­‐1	  cells	  (right).	  
The	  mean	  of	  3	  experiments	  is	  shown.	  








































Figure	  3.9.	  Transfection	  with	  PAI-­‐1	  decreases	  cell	  adhesion	  and	  this	  is	  inhibited	  by	  
vitronectin.	   A,	   Adhesion	   is	   significantly	   lower	   in	   MKN45	   E2C	   PAI-­‐1	   cells	   (right)	  
compared	  with	  MKN45	   E2C	   cells	   (left).	  B,	   Adhesion	   is	   not	   significantly	   different	   in	  
MKN45	  E2-­‐C	  cells	  (left)	  and	  MKN45	  E2C	  PAI-­‐1	  cells	  (right)	   if	  the	  assay	   is	  performed	  
on	  vitronectin-­‐coated	  plates.	  The	  mean	  of	  3	  experiments	  is	  shown.	  
	  























Figure	   3.10.	   Transfection	  with	   PAI-­‐1	   has	   no	   effect	   on	   invasion	   in	   an	   organotypic	  
assay.	   A,	   Representative	   image	   of	   an	   organotypic	   culture,	   showing	   calculation	   of	  
invasion	  using	  the	  ratio	  of	   length	  of	  a	   line	  drawn	  along	  the	   interface	  between	  cells	  
and	   the	   gel	   (X)	   to	   the	   length	   of	   a	   straight	   line	   (Y).	   Arrows	   indicate	  myofibroblast	  
nuclei	   within	   the	   gel.	   	   B,	   Invasion	   in	   an	   organotypic	   culture	   is	   not	   significantly	  
different	  in	  MKN45	  E2-­‐C	  cells	  (left)	  and	  MKN45	  E2C	  PAI-­‐1	  cells	  (right).	  Results	  from	  3	  
experiments	  are	  shown.	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3.3.9	  Transfection	  with	  PAI-­‐1	  increases	  in	  vivo	  tumour	  growth	  
To	   examine	   the	   effect	   of	   PAI-­‐1	   overexpression	   on	   in	   vivo	   tumour	   growth	  
subcutaneous	   xenografts	   were	   established	   in	   BALB/c	   nu/nu	   mice.	   	   MKN45	   cells	  
overexpressing	  PAI-­‐1	  grew	  to	  a	  larger	  volume	  than	  those	  transfected	  with	  E2-­‐C	  alone	  	  
(Figure	  3.11A).	  
	  











































Figure	   3.11.	   Transfection	   with	   PAI-­‐1	   increases	   in	   vivo	   tumour	   growth.	   A,	   In	   a	  
subcutaneous	  xenograft	  model	  in	  BALB/c	  nu/nu	  mice,	  MKN45	  cells	  transfected	  with	  
PAI-­‐1	  exhibited	  higher	  tumour	  volume	  at	  day	  14	  compared	  with	  MKN45	  E2-­‐C	  cells.	  B,	  
Increased	   tumour	   growth	   of	   xenografts	   composed	   of	   MKN45	   E2-­‐C	   PAI-­‐1	   cells	  
compared	  to	  MKN45	  E2-­‐C	  cells.	  Results	  from	  4-­‐5	  animals	  are	  shown.	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3.4	  Discussion	  	  
The	   results	   in	   this	   chapter	   show	   that	   CAMs	   are	   the	   principal	   source	   of	   PAI-­‐1	   in	   a	  
model	  of	  stromal-­‐epithelial	   interaction	  in	  gastric	  cancer.	  	  The	  use	  of	  CM	  has	  shown	  
that	  soluble	  mediators	  from	  one	  cell	  type	  do	  not	  affect	  PAI-­‐1	  expression	  in	  the	  other	  
type.	  	  PAI-­‐1	  exhibited	  differing	  effects	  on	  cell	  migration;	  it	  suppressed	  the	  migration	  
of	  AGS	  cells	  and	  CAMs	  but	  enhanced	  migration	  of	  NTMs.	   Interestingly,	  when	  PAI-­‐1	  
was	  overexpressed	   in	  MKN45	  cells	   this	  did	  not	  alter	  cell	  proliferation,	  migration	  or	  
invasion	  but	  did	  decrease	  cell	  adhesion	  and	   in	  vivo	   in	  a	  xenograft	  model	  there	  was	  
increased	  tumour	  growth.	  	  
	  
Two	   different	   gastric	   cancer	   cell	   lines	   exhibited	   low	   expression	   of	   PAI-­‐1.	   	   In	   vivo,	  
however,	   there	   is	   a	   well-­‐recognised	   link	   between	   PAI-­‐1	   overexpression	   in	   gastric	  
cancer	   cells	   and	   disease	   progression	   (102).	   To	   model	   this	   experimentally,	   MKN45	  
cells	   overexpressing	   PAI-­‐1	  were	   therefore	   generated	   in	   an	   attempt	   to	   recapitulate	  
increased	  PAI-­‐1	  expression	  in	  a	  cell-­‐autonomous	  manner.	  	  	  It	  is	  possible	  that	  the	  PAI-­‐
1	   secreted	   by	   PAI-­‐1	   overexpressing	  MKN45	   cells	   differs	   in	   activity	   compared	  with	  
PAI-­‐1	   secreted	   endogenously.	   	   Although	   the	   use	   of	   gastric	   cancer	   cell	   lines	   has	  
allowed	  us	  to	  use	  a	  homogenous	  cell	  population,	  it	  is	  important	  to	  understand	  that	  
cell	  lines	  are	  prone	  to	  genotypic	  and	  phenotypic	  drift	  during	  continuous	  culture	  and	  
that	  this	  may	  mean	  they	  no	  longer	  possess	  the	  same	  characteristics	  of	  the	  tissue	  of	  
origin.	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The	  experimental	  approach	  to	  study	  cell	  migration	  involved	  scratch	  migration	  assays	  
and	  Boyden	  chambers.	  	  Scratch	  migration	  assays	  study	  cell	  movement	  into	  an	  empty	  
space	  in	  2	  dimensions,	  while	  Boyden	  chambers	  measure	  a	  chemotactic	  response	  as	  
cells	  migration	  along	  a	  concentration	  gradient.	   	   Scratch	  wound	  assays	  can	  be	  used	  
for	  both	  MKN45	  and	  AGS	  cells,	  but	  MKN45	  cells	  do	  not	  migrate	  in	  Boyden	  chambers.	  	  
The	   organotypic	   co-­‐culture	   system	   replicates	   more	   accurately	   the	   movement	   of	  
tumour	   cells	   in	   vivo,	   by	   modelling	   the	   interactions	   between	   cancer	   cells,	  
myofibroblasts	  and	  extracellular	  matrix.	   	   	  Regardless	  of	   the	  experimental	  approach	  
used	  to	  study	  cell	  movement,	  no	  difference	  in	  cell	  migration	  was	  observed	  as	  a	  result	  
of	  PAI-­‐1	  overexpression.	  
	  
The	  EdU	  proliferation	  assay	  allows	  studies	  of	  those	  cells	   in	  a	  population	  that	  are	   in	  
the	   S-­‐phase	   of	   the	   cell	   cycle.	   It	   is	   worth	   stressing	   that	   this	   does	   not	   necessarily	  
represent	   tumour	   growth	   which	   reflects	   the	   balance	   of	   cell	   proliferation	   and	   cell	  
death.	  This	  investigation	  did	  not	  examine	  apoptotic	  cells	  which	  would	  merit	  further	  
work	   in	   the	   future.	   	   Nevertheless	   in	   vivo	   in	   a	   xenograft	   model,	   the	   PAI-­‐1	   over-­‐
expressing	   cells	   were	   associated	   with	   increased	   tumour	   growth.	   Taking	   the	   two	  
observations	   together,	   it	   would	   appear	   that	   the	   link	   between	   PAI-­‐1	   and	   tumour	  
growth	  is	  not	  directly	  attributable	  to	  increased	  cancer	  cell	  proliferation.	  
	  
In	  gastric	  cancer,	  high	  PAI-­‐1	  expression	  has	  been	  shown	  to	  be	  a	  marker	  of	  advanced	  
tumour	  stage	  (104),	  although	  not	  all	  studies	  are	  in	  agreement	  (223,224).	  	  	  This	  may	  
arise	   from	   differences	   in	   the	   methods	   of	   quantification	   and	   the	   source	   of	   PAI-­‐1	  
studied.	   	   Some	   studies	   have	   examined	   PAI-­‐1	   expression	   in	   the	   tumour	   tissue	   by	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ELISA,	   although	   this	   approach	   does	   not	   distinguish	   between	   PAI-­‐1	   of	   cancer	   or	  
stromal	   cell	   origin	   (104,221).	   	   Others	   have	   visualised	   PAI-­‐1	   expression	   by	  
immunohistochemistry	   and	   only	   quantified	   staining	   in	   the	   cancer	   (epithelial)	   cells	  
(220).	  	  In	  other	  cancers,	  PAI-­‐1	  expression	  has	  been	  localized	  to	  the	  stroma	  (225),	  the	  
epithelial	  cells	  (226)	  or	  to	  both	  the	  stromal	  and	  epithelial	  compartments	  (227).	  	  Our	  
data	   show	   high	   PAI-­‐1	   expression	   in	   cultured	   stromal	   cells	   and	   low	   expression	   in	  
cultured	   cancer	   cells.	   	   Interestingly,	   there	  was	   no	   evidence	   for	   cross-­‐talk	   between	  
cancer	   cells	   and	   myofibroblasts	   with	   respect	   to	   control	   of	   PAI-­‐1	   expression.	  
Moreover,	  although	  PAI-­‐1	  expression	   in	  MKN45	  E2C	  PAI-­‐1	  cells	   remained	  relatively	  
low	  compared	  with	  myofibroblasts,	  it	  was	  still	  sufficient	  to	  enhance	  tumour	  growth	  
in	  vivo.	  
	  
The	  uPA	   system	   is	   part	  of	   a	   cascade	  of	   extracellular	  proteases	   capable	  of	   exerting	  
effects	   on	   cell	   migration,	   adhesion	   and	   invasion.	   	   When	   activated	   by	   binding	   to	  
uPAR,	  uPA	  cleaves	  its	  main	  substrate	  plasminogen,	  which	  in	  turn	  cleaves	  proteins	  in	  
the	  ECM,	  releasing	  growth	  factors	  and	  MMPs,	  and	  triggers	  the	  fibrinolytic	  cascade.	  	  
This	  promotes	  cell	  detachment,	  migration	  and	  invasion	  (215,228).	  	  PAI-­‐1	  is	  the	  main	  
physiological	   inhibitor	  of	  uPA,	  and	  it	   is	  able	  to	  suppress	  cell	  migration	  and	  invasion	  
by	   inhibiting	   proteolysis	   (229 ).	   	   	   PAI-­‐1	   is	   also	   able	   to	   interact	   with	   integrins,	  
vitronectin	  and	  lipoprotein	  receptor-­‐related	  protein	  1	  (LRP-­‐1)	  (230),	  which	  enables	  it	  
to	   influence	   intracellular	   signalling	   cascades	  which	   in	   turn	   lead	   to	   a	   range	  of	   uPA-­‐
independent	   effects	   on	   cell	   behaviour,	   which	   may	   be	   in	   opposition	   to	   those	  
occurring	  as	  a	  result	  of	  decreased	  extracellular	  proteolysis.	  	  The	  net	  influence	  of	  PAI-­‐
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1	  both	   in	  experimental	  and	  in	  clinical	  conditions	   is	  therefore	  presumably	  the	  result	  
of	  a	  balance	  between	  uPA-­‐related	  and	  uPA-­‐independent	  interactions.	  	  	  
	  
We	   did	   not	   show	   any	   effect	   of	   PAI-­‐1	   overexpression	   on	   cell	   migration.	   	   In	   the	  
literature,	  reports	  about	  the	  role	  of	  PAI-­‐1	  in	  cell	  migration	  are	  conflicting	  (231,232).	  	  
PAI-­‐1	   overexpression	   would	   be	   predicted	   to	   decrease	   cell	   migration	   through	   its	  
ability	   to	   suppress	  proteolysis,	  but	  even	  when	   it	  does,	   the	  mechanism	  may	  not	  be	  
uPA-­‐dependent	  (233).	  	  
	  
An	   example	   of	   PAI-­‐1’s	   uPA–independent	   effects	   lies	   in	   its	   interaction	   with	  
vitronectin.	   	   Vitronectin	   is	   a	   component	   of	   the	   extracellular	   matrix	   capable	   of	  
binding	  both	  to	  PAI-­‐1	  (92)	  and	  uPAR	  (234).	  	  This	  interaction	  enhances	  the	  activity	  of	  
PAI-­‐1	   by	   stabilizing	   its	   active	   conformation,	   leading	   to	  more	   effective	   inhibition	   of	  
proteolysis.	  	  Its	  binding	  to	  uPAR	  stabilizes	  the	  cell’s	  connection	  to	  the	  ECM,	  making	  it	  
less	  able	  to	  de-­‐adhere.	  	  	  
	  
Our	   results	   show	   in	   the	   presence	   of	   vitronectin,	   the	   decreased	   adhesion	   of	   PAI-­‐1	  
overexpressing	   cells	   was	   partially	   reversed.	   	   This	   is	   in	   agreement	   with	   published	  
data,	  where	  stable	  transfection	  of	  PAI-­‐1	  enhanced	  vitronectin	  binding	  and	  increased	  
cell	   adhesion	   (235).	   	   It	   may	   be	   that	   when	   the	   adhesion	   assay	   is	   performed	   on	  
vitronectin,	   the	   cell	   membrane-­‐associated	   uPAR	   binds	   to	   it,	   keeping	   the	   cell	  
anchored	  to	  the	  extracellular	  matrix	  and	  therefore	  less	  able	  to	  de-­‐adhere.	  	  Without	  
vitronectin	   however,	   we	   observed	   a	   decrease	   in	   cell	   adhesion	   when	   PAI-­‐1	   was	  
overexpressed	   in	   cancer	   cells.	   	   PAI-­‐1	   has	   previously	   been	   shown	   to	   decrease	   cell	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adhesion	  by	  its	  ability	  to	  disrupt	  the	  interaction	  between	  uPAR	  and	  integrins	  when	  it	  
is	  bound	  to	  the	  uPA-­‐uPAR	  complex	  (236).	   	   It	  remains	  uncertain	  whether	  or	  not	  this	  
effect	   contributes	   to	   the	   in	   vivo	   finding	   that	   PAI-­‐1	   overexpression	   resulted	   in	  
increased	   xenograft	   growth.	   	   In	   particular,	   xenograft	   growth	   is	   influenced	   by	   a	  
number	  of	   factors	  we	  have	  not	  studied	   in	  vitro,	   including	  the	  role	  of	  other	  stromal	  
cells	  (such	  as	  endothelial	  cells	  and	  inflammatory	  cells)	  and	  the	  response	  of	  tumours	  
to	  hypoxia	  or	  acidosis.	  
	  
The	  present	  results	  illustrate	  the	  complexity	  of	  PAI-­‐1	  in	  gastric	  cancer.	  	  Even	  so,	  the	  
data	  indicate	  that	  PAI-­‐1	  expressing	  cancer	  cells	  promote	  tumour	  growth	  in	  vivo	  and	  
this	   provides	   a	   basis	   for	   further	   study.	   	   In	   this	   context	   it	   is	   important	   to	   note,	  
however,	   that	   there	   are	   multiple	   pathways	   involving	   extracellular	   proteolysis	   in	  
cancer	   that	   remain	  only	  partially	   characterised.	  Similarly,	   the	   interactions	  between	  
myofibroblasts	   and	   cancer	   cells	   in	   vivo	   are	   still	   incompletely	   understood.	   In	   both	  
cases,	   it	   is	   apparent	   that	   these	   limitations	   restrict	   interpretation	  of	   studies	   on	   the	  




1. The	  main	  source	  of	  PAI-­‐1	  in	  cultured	  cells	  derived	  from	  gastric	  cancers	  is	  the	  
CAM.	  
2. CAM	  and	  cancer	  cell-­‐derived	  soluble	  mediators	  do	  not	  alter	  PAI-­‐1	  expression.	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3. Overexpression	   of	   PAI-­‐1	   in	   MKN45	   cells	   does	   not	   alter	   cell	   migration,	  
proliferation	   or	   invasion.	   	   PAI-­‐1	   overexpression	   results	   in	   decreased	   cell	  
adhesion	  and	  enhances	  xenograft	  growth	  (Figure	  3.12).	  









Figure	  3.12.	  Conflicting	  effects	  of	  PAI-­‐1	  in	  gastric	  cancer.	  In	  gastric	  cancer,	  PAI-­‐1	  is	  
secreted	  by	  CAMs.	   	  PAI-­‐1	  decreases	  the	  migration	  of	  gastric	  cancer	  cells	  and	  CAMs	  
but	  stimulates	  migration	  of	  NTMs.	  	  Overexpression	  of	  PAI-­‐1	  in	  xenografts	  enhances	  
tumour	  growth.	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Myofibroblasts	   stimulate	   tumour	   growth	   in	   a	   variety	   of	   cancers	   (237).	   	   Indeed,	   in	  
gastric	   cancer	   evidence	   from	   a	   subcutaneous	   xenograft	   study	   has	   shown	   that	   the	  
addition	   of	   CAMs	   to	   cancer	   cells	   resulted	   in	   a	   larger	   tumour	   (43).	   	   The	   effect	   of	  
myofibroblasts	  from	  normal	  gastric	  tissue	  or	  from	  tissue	  adjacent	  to	  the	  tumour	  has	  
not	  yet	  been	  firmly	  established	  and	  this	  study	  extended	  the	  model	  of	  myofibroblast-­‐
stimulated	  xenograft	  growth	  to	  include	  NTMs	  and	  ATMs.	  	  
	  
Myofibroblasts	   in	   tumours	   are	   thought	   to	   arise	   from	   the	   transformation	   of	   tissue	  
fibroblasts,	   from	   epithelial-­‐to-­‐mesenchymal	   transition	   of	   cancer	   cells	   or	   from	   the	  
influx	  of	  mesenchymal	  stromal	  cells	  from	  the	  bone	  marrow	  (34).	  	  This	  study	  further	  
characterised	  the	  origin	  of	  myofibroblasts	   in	  gastric	  cancer	  xenografts	  with	  the	  use	  
of	  species-­‐specific	  staining	  and	  fluorescent	  labelling	  of	  cancer	  cells.	  
	  
Little	  is	  known	  of	  the	  systemic	  effect	  a	  tumour	  has	  on	  the	  host	  organism.	  	  Molecules	  
released	   into	   the	  circulation	  affect	  a	  distant	  organ’s	  ability	   to	  host	  metastatic	   cells	  
(238)	  or	  instruct	  the	  bone	  marrow	  to	  release	  cells	  which	  are	  then	  incorporated	  into	  
the	   tumour	   (239).	   	   The	   contribution	   of	   stromal	   cells	   to	   the	   systemic	   effect	   of	   a	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tumour	   remains	   unknown	  and	   this	   study	   begins	   to	   examine	   the	   effect	   of	   stromal-­‐
epithelial	  interaction	  on	  the	  growth	  of	  a	  distant	  tumour.	  
	  
4.1.1	  Aims	  
1. To	   develop	   and	   characterise	   a	   subcutaneous	   MKN45	   xenograft	   system	  
capable	  of	  revealing	  the	  effect	  of	  myofibroblasts	  on	  tumour	  growth.	  
2. To	  determine	  the	  effect	  of	  CAMs,	  ATMs	  and	  NTMs	  on	  xenograft	  growth.	  
3. To	  study	  the	  effect	  of	  long-­‐range	  interactions	  between	  tumours.	  




4.2.1	  Cell	  culture	  
Primary	   gastric	   myofibroblasts,	   MKN45	   cells	   and	   AGS	   cells	   were	   cultured	   as	  
described	  in	  2.2.1-­‐2.	  	  
	  
4.2.2.	  Subcutaneous	  xenografts	  
Cell	  preparation	  was	  conducted	  as	  in	  2.2.3.	  	  Aliquots	  of	  cancer	  cells	  were	  prepared	  in	  
100μl	   PBS	   and	   injected	   subcutaneously.	   When	   MKN45	   cells	   were	   injected	   in	  
combination	  with	  myofibroblasts,	  1	  x	  105	  cells	  and	  5	  x	  104	  myofibroblasts	  were	  used.	  	  
The	  two	  cell	  types	  were	  mixed,	  centrifuged,	  re-­‐suspended	  in	  PBS	  and	  administered	  
as	   a	   single	   injection.	   For	   AGS	   cells,	   5	   x	   106	   AGS	   cells	   with	   or	   without	   2.5	   x	   105	  
myofibroblasts	  were	  used.	  	  Tissues	  were	  harvested	  as	  described	  in	  2.2.4.	  
	  
4.2.3	  Haematoxylin	  and	  Eosin	  (H&E)	  staining	  
Tissues	  were	  paraffin-­‐embedded	  and	  processed	  for	  H&E	  staining	  by	  the	  Department	  
of	  Pathology,	  School	  of	  Veterinary	  Science,	  University	  of	  Liverpool.	  
	  
4.2.4	  Immunohistochemistry	  
Sections	  were	  stained	  for	  Ki-­‐67,	  cleaved	  caspase-­‐3	  and	  αSMA	  by	  the	  Department	  of	  
Cellular	  Pathology,	  Royal	   Liverpool	  University	  Hospital.	   	  A	   field	  of	   fixed	  dimensions	  
was	   superimposed	   on	   an	   area	   of	   the	   section	   containing	   cancer	   cells	   (rather	   than	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necrotic	  or	  ulcerated	  areas,	  or	  areas	  of	  inflammatory	  infiltrate)	  and	  this	  was	  scored	  
on	  a	  4-­‐point	  scale	  (0	  =	  no	  staining,	  1	  =	  <10%	  cells	  positive,	  2	  =	  10-­‐50%	  cells	  positive,	  3	  
=	  50-­‐90%	  cells	  positive,	  4	  =	  >90%	  cells	  positive).	  
	  
4.2.5	  Immunofluorescence	  
	  Frozen	   sections	   of	   tumour	   tissue	   and	   mouse	   stomach	   were	   processed	   for	  
immunofluorescence	  as	  described	  in	  2.2.6a.	  	  




4.3.1	  Tumour	  size	  is	  proportional	  to	  the	  number	  of	  MKN45	  cells	  administered.	  	  
In	  order	  to	  generate	  xenografts	  of	  an	  appropriate	  volume	  over	  a	  suitable	   length	  of	  
time	  animals	  were	   injected	  with	  varying	  numbers	  of	  MKN45	  cells	  and	  the	  resulting	  
xenograft	  volumes	   followed	  over	   time.	   	  The	  same	  experiment	  was	  performed	  with	  
AGS	   cells	   but	   subcutaneous	   injections	   of	   up	   to	   5	   x	   106	   cells	   yielded	   no	   tumours.	  	  
Animals	  were	  also	  injected	  with	  CAMs	  alone	  and	  again	  no	  tumours	  resulted.	  	  	  
	  
Animals	   injected	   with	   5	   x	   106	  MKN45	   cells	   developed	   visible	   tumours	   earlier	   and	  
exhibited	  faster	  tumour	  growth	  compared	  to	  smaller	  numbers	  of	  cells	  (Figure	  4.1A).	  	  
At	   a	   given	   time	   point	   tumour	   volume	  was	   directly	   proportional	   to	   the	   number	   of	  
injected	   cells	   (Figure	   4.1B).	   	   However,	   animals	   with	   a	   high	   tumour	   burden	  
experienced	  significant	  weight	  loss	  and	  in	  two	  cases	  this	  necessitated	  sacrifice.	  	  
	  
Injections	  of	  fewer	  MKN45	  cells	  resulted	  in	  slower	  tumour	  growth	  and	  consequently	  
longer	  animal	  survival.	  	  The	  yield	  of	  tumours	  was	  decreased	  but	  where	  tumours	  did	  
develop,	   their	   growth	   was	   more	   consistent.	   	   The	   reasons	   for	   sacrifice	   in	   these	  
animals	  were	  tumour	  dimensions	  or	  ulceration.	  























































Figure	  4.1.	  Tumour	  size	  is	  proportional	  to	  the	  number	  of	  MKN45	  cells	  injected.	  A,	  
Use	   of	   higher	   MKN45	   cell	   number	   at	   subcutaneous	   injection	   resulted	   in	   faster	  
tumour	  growth	  and	  earlier	  sacrifice	  of	  the	  mouse.	  	  Fractions	  denote	  the	  proportion	  
of	  subcutaneous	  injections	  which	  eventually	  yielded	  a	  tumour.	  B,	  Tumour	  volume	  on	  
day	  14	  is	  directly	  related	  to	  MKN45	  cell	  number.	  Mean	  results	  from	  4-­‐6	  animals	  are	  
shown.	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4.3.2	  Myofibroblasts	  enhance	  xenograft	  growth.	  
The	  addition	  of	  myofibroblasts	  to	  MKN45	  cells	  stimulated	  tumour	  growth.	  	  Addition	  
of	  NTMs,	  CAMs	  and	  ATMs	  all	  potentiated	  tumour	  growth	  to	  the	  same	  extent	  (Figure	  
4.2A).	   	   The	   tumour	   yield	   per	   injection	   was	   also	   improved	   by	   the	   addition	   of	  
myofibroblasts,	  as	  only	  2/5	  injections	  produced	  a	  tumour	  when	  1	  x	  105	  MKN45	  cells	  
were	   injected	  alone,	  whereas	   in	  combination	  with	  myofibroblasts	   this	   increased	  to	  
5/5	   in	   all	   but	   one	  myofibroblast	   type	   (Figure	   4.3).	   	   This	   experiment	  was	   repeated	  
using	  AGS	  cells	  with	  CAMs	  but	  this	  did	  not	  yield	  any	  visible	  or	  palpable	  tumours.	  
	  
The	   use	   of	   CAM/ATM	   paired	   samples	   allowed	   comparison	   of	  myofibroblasts	   from	  
the	  same	  patient.	   	   In	   the	  case	  of	  patient	  9,	  ATMs	  potentiated	   tumour	  growth	   to	  a	  
greater	   extent	   than	   CAMs	   (Figure	   4.2B).	   	   However,	   when	   myofibroblasts	   from	  
patient	   11	  were	   used,	   the	   CAMs	   and	   ATMs	   enhanced	   tumour	   growth	   to	   a	   similar	  
degree	  (Figure	  4.2C).	  












































































Figure	  4.2.	  Myofibroblasts	   enhance	  xenograft	   growth.	   	  A,	  Tumours	  containing	  1	  x	  
105	   MKN45	   cells	   with	   5	   x	   104	   NTMs,	   CAMs	   or	   ATMs	   all	   achieve	   a	   larger	   tumour	  
volume	  on	  day	  23	  than	  those	  composed	  of	  1	  x	  105	  MKN45	  cells	  alone.	  Results	  from	  
two	  CAMs	  with	  their	  corresponding	  ATMs	  and	  two	  NTMs	  are	  shown,	  5	  animals	  per	  
group.	  B,	  ATM9	  potentiates	  tumour	  growth	  more	  than	  CAM9,	  as	  shown	  by	  tumour	  
volume	  on	  day	  23.	  Mean	  results	  from	  5	  animals	  are	  shown;	  horizontal	  bars	  represent	  
statistical	   significance	   by	   Kruskal-­‐Wallis	   test	   with	   Dunn’s	   post-­‐hoc	   comparison.	   C,	  
CAM11	   and	   ATM11	   potentiate	   tumour	   growth	   to	   the	   same	   extent,	   as	   tumours	   of	  
similar	  volumes	  develop	  by	  day	  23.	  Mean	  results	  from	  5	  animals	  are	  shown.	  	  











































































Figure	  4.3.	  Myofibroblasts	  stimulate	  MKN45	  xenograft	  growth.	  A,	  CAMs	  stimulate	  
MKN45	   xenograft	   growth.	   B,	   NTMs	   stimulate	   MKN45	   xenograft	   growth.	   C,	   ATMs	  
stimulate	  MKN45	  xenograft	  growth.	  	  All	  experiments	  used	  1	  x	  105	  MKN45	  cells	  with	  
or	  without	  5	  x	  104	  myofibroblasts.	  	  Fractions	  denote	  the	  proportion	  of	  subcutaneous	  
injections	   which	   eventually	   yielded	   a	   tumour.	   Mean	   results	   from	   5	   animals	   are	  
shown.	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4.3.3	  Tumours	  with	  or	  without	  myofibroblasts	  exhibit	  similar	  features.	  
In	   situ	   the	   tumours	   appeared	   as	   subcutaneous	   masses,	   whose	   mean	   diameter	  
approached	   1.2cm	   at	   around	   the	   same	   time	   as	   developing	   ulceration	   at	   the	   skin	  
surface.	   	   Macroscopically	   the	   tumours	   were	   firm	   lumps	   of	   tissue	   which	   were	  
adherent	  to	  but	  easily	  removed	  from	  the	  underlying	  intercostal	  muscles.	  	  Where	  no	  
ulceration	  had	  occurred,	  the	  overlying	  skin	  was	  normal	  and	  had	  not	  adhered	  to	  the	  
tumour	  (Figure	  4.4).	  
	  
Histological	   examination	   revealed	   features	   of	   poorly	   differentiated	   gastric	  
adenocarcinomas.	   	   Low	   power	   views	   show	   areas	   of	   cancer	   cells	   with	   patches	   of	  
necrosis	   (Figure	   4.5,	   images	   in	   left	   column).	   	   At	   higher	   power	   cancer	   cells	   with	  
atypical	  nuclei	  and	  a	  high	  nuclear	  to	  cytoplasmic	  ratio	  are	  visible	  (Figure	  4.5,	  images	  
in	  right	  column).	  	  The	  areas	  of	  necrosis	  are	  bordered	  by	  cell	  debris.	  	  Ulceration	  of	  the	  
tumour	  into	  the	  skin	  surface	  is	  seen	  (Figure	  4.6A-­‐B).	  	  Invasion	  into	  the	  muscle	  is	  also	  
a	  feature	  of	  these	  tumours	  (Figure	  4.6C-­‐D).	  	  Development	  of	  blood	  vessels	  within	  the	  
tumour	  parenchyma	  is	  evidence	  of	  angiogenesis	  (Figure	  4.6E).	  	  Post-­‐mortem	  the	  liver	  
and	   lungs	   of	   the	   mice	   were	   removed	   and	   examined	   for	   macroscopic	   evidence	   of	  
distant	  metastasis	  and	  none	  was	  found.	  
	  
All	  of	  the	  features	  above	  were	  noted	  in	  xenografts	  composed	  of	  MKN45	  cells	  alone	  
and	   those	   containing	  myofibroblasts.	   	   An	   independent	   pathologist	   scored	   sections	  
for	   necrosis,	   stromal	   content,	   invasion	   and	   presence	   of	   blood	   vessels	   and	   no	  
difference	  between	  groups	  was	  identified.	  
















Figure	   4.4.	   Similar	   macroscopic	   appearance	   of	   subcutaneous	   xenografts	   with	   or	  
without	  myofibroblasts.	   	   A,	   B	  Representative	   images	  of	  subcutaneous	  MKN45	  cell	  
xenografts	   in	  situ	  and	  ex	  vivo	  demonstrating	  tumour	  size	  and	  superficial	  ulceration.	  
C,	   D	  Representative	   images	  of	  MKN45	  and	  ATM11	   xenografts.	  E,	   F	   An	  example	  of	  
MKN45	  and	  CAM11	  xenograft.	  Note	  the	  lack	  of	  skin	  ulceration	  in	  this	  example.	  G,	  H	  
Images	  of	  MKN45	  and	  NTM2	  xenografts.	  	  


















Figure	   4.5.	   Tumours	   with	   or	   without	   myofibroblasts	   exhibit	   similar	   histological	  
features.	   	   A-­‐C,	   Representative	   images	   of	   sections	   from	   tumours	   composed	   of	  
MKN45	  alone.	  D-­‐F,	   Sections	   from	   tumours	   containing	  MKN45	  and	  ATM1	  cells.	  G-­‐I,	  
Sections	   from	   tumours	   containing	   MKN45	   and	   CAM1	   cells.	   J-­‐L,	   Sections	   from	  
tumours	  containing	  MKN45	  and	  NTM	  cells.	  In	  all	  cases	  H&E	  staining.	  Note	  epithelial	  
cells	  (white	  arrows)	  and	  areas	  of	  necrosis	  (black	  arrows).	  









Figure	   4.6.	   Subcutaneous	   MKN45	   xenografts	   with	   or	   without	   myofibroblasts	  
exhibit	   skin	   ulceration,	   muscle	   invasion	   and	   angiogenesis.	   	   A-­‐B,	   Representative	  
images	  of	  H&E	  stained	  tumour	  sections	  showing	  ulceration	  at	  the	  skin	  surface.	  C-­‐D,	  
Invasion	  into	  muscle.	  E,	  Formation	  of	  new	  vessels	  (arrow).	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4.3.4	  The	  presence	  of	  myofibroblasts	  in	  a	  xenograft	  suppresses	  the	  growth	  of	  a	  
contralateral	  tumour	  composed	  of	  MKN45	  cells	  alone.	  
A	  bilateral	  model	  of	  xenograft	  growth	  was	  developed	  in	  which	  the	  right	  flank	  of	  the	  
mouse	  was	  injected	  with	  MKN45	  cells	  and	  CAMs	  and	  the	  left	  with	  MKN45	  cells	  alone	  
(Figure	  4.7A-­‐B).	  	  It	  was	  noticed	  that	  when	  both	  sides	  were	  injected	  with	  MKN45	  cells	  
alone,	   the	   resulting	   tumours	   were	   of	   equal	   size.	   	   When	   the	   right	   side	   contained	  
CAMs,	  however,	  the	  left-­‐sided	  tumour	  was	  smaller	  or	  did	  not	  appear	  (Figure	  4.7C-­‐D).	  	  	  
	  
In	  mice	  with	  bilateral	  MKN45	  cell	  tumours,	  the	  appearance	  of	  the	  tumours	  occurred	  
at	   the	   same	   time.	   	   In	   mice	   where	   the	   right	   side	   contained	   CAMs,	   the	   left-­‐sided	  
tumour’s	  appearance	  was	  delayed	  or	  did	  not	  occur	  at	  all	  within	  the	  42	  days	  of	  the	  
experiment	  (Figure	  4.8).	  	  	  
	  
This	  finding	  applied	  to	  most	  but	  not	  all	  CAMs.	  	  	  In	  the	  case	  of	  CAM7,	  neither	  the	  side	  
containing	  CAMs	  nor	  the	  one	  injected	  with	  MKN45	  cells	  alone	  developed	  a	  tumour.	  	  
CAMs	  2	  and	  12	  failed	  to	  stimulate	  local	  xenograft	  growth	  but	  did	  not	  seem	  to	  affect	  
the	   contralateral	   tumour.	   	   The	   experiment	  was	   repeated	   for	   these	   CAMs	   and	   the	  
result	  found	  to	  be	  the	  same.	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Figure	  4.7.	  The	  presence	  of	  myofibroblasts	  in	  a	  xenograft	  suppresses	  the	  growth	  of	  
a	  contralateral	  tumour	  composed	  of	  MKN45	  cells	  alone.	  	  A-­‐B,	  Experimental	  design.	  
C,	   Larger	   volume	   of	   MKN45	   tumour	   when	   contralateral	   to	   a	   tumour	   without	  
myofibroblasts.	  Mean	  results	  from	  11	  CAMs	  are	  shown	  (the	  result	  for	  each	  CAM	  was	  
the	  mean	  of	   the	   results	   from	  3	  mice	   per	   CAM).	  D,	   Representative	   photographs	   of	  
MKN45	   tumours	   demonstrating	   smaller	  MKN45	   tumour	   grown	   opposite	   a	   tumour	  
containing	  myofibroblasts	  (arrow).	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Figure	   4.8.	   The	   time	   taken	   for	   a	   MKN45	   tumour	   to	   sprout	   is	   longer	   when	   the	  
contralateral	   tumour	   contains	   myofibroblasts.	   Median	   time	   to	   sprout	   (±	  
interquartile	   range)	   for	  MKN45	   cells	  on	  both	   sides	   is	   similar	   (bottom	  blue	  and	   red	  
bars)	  whereas	  the	  time	  taken	  for	  a	  MKN45	  tumour	  contralateral	  to	  a	  MKN45	  +	  CAM	  
tumour	   to	   sprout	   is	   longer	   (blue	  bars)	   than	   the	  MKN45	  +	  CAM	   tumour	   (red	  bars).	  	  
Results	  from	  3	  mice	  per	  CAM	  and	  6	  MKN45	  alone	  mice	  are	  shown,	  IQ	  range	  shown	  
when	   more	   than	   2	   tumours	   developed	   in	   that	   group.	   	   Numbers	   represent	   the	  
number	  of	  tumours	  that	  developed	  from	  the	  subcutaneous	  injections.	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4.3.5	  Immunohistochemistry	  demonstrates	  no	  difference	  in	  cell	  proliferation,	  
apoptosis	  or	  myofibroblast	  staining	  in	  tumours	  composed	  of	  MKN45	  cells	  
alone	  or	  with	  myofibroblasts.	  
Immunohistochemical	   staining	   for	   Ki-­‐67,	   cleaved	   caspase-­‐3	   and	   α-­‐SMA	   was	   then	  
performed	   to	   further	   characterise	   MKN45	   cell	   xenografts	   with	   or	   without	   CAM	  
(Figure	   4.9).	   	   Ki-­‐67	   staining	   demonstrated	   high	   proliferation	   rates	   in	   both	  MKN45	  
alone	  xenografts,	  and	  MKN45	  plus	  myofibroblasts	  (all	  tumours	  scored	  4),	  suggesting	  
the	  altered	  tumour	  size	  is	  not	  due	  to	  changes	  in	  cell	  proliferation	  rates.	  	  Staining	  for	  
cleaved	   caspase-­‐3	   revealed	   consistently	   low	   rates	   of	   apoptosis,	   with	   all	   sections	  
scoring	  1.	  	  Finally,	  the	  pattern	  of	  α-­‐SMA	  staining	  showed	  that	  all	  tumours	  contained	  
myofibroblasts	   (even	   if	   they	  had	  not	  been	   injected	  with	  myofibroblasts)	  suggesting	  
that	   there	   is	   a	   mouse-­‐derived	   source	   of	   myofibroblasts	   in	   these	   tumours.	  	  
Immunohistochemical	   staining	   indicated	   cell	   proliferation,	   apoptosis	   and	  
myofibroblast	  content	  per	  unit	  area	  were	  similar	  regardless	  of	  tumour	  size.	  
























Figure	   4.9.	   Immunohistochemistry	   for	   Ki67,	   α-­‐SMA	   and	   cleaved	   caspase-­‐3	  
demonstrates	   no	   difference	   in	   cell	   proliferation,	   apoptosis	   or	   myofibroblast	  
content	   in	   tumours	   composed	   of	   MKN45	   cells	   alone	   or	   in	   combination	   with	  
myofibroblasts.	   A-­‐C,	   Negative	   control	   (no	   primary	   antibody)	   D-­‐F,	   Representative	  
images	  of	  Ki-­‐67	  staining	   in	  areas	  of	   tumour	  containing	  cancer	  cells	   showing	  similar	  
proportions	  of	  proliferating	  cells.	  G-­‐I,	  Cleaved	  caspase-­‐3	  staining	   in	  areas	  of	  cancer	  
cells	   showing	   no	   difference	   in	   apoptosis.	   J-­‐L,	   α-­‐SMA	   staining	   showing	   similar	  
distribution	   and	   number	   of	   myofibroblasts.	   	   Fields	   containing	   cancer	   cells	   (rather	  
than	  necrotic	  or	  ulcerated	  areas,	  or	  areas	  of	   inflammatory	   infiltrate)	  were	  selected	  
and	  scored.	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4.3.6.	  Tumours	  injected	  with	  human	  myofibroblasts	  stain	  positively	  for	  human	  
vimentin.	  
To	   attempt	   to	   distinguish	   myofibroblasts	   of	   human	   origin	   from	   those	   of	   mouse	  
origin,	   two	   primary	   antibodies	   for	   vimentin	   were	   used	   in	   immunofluorescence	  
experiments.	   	   One	   was	   non-­‐species	   specific	   and	   the	   other	   targeted	   the	   human	  
vimentin	  V9	  filament.	  	  Tumour	  sections	  were	  examined	  by	  confocal	  microscopy.	  	  The	  
human	  vimentin-­‐specific	  antibody	  only	  exhibited	  positive	  staining	  on	  sections	   from	  
tumours	  injected	  with	  human	  myofibroblasts	  (Figure	  4.10A).	  	  Sections	  from	  tumours	  
composed	   of	   MKN45	   cells	   alone	   were	   only	   positive	   for	   vimentin	   when	   the	   non	  
species-­‐specific	   antibody	   was	   used,	   suggesting	   that	   the	   stromal	   cells	   in	   these	  
tumours	  were	  mouse-­‐derived	  (Figure	  4.10B).	  











Figure	   4.10.	   Tumours	   injected	   with	   human	   myofibroblasts	   stain	   positively	   for	  
human	   vimentin.	   	   A,	   Representative	   images	   taken	   using	   confocal	   fluorescence	  
microscopy	  showing	  vimentin	  (FITC)	  and	  human	  vimentin	  V9	  filament	  (TXR)	  staining.	  
This	   reveals	  myofibroblasts	   stained	  with	   both	   antibodies	   in	   tumours	   composed	   of	  
MKN45	   +	   CAM3	   (arrows).	   B,	   In	   MKN45	   tumours	   there	   is	   no	   positive	   staining	   for	  
human	  vimentin	  but	  myofibroblasts	  do	  stain	  for	  vimentin	  (arrow).	  From	  left	  to	  right:	  
localisation	  of	  non	  species-­‐specific	  vimentin	  conjugated	  to	  FITC	  secondary	  antibody,	  
human	   vimentin	   V9	   filament	   localisation	   using	   TXR-­‐labelled	   secondary	   antibody,	  
merged	  images.	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4.3.7	  MKN45E2-­‐C	  cells	  are	  not	  identified	  in	  the	  tumours	  containing	  CAMs,	  
suggesting	  cell	  migration	  towards	  tumours	  containing	  CAMs	  is	  not	  
responsible	  for	  the	  smaller	  contralateral	  tumour	  size.	  
In	   4.3.4	  we	   showed	   that	  MKN45	   cell	   xenografts	   contralateral	   to	   a	  MKN45	   +	   CAM	  
xenograft	  appeared	  later	  and	  achieved	  a	  smaller	  volume	  than	  those	  contralateral	  to	  
MKN45	  cells	  alone.	  	  In	  order	  to	  investigate	  whether	  the	  migration	  of	  cells	  from	  one	  
side	  towards	  the	  side	  containing	  CAMs	  was	  responsible	  for	  this	  effect,	  MKN45	  E2-­‐C	  
cells	   were	   injected	   opposite	   tumours	   composed	   of	   MKN45	   cells	   +	   CAMs	   (Figure	  
4.11A).	  	  	  
	  
Examination	  of	  frozen	  sections	  under	  a	  TXR	  filter	  did	  not	  reveal	  any	  red	  cells	  in	  the	  
contralateral	   tumour,	   although	   the	   E2-­‐C	   cells	   were	   seen	   in	   the	   tumours	   which	  
appeared	   at	   the	   site	   of	   their	   injection	   (Figure	   4.11B).	   	   Results	   from	   EdU	   staining	  
confirmed	  the	  findings	  (Figure	  4.9D-­‐F)	   that	  xenografts	  contain	  areas	  of	  cancer	  cells	  
exhibiting	  high	  proliferation	  (figure	  4.12A).	  	  This	  suggested	  that	  the	  cells	  injected	  at	  
one	  site	  did	  not	  make	  their	  way	  to	  the	  CAM-­‐containing	  tumour.	  
	  
4.3.8	  Myofibroblasts	  do	  not	  colocalise	  with	  E2-­‐C	  positive	  cells,	  suggesting	  the	  
myofibroblasts	  are	  not	  derived	  from	  MKN45	  cells.	  
In	   order	   to	   investigate	   the	   origin	   of	  myofibroblasts	  within	  MKN45	   cell	   xenografts,	  
sections	   from	  MKN45	  E2-­‐C	   tumours	  were	  examined	   for	  co-­‐localisation	  of	  E2-­‐C	  and	  
vimentin.	   	   This	   would	   show	   whether	   the	   epithelial	   MKN45	   cells	   had	   acquired	  
mesenchymal	   markers,	   which	   would	   be	   evidence	   for	   epithelial-­‐mesenchymal	  
transition	  (EMT).	   	  No	  cells	  were	  found	  which	  were	  both	  E2-­‐C	  and	  vimentin	  positive	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(Figure	  4.12A),	  indicating	  that	  the	  myofibroblasts	  were	  not	  a	  product	  of	  EMT	  of	  the	  
MKN45	  cells.	  	  	  
	  
4.3.9	  Tumours	  contains	  areas	  of	  cells	  with	  a	  high	  proliferative	  rate;	  these	  colocalise	  
with	  E2-­‐C	  positive	  cells	  
Use	  of	  fluorescent	  MKN45	  cells	  demonstrated	  that	  EdU	  positive	  cells	  colocalise	  with	  
E2-­‐C	  positive	  cells	  (figure	  4.12B)	  showing	  that	  the	  source	  of	  the	  proliferating	  cells	  is	  
indeed	  the	  MKN45	  E2-­‐C	  cells	  injected	  at	  the	  start	  of	  the	  experiment.	  











Figure	  4.11.	  MKN45	  E2-­‐C	  cells	  are	  not	  identified	  in	  the	  tumours	  containing	  CAMs.	  	  
A,	   Experimental	   design	   showing	   MKN45	   E2-­‐C	   xenografts	   contralateral	   to	   ones	  
composed	   of	   MKN45	   cells	   +	   CAMs.	   B,	   Representative	   fluorescence	   microscopy	  
images	  demonstrating	  no	  evidence	  of	  E2-­‐C	  positive	  cells	  (TXR	  filter)	  in	  the	  MKN45	  +	  
CAM	  tumours	  (bottom	  row)	  compared	  to	  the	  MKN45	  E2-­‐C	  tumours	  (top	  row).	  	  Areas	  
of	   proliferating	   cells	   are	   identified	   by	   EdU	   positivity.	   From	   left	   to	   right:	   EdU	  
localisation	   using	   FITC-­‐labelled	   secondary	   antibody,	   E2-­‐C	   visualisation	   under	   TXR	  
filter,	  merged	  images.	  
	  









Figure	  4.12.	  E2-­‐C	  cells	  do	  not	  colocalise	  with	  myofibroblasts	  but	  proliferate	  in	  vivo.	  
A,	  Myofibroblast	   (arrow)	   does	   not	   colocalise	   with	   E2-­‐C	   +ve	   cells,	   suggesting	   EMT	  
does	   not	   occur.	   From	   left	   to	   right:	   vimentin	   localisation	   using	   FITC-­‐labelled	  
secondary	   antibody,	   E2-­‐C	   visualisation	   under	   TXR	   filter,	   merged	   images.	   B,	   E2-­‐C	  
positive	  cells	  colocalise	  with	  EdU	  positive	  cells,	  suggesting	  that	  the	  proliferating	  cells	  
within	  a	  tumour	  are	  MKN45	  E2-­‐C	  cells.	  Left	  panel	  shows	  EdU	  localisation	  using	  FITC-­‐
labelled	   secondary	   antibody,	   centre	   panel	   shows	   E2-­‐C	   localisation	  under	   TXR	   filter	  
and	  right	  panel	  shows	  merged	  images.	  




The	   present	   study	   has	   characterised	   a	   model	   for	   gastric	   tumour	   xenografts	   using	  
MKN45	  cells.	  Tumour	  growth	  is	  accelerated	  by	  the	  addition	  of	  gastric	  myofibroblasts,	  
and	  CAMs,	  ATMs	  and	  NTMs	  are	  equally	  effective	  in	  this	  regard.	  	  Tumours	  generated	  
without	   or	   with	   myofibroblasts	   are	   macroscopically	   similar	   and	   demonstrate	  
histological	   features	   of	   a	   poorly	   differentiated	   carcinoma	   with	   areas	   of	   necrosis.	  	  
Interestingly,	   MKN45	   cell	   xenografts	   injected	   contralateral	   to	   MKN45	   plus	   CAM	  
xenografts	   are	   smaller	   and	   develop	   later	   than	   those	   opposite	   xenografts	   without	  
CAMs.	  	  	  
	  
The	   present	   subcutaneous	   xenograft	   model	   reconstitutes	   in	   vivo	   a	   tumour	  
microenvironment	  based	  on	   interactions	  between	  myofibroblasts	   and	   cancer	   cells.	  	  
It	   is	   important	   to	   recognise	   that	   the	   growth	   of	   xenografts	   is	   also	   influenced	   by	  
mouse-­‐derived	  responses	  to	  these	  tumours,	  including	  the	  influx	  of	  endothelial	  cells,	  
mouse	   myofibroblasts,	   immune	   cells	   and	   MSCs.	   Inevitably,	   the	   use	   of	  
immunosuppressed	  mice	  influences	  the	  immune	  component	  of	  the	  host	  response	  to	  
a	  tumour.	   	  Thus	  while	  subcutaneous	  xenografts	   in	   immunosuppressed	  mice	  do	  not	  
fully	  reproduce	  the	  cancer	  microenvironment	  they	  nevertheless	  provide	  a	  basis	   for	  
studying	  the	  interactions	  between	  cancer	  cells	  and	  key	  stromal	  cell	  types.	  
	  
In	   order	   to	   circumvent	   the	   use	   of	   immunosuppressed	   animals,	   mouse	   models	   of	  
gastric	   cancer	   have	   been	   developed.	   	   Chronic	   H.	   felis	   infection	   in	   C57BL/6	   mice	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mimics	   the	   effect	   of	   H.	   Pylori	   in	   humans,	   a	   potent	   gastric	   carcinogen	   which	  
eventually	   leads	   to	   the	  development	  of	  gastric	  dysplasia,	  metaplasia	  and	  neoplasia	  
closely	  mirroring	  the	  sequence	  of	  lesions	  seen	  in	  the	  development	  of	  human	  gastric	  
cancer	   (185).	   	   This	  process	   can	  be	  accelerated	  by	   combining	  H.	   felis	   infection	  with	  
the	  use	  of	   insulin-­‐gastrin	  (INS-­‐GAS)	  mice,	  a	  genetically-­‐engineered	  mouse	  model	  of	  
hypergastrinaemia	   (187).	   	   These	   models	   have	   been	   limited	   by	   modest	   gastric	  
pathology	  and	  slow	  time	  course,	  and	  are	  affected	  by	  environmental	  conditions	  such	  
as	  housing,	  temperature	  and	  humidity.	  
	  
The	   histological	   and	   immunohistochemical	   analysis	   of	   the	   tumours	   did	   not	   reveal	  
significant	   differences	   between	   xenografts	   with	   or	   without	   myofibroblasts	   with	  
respect	   to	   tumour	   composition	   or	   architecture	   in	   spite	   of	   differences	   in	   tumour	  
growth.	   	   It	  may	  be	  that	  myofibroblasts	  act	  at	   the	  time	  of	  cell	   injection	  to	  promote	  
MKN45	  cell	  survival,	   increasing	  the	  proportion	  of	   injected	  MKN45	  cells	  which	  grow	  
to	  form	  a	  tumour.	   	  This	  would	  explain	  why,	  at	  the	  time	  of	  harvesting,	  there	  are	  no	  
differences	  in	  cell	  proliferation	  or	  apoptosis.	  	  Although	  these	  processes	  contribute	  to	  
the	  growth	  of	  tumours,	  it	  may	  be	  that	  the	  difference	  we	  observed	  is	  attributable	  to	  
other	  processes,	  such	  as	  angiogenesis,	  hypoxia	  and	  ability	  to	  invade.	  	  Clearly	  further	  
work	  is	  required	  to	  characterise	  the	  mechanism	  of	  myofibroblasts.	  	  
	  
The	  use	  of	  α-­‐SMA	  and	  vimentin	  staining	  to	  identify	  myofibroblasts	  is	  established.	  	  It	  
is	   important	   to	   remember,	   however,	   that	   neither	   of	   these	   markers	   is	   restricted	  
entirely	   to	   expression	   in	   myofibroblasts.	   	   Endothelial	   cells	   are	   able	   to	   express	  
vimentin	  (240)	  and	  α-­‐SMA	  is	  expressed	  by	  pericytes	  (241).	  Staining	  with	  markers	  for	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these	   cells	   (which	   are	   also	   found	   in	   the	   tumour	   stroma)	  would	   have	   aided	   in	   the	  
definitive	  identification	  of	  myofibroblasts.	  	  The	  use	  of	  human-­‐specific	  fluorescence	  in	  
situ	   hybridisation	   in	   combination	   with	   immunohistochemistry	   may	   accurately	  
identify	  myofibroblasts	  of	  human	  origin.	  
	  
The	   finding	   that	   MKN45	   cells	   formed	   tumours	   more	   readily	   than	   AGS	   cells	   is	   in	  
agreement	   with	   published	   literature,	   where	   examples	   of	   MKN45	   cell	   xenografts	  
(242,243,244)	  and	  xenografts	  using	  other	  gastric	  cancer	  cell	  lines,	  such	  as	  MGC-­‐803	  
and	   SGC-­‐7901	   cells	   (245)	   abound	   compared	   with	   AGS	   cell	   xenografts.	   	   Although	  
examples	   of	   AGS	   xenografts	   do	   exist,	   they	   use	   higher	   cell	   numbers	   than	   we	  
attempted	   (246 ).	   	   The	   lack	   of	   subcutaneous	   masses	   even	   in	   the	   presence	   of	  
myofibroblasts	  precluded	  the	  use	  of	  AGS	  cells	  in	  further	  experiments.	  	  
	  
Our	   finding	   that	   CAMs	   stimulated	   xenograft	   growth	   is	   in	   agreement	  with	  previous	  
data,	  where	   the	   growth	  of	  MKN45	   cells	   injected	   subcutaneously	   in	   SCID	  mice	  was	  
potentiated	   by	   gastric	   CAMs	   (43).	   	   Similar	   findings	   have	   been	   obtained	   in	   a	  
subcutaneous	   xenograft	   study	   in	   breast	   cancer	   using	   α-­‐SMA	   positive	   cancer-­‐
associated	   myofibroblasts	   (48)	   and	   in	   a	   prostate	   cancer	   study,	   where	   fibroblasts	  
from	   prostate	   cancers	   stimulated	   the	   growth	   of	   tissue	   recombinants	   implanted	  
beneath	   the	   renal	   capsule	   of	   athymic	   mice	   (47).	   	   	   Both	   of	   these	   studies	   also	  
examined	  the	  effect	  of	  fibroblasts	  taken	  from	  normal	  tissue	  and	  found	  that	  they	  did	  
not	   stimulate	   tumour	   growth.	   	   This	   would	   initially	   seem	   to	   be	   in	   contrast	   to	   our	  
finding	   that	  NTMs	   stimulated	   xenograft	   growth	   as	   effectively	   as	   CAMs.	   	   However,	  
the	   populations	   of	   fibroblasts	   from	   normal	   prostate	   and	   breast	   tissue	   in	   these	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studies	   were	   not	   α-­‐SMA-­‐expressing,	   a	   feature	   which	   denotes	   an	   ‘activated,’	  
myofibroblast	  phenotype	   (247).	  The	  NTMs	   in	  our	  study	  express	  α-­‐SMA,	  which	  may	  
be	   a	   reflection	   of	   the	   constant	   cycle	   of	   damage	   and	   repair	   in	   the	   normal	   gastric	  
epithelium,	   resulting	   in	   a	   larger	   population	   of	   activated	   myofibroblasts.	   	   Indeed,	  
myofibroblasts	  are	  found	  at	  the	  sites	  of	  gastric	  ulcers	  (248).	  	  Perhaps	  the	  ability	  of	  a	  
mesenchymal	  cell	  to	  stimulate	  xenograft	  growth	  is	  dependent	  on	  its	  possession	  of	  an	  
activated	  phenotype.	  	  
	  
The	  addition	  of	  ATMs	  to	  MKN45	  cells	  also	  enhanced	  tumour	  growth.	  	  In	  the	  case	  of	  
patient	   9,	   use	   of	   the	  ATM	  potentiated	   tumour	   growth	   significantly	  more	   than	   the	  
CAM.	  	  There	  are	  in	  vitro	  data	  to	  suggest	  that	  ATMs	  are	  more	  capable	  of	  modulating	  
the	   behaviour	   of	   cancer	   cells	   than	   NTMs	   or	   CAMs	   (46).	   	   However,	   this	   was	   not	  
confirmed	  by	  the	  data	   from	  patient	  11,	  where	  CAMs	  and	  ATMs	  stimulated	  tumour	  
growth	  to	  a	  similar	  degree.	  
	  
Histology	  of	  these	  tumours	  revealed	  invasion	  into	  the	  skin	  and	  muscle,	  angiogenesis	  
and	   areas	   of	   necrosis.	   Staining	   for	   α-­‐SMA	   did	   not	   show	   any	   differences	   in	  
myofibroblast	   content,	   regardless	   of	   whether	   tumours	   had	   been	   co-­‐injected.	   	   In	  
tumours	  injected	  with	  MKN45	  cells	  alone	  the	  positive	  α-­‐SMA	  staining	  is	  likely	  to	  have	  
arisen	  from	  mouse-­‐derived	  stromal	  cells.	   	   In	  tumours	  where	  human	  myofibroblasts	  
were	  co-­‐injected,	  these	  could	  not	  be	  distinguished	  from	  the	  mouse-­‐derived	  stroma	  
using	  α-­‐SMA	  staining.	   	  However,	   the	  positive	   staining	  of	   cells	   in	  MKN45	  with	  CAM	  
xenografts	   using	   human-­‐specific	   and	   the	   non	   species-­‐specific	   vimentin	   antibodies	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demonstrated	   that	   it	   is	   likely	   that	   the	   injected	   CAMs	   persist	   in	   the	   tumour	  weeks	  
after	  injection.	  	  	  
	  
Most	  xenograft	  studies	  involving	  the	  co-­‐injection	  of	  cancer	  cells	  and	  myofibroblasts	  
do	  not	  distinguish	  between	  mouse	  and	  human-­‐derived	  myofibroblasts,	  choosing	  to	  
use	   α-­‐SMA	   staining	   as	   a	   non	   species-­‐specific	   marker	   of	   myofibroblast	   content	  
(249,250).	  	  Attempts	  to	  identify	  the	  origin	  of	  the	  stroma	  in	  subcutaneous	  xenografts	  
have	   shown	  mixed	   results.	   	   One	   study	   identified	  mouse-­‐derived	  myofibroblasts	   in	  
subcutaneous	  xenografts	  established	  from	  a	  breast	  cancer	  cell	  line	  by	  demonstrating	  
positive	  α-­‐SMA	  staining	  and	  an	  absence	  of	  human	  cytokeratin	  (251).	  	  Another	  study	  
also	   suggested	   that	   the	   stroma	   is	   host-­‐derived	   by	   showing	   that	   stromal	   cells	  
implanted	  together	  with	  cancer	  cells	   into	  mice	  are	  replaced	  by	  host-­‐derived	  stoma	  
over	  a	  period	  of	  weeks	   (252).	   	  Studies	  using	  mice	  expressing	  GFP	  have	  shown	  that	  
subcutaneous	   tumours	   in	  mice	   acquire	   host	   stroma.	   	   One	   group	   created	   tumours	  
with	   GFP-­‐labelled	   stroma	   by	   subcutaneously	   implanting	   cancer	   cells	   into	   GFP-­‐
expressing	  mice.	   	   These	   tumours,	   when	   implanted	   into	   other	  mice,	   retained	   their	  
GFP-­‐positive	   stroma	  after	   4	  weeks	  but	   the	  persisting	   cells	  were	   thought	   to	  mainly	  
represent	   endothelial	   cells	   rather	   than	   myofibroblasts	   (250).	   	   Another	   group	  
established	  subcutaneous	  pancreatic	  xenografts	  and	  sequentially	  passaged	  them	  in	  
red	   fluorescent	   protein	   (RFP),	   GFP	   and	   cyan	   fluorescent	   protein-­‐expressing	   mice,	  
showing	  the	  progressive	  acquisition	  of	  red,	  green	  and	  cyan-­‐fluorescent	  stroma	  from	  
the	  host	  mouse	  but	  also	  persistence	  of	  the	  RFP	  expressing	  stroma	  throughout	  the	  in	  
vivo	  passages	   (253).	   	  These	  studies	  have	  not	   identified	  which	  cells	   in	   the	  host	  give	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rise	  to	  the	  stroma	  but	  there	  is	  emerging	  evidence	  that	  some	  of	  the	  CAMs	  are	  derived	  
from	  bone	  marrow-­‐derived	  MSCs	  (254).	  	  
	  
The	   finding	   that	   E2-­‐C	   positive	   cells	   do	   not	   colocalise	   with	   vimentin-­‐stained	   cells	  
reinforces	   the	   notion	   that	   the	   MKN45	   cells	   within	   the	   tumour	   do	   not	   acquire	  
mesenchymal	  markers,	  suggesting	  EMT	  does	  not	  occur.	  	  The	  origin	  of	  myofibroblasts	  
within	  tumours	  continues	  to	  be	  debated,	  and	  EMT	  of	  cancer	  cells	  has	  been	  shown	  to	  
be	   a	   source	   of	   some	   myofibroblasts	   in	   some	   tumours	   (255).	   	   However,	   in	   vitro	  
evidence	   suggests	   myofibroblasts	   can	   arise	   from	   normal	   fibroblasts,	   present	   in	  
normal	   tissues	   (256),	   or	  may	  be	   from	  bone	  marrow-­‐derived	  mesenchymal	   stromal	  
cells	  (62).	  
	  
The	   finding	   that	   when	   a	   tumour	   contains	   CAMs,	   the	   growth	   of	   a	   contralateral	  
tumour	   containing	  MKN45	   cells	   alone	  was	   suppressed	  was	   unexpected.	   	   It	   seems	  
that	  in	  addition	  to	  the	  short-­‐range	  stromal-­‐epithelial	  signals	  co-­‐ordinating	  increased	  
local	   tumour	   growth,	   a	   long-­‐range	   factor	   influenced	   distant	   tumour	   growth.	   As	  
immunohistochemical	   staining	   did	   not	   show	   any	   difference	   in	   proliferation	   or	  
apoptosis	  once	   the	   tumour	  had	  developed,	   it	  may	  be	   that	   the	  effect	  was	  due	   to	  a	  
delay	  in	  the	  initiation	  of	  tumour	  growth	  rather	  than	  the	  rate	  of	  proliferation	  within	  
the	  tumour.	  	  There	  is	  now	  evidence	  to	  suggest	  that	  tumours	  release	  systemic	  factors	  
capable	  of	  affecting	  the	  growth	  of	  a	  distant	  tumour	  (257),	  which	  supports	  the	  notion	  
that	   a	   factor	   released	   from	   the	   CAM-­‐bearing	   tumour	   could	   mediate	   growth	  
suppression.	   	  Holmberg	  et	  al.	   showed	  that	  TGFβIgh3	   is	   released	   from	  stromal	  cells	  
and	   its	   systemic	  administration	   suppresses	   the	  growth	  of	   subcutaneous	  xenografts	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containing	  CAMs	  (43).	  	  It	  has	  also	  been	  shown	  that	  cells	  from	  tumours	  are	  released	  
into	  the	  circulation	  and	  can	  lodge	  in	  a	  distant	  tumour	  (258);	  it	  may	  be	  that	  the	  signal	  
released	  from	  the	  CAM-­‐bearing	  tumour	  encouraged	  cells	  to	  migrate	  towards	  it.	  
	  
Chapter	   3	   demonstrated	   that	   FMT	   is	   a	   good	   method	   for	   detecting	   E2-­‐C-­‐labelled	  
tumours,	   having	   shown	   that	   tumours	   containing	   these	   cells	   are	   much	   more	  
fluorescent	   than	   tumours	   composed	   of	   untransfected	   cells.	   The	   sensitivity	   of	   FMT	  
for	  small	  numbers	  of	  fluorescent	  cells	  within	  a	  tumour	  mass	  remains	  undetermined,	  
so	  to	  establish	  whether	  E2-­‐C	  positive	  cells	  were	  present	  in	  a	  tumours	  contralateral	  to	  
one	   containing	   MKN45	   E2-­‐C	   cells	   frozen	   sections	   from	   these	   tumours	   were	  
examined,	   an	   approach	   which	   ought	   to	   be	   sensitive	   even	   for	   individual	   cells.	   	   By	  
examining	  tumour	  sections	  for	  evidence	  of	  E2-­‐C	  positive	  cells	  we	  did	  not	  identify	  any	  
evidence	  of	  cell	  migration	  between	  2	  tumours.	  	  This	  conflicts	  with	  the	  evidence	  that	  
cell	  migration	  contributes	  to	  the	  seeding	  of	  distant	  tumours	  (256).	  	  	  
	  
Macroscopically	   and	   histologically	   tumours	   with	   or	   without	   myofibroblasts	   were	  
indistinguishable,	  emphasising	  the	  ability	  of	  MKN45	  cells	  to	  recruit	  stroma	  from	  the	  
host	  mouse.	   	   Identification	  of	  mouse	  vs.	  human	  derived	  myofibroblasts	  will	  enable	  
further	   characterisation	   of	   the	   stroma	   within	   these	   xenografts.	   	   Discovering	   how	  
tumours	   containing	   myofibroblasts	   exhibit	   differing	   growth	   rates	   will	   rely	   on	   the	  
investigation	  of	  factors	  such	  as	  extracellular	  protease	  activity	  and	  the	  contribution	  of	  
mesenchymal	   stromal	   cells.	   	   Tumours	   containing	   myofibroblasts	   exert	   a	   systemic	  
effect,	  capable	  of	  suppressing	  the	  growth	  of	  a	  distant	  tumour.	  	  In	  order	  to	  study	  the	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role	   of	   cell	   migration	   in	   this	   process,	   labelling	   tumour	   cells	   will	   allow	   their	  
visualisation	  within	  another	  tumour.	  




1. Subcutaneous	  MKN45	  cell	  xenografts	  grow	  adequately	  in	  BALB/c	  nu/nu	  mice.	  
2. Xenograft	  growth	  is	  potentiated	  by	  the	  addition	  of	  myofibroblasts;	  this	  is	  not	  
accounted	   for	   by	   differences	   in	   cell	   proliferation	   rate,	   apoptosis	   or	   final	  
stromal	  content.	  
3. A	   xenograft	   containing	   CAMs	   suppresses	   the	   growth	   of	   a	   contralateral	  
xenograft	   without	   CAMs,	   demonstrating	   that	   a	   long-­‐range	   signal	   can	   be	  
generated	  as	  a	  result	  of	  stromal-­‐epithelial	  interactions	  (Figure	  4.13).	  









Figure	  4.13.	  Myofibroblasts	  enhance	  xenograft	  growth	  and	   their	   co-­‐injection	   into	  
one	   xenograft	   can	   affect	   the	   growth	   of	   another,	   distant	   tumour.	  Myofibroblasts	  
potentiate	  the	  growth	  of	  a	  xenograft.	   	  The	  interaction	  between	  myofibroblasts	  and	  
tumour	  cells	  results	  in	  the	  suppression	  of	  the	  growth	  of	  a	  distant	  xenograft.	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MMPs	  are	  a	  diverse	  group	  of	  proteases	  that	  are	  released	  into	  the	  extracellular	  milieu	  
where	  they	  exert	  a	  variety	  of	  effects	  not	  limited	  to	  the	  degradation	  of	  components	  
of	  the	  ECM	  (259).	  	  The	  contribution	  of	  myofibroblasts	  to	  the	  proteolytic	  extracellular	  
environment	   has	   been	   assessed	   using	   proteomic	   analysis	   of	   the	   myofibroblast	  
secretome	   (212).	   	   This	   identified	   a	   differential	   abundance	   of	   neo-­‐N-­‐termini	   (ie	  
cleavage	   products)	   in	   the	   secretomes	   of	   gastric	   cancer-­‐associated	   myofibroblasts	  
(CAMs)	   compared	   with	   controls,	   consistent	   with	   cleavage	   of	   matrix	  
metalloproteinases	  (MMP)-­‐1,	  -­‐2	  and	  -­‐3	  and	  cathepsin	  B	  (Table	  5.1).	  	  
	  
MMPs	   -­‐1,	   -­‐2	   and	   -­‐3	   share	   similarities	   in	   structure	   (Table	   5.2).	   	   Cathepsin	   B	   is	   a	  
lysosomal	  protease	  but	  aberrant	  expression	  of	  this	  protein	  has	  been	  demonstrated	  
in	   cancer	   (260).	   	   This	  work	  extended	   the	  assessment	  of	  protease	  activity	   to	   the	   in	  
vivo	  subcutaneous	  model	  of	  myofibroblast-­‐stimulated	  xenograft	  growth.	  
	  
Organotypic	   cultures	   provide	   a	   three-­‐dimensional	   model	   of	   myofibroblast-­‐
stimulated	   invasion	   (261).	   	   They	   replicate	   the	   pattern	   of	   invasion	   seen	   in	   human	  
cancers	   more	   accurately	   and	   allow	   the	   study	   of	   different	   stromal	   cell	   types	   and	  
individual	  MMPs.	   	  Using	   specific	  MMP	   inhibitors	   the	   contribution	  of	  each	  MMP	   to	  
cancer	  cell	  invasion	  has	  been	  assessed.	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Description	   Functional	  
Classification	  
Cleavage	  site	  
Cathepsin	  B	   protease	   Cathepsin	  B	  
heavy	  chain	  
CD99	  antigen	   binding	  protein	  	   Extracellular	  
domain	  
Collagen	  alpha-­‐2(VI)	  chain	   ECM	  	   Nonhelical	  region	  
HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐1	  
alpha	  chain	  
receptor	  	   Alpha-­‐1	  region	  
HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐7	  
alpha	  chain	  
receptor	  	   Alpha-­‐1	  region	  
HLA	  class	  I	  histocompatibility	  antigen,	  
Cw-­‐7	  alpha	  chain	  
receptor	  	   Alpha-­‐1	  region	  
Interstitial	  collagenase	  (MMP-­‐1)	   protease	   Propeptide	  
Latent-­‐transforming	  growth	  factor	  beta-­‐
binding	  protein,	  isoform	  1S	  
binding	  protein	   Main	  chain	  
Lysyl	  oxidase	  homolog	  2	   enzyme	   SRCR1	  domain	  
Major	  prion	  protein	   unknown	   Main	  chain	  
Pro-­‐neuregulin-­‐1,	  membrane-­‐bound	  
isoform	  
ligand	   Main	  chain	  
Stromelysin-­‐1	  (MMP-­‐3)	   protease	   Propeptide	  
Tumor	  necrosis	  factor	  receptor	  
superfamily	  member	  10D	  
receptor	   TBFR-­‐Cys	  1	  repeat	  
	  
Table	   5.1	   Analysis	   of	  myofibroblast	   secretomes	   revealed	   13	   proteins	   exhibiting	   the	  
formation	   of	   unique	   neo-­‐N-­‐termini	   in	   CAMs	   relative	   to	   their	   ATM	   counterparts,	  
excluding	   those	   representing	   removal	   of	   a	   signal	   sequence.	   Functional	   classification	  
and	  cleavage	  sites	  were	  manually	  annotated	  using	  the	  Uniprot	  database.	  This	  analysis	  
identified	   cleavages	   in	   the	   pro-­‐peptide	   domains	   of	   MMP-­‐1	   and	  MMP-­‐3	   and	   in	   the	  
cathepsin	  B	  heavy	  chain	  (Adapted	  from	  (2)).	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Name	   Aliases	   Class	  	   How	   the	   protein	  












Tyrosine,	   aspartic	   acid	  
and	   glycine	   amino	   acids	  






72kDa	  Type	  IV	  Collagenase	  
Gelatinase	  A	  	  





Fibronectin	   type	   II	  












Table	  5.2	  Nomenclature	  and	  classification	  of	  MMPs	  -­‐1,	  -­‐2	  and	  -­‐3	  based	  on	  class	  and	  
deviation	  from	  the	  generic	  MMP	  structure	  shown	  in	  Figure	  1.5.	  




1. To	  examine	  the	  effect	  of	  myofibroblast-­‐derived	  proteases	  in	  an	  in	  vivo	  model	  
of	  myofibroblast-­‐stimulated	  tumour	  growth.	  
2. To	   determine	   the	   effect	   of	   myofibroblasts	   on	   cell	   invasion	   in	   a	   3D	  
organotypic	  cell	  culture	  model.	  
3. To	  examine	  the	  contribution	  of	  individual	  MMPs	  to	  cell	  invasion.	  




5.2.1	  Cell	  culture	  
Primary	  gastric	  myofibroblasts	  and	  MKN45	  cells	  were	  cultured	  as	  detailed	  in	  2.2.1-­‐2.	  	  	  
	  
5.2.2	  Subcutaneous	  xenografts	  
Cells	   for	   injection	   were	   trypsinised,	   counted	   and	   aliquots	   containing	   appropriate	  
numbers	  of	   cells	  prepared	  as	  described	   in	  2.2.3.	   	  MKN45	  cell	   doses	   (5	   x	  105	  when	  
injected	  alone	  or	  1	  x	  105	  when	  injected	  with	  5	  x	  104	  CAM4	  cells)	  were	  calculated	  so	  
that	  tumours	  attained	  approximately	  equal	  volumes	  at	  a	  similar	  time,	  as	  described	  in	  
2.2.4.	  
	  
5.2.3	  FMT	  imaging	  
MMPSense	   750	   FASTTM,	   ProSense	   750	   FASTTM	   and	   Cat	   B	   750	   FASTTM	   (100μl)	  were	  
administered	  by	  IV	  tail	  vein	  injection	  under	  GA	  and	  FMT	  imaging	  performed	  before	  
injection	  and	  6	  and	  24	  h	  post	  injection,	  as	  detailed	  in	  2.2.5a.	  	  The	  fluorescent	  signal	  
at	   750nm	   in	   the	   region	   of	   the	   tumour	   was	   quantified	   using	   TrueQuant	   software.	  	  
Where	  animals	  were	   imaged	  using	  more	  than	  one	  reagent,	  an	   interval	  of	  96	  h	  was	  
left	  between	  injections.	  	  If	  this	  was	  not	  possible,	  the	  baseline	  signal	  prior	  to	  injection	  
was	  subtracted	  from	  the	  final	  signal.	  
	  
	  	   	   157	  
5.2.4	  Organotypic	  cultures	  
Organotypic	   cultures	   were	   established	   as	   described	   in	   2.2.16,	   with	   5	   x	   105	   CAM4	  
cells	  seeded	  on	  day	  1	  and	  2	  x	  106	  MKN45	  cells	  added	  to	  the	  top	  on	  day	  2.	   	  Where	  
treatments	  with	  MMP	   inhibitors	  were	   used,	   the	  MMP	   inhibitor	  was	   added	   to	   the	  
gels	  on	  day	  1	  and	  also	  to	  the	  FM	  used	  to	  replenish	  the	  cultures	  every	  48	  h.	  	  MMP-­‐2	  
inhibitor	  I	  was	  used	  at	  6μM	  and	  MMP-­‐3	  Inhibitor	  IV	  was	  used	  at	  30μM.	  
	  
Gels	   were	   paraffin-­‐embedded,	   cut	   and	   stained	   with	   H&E	   or	   for	   Ki-­‐67,	   cleaved	  
caspase-­‐3	   and	   α-­‐SMA	   by	   the	   Department	   of	   Cellular	   Pathology,	   Royal	   Liverpool	  
University	   Hospital.	   	   Quantification	   of	   invasion	   was	   carried	   out	   using	   ImageJ	  
software.	   	   Quantification	   of	   immunohistochemical	   staining	   was	   performed	   by	  
counting	   positive	   cells	   within	   a	   150μm	   x	   120μm	   field	   in	   the	   MKN45	   cell	   layer.	  	  
Experiments	  were	  carried	  out	  in	  triplicate	  and	  the	  mean	  result	  reported.	  




5.3.1	  ProSense	  750	  FASTTM	  activity	  is	  not	  significantly	  altered	  in	  xenografts	  
containing	  CAMs.	  
In	  order	  to	  examine	  protease	  activity	  in	  vivo,	  xenografts	  were	  generated	  and	  imaged	  
6	   h	   post	   IV	   injection	   of	   ProSense	   750	   FASTTM,	   a	   reagent	   which	   fluoresces	   when	  
cleaved	   by	   cathepsins	   B,	   L,	   S	   or	   plasmin.	   	   There	   was	   no	   significant	   difference	   in	  
ProSense	  750	  FASTTM	  activity	  between	  tumours	  composed	  of	  MKN45	  cells	  alone	  and	  
those	   composed	   of	   MKN45	   cells	   and	   CAMs	   (Figures	   5.1-­‐2).	   	   In	   order	   to	   achieve	  
similar-­‐sized	   subcutaneous	   tumours	   at	   the	   time	   of	   imaging,	   xenografts	   were	  
generated	  using	  5	  times	  more	  MKN45	  cells	  when	  they	  were	  injected	  without	  CAMs.	  	  
The	  tumour	  volume	  in	  both	  groups	  at	  the	  time	  of	   imaging	  was	  found	  to	  be	  similar,	  
thereby	   eliminating	   differences	   in	   protease	   activity	   due	   to	   tumour	   volume	   (Figure	  
5.2B).	  
	  	  	  
5.3.2	  Cathepsin	  B	  activity	  is	  not	  significantly	  altered	  in	  xenografts	  containing	  
CAMs.	  
In	   order	   to	   examine	   the	   contribution	   of	   cathepsin	   B	   to	   the	   protease	   activity	   in	  
xenografts,	  tumours	  were	  generated	  as	  above	  and	  imaged	  24	  h	  post	  IV	  injection	  of	  
Cat	  B	  750	  FASTTM,	  a	  reagent	  which	  fluoresces	  when	  cleaved	  by	  cathepsin	  B.	   	  There	  
was	  no	  significant	  difference	  in	  cathepsin	  B	  activity	  between	  tumours	  composed	  of	  
MKN45	  cells	  alone	  and	  those	  composed	  of	  MKN45	  cells	  and	  CAMs	  (Figure	  5.3).	  	  The	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tumour	   volume	   at	   the	   time	   of	   imaging	   was	   similar	   between	   groups,	   as	   described	  
above.	  






Figure	  5.1.	   ProSense	  750	   FASTTM	  activity	   is	   not	   significantly	   altered	   in	   xenografts	  
containing	   CAMs.	  A,	   Representative	   FMT	   images	   illustrating	   signal	   at	   750nm	   from	  
mice	  bearing	  xenografts	  composed	  of	  MKN45	  cells	  alone.	  B,	  FMT	  images	  illustrating	  
signal	  at	  750nm	  from	  mice	  bearing	  xenografts	  composed	  of	  MKN45	  cells	  and	  CAM4.	  























































Figure	  5.2.	   ProSense	  750	   FASTTM	  activity	   is	   not	   significantly	   altered	   in	   xenografts	  
containing	  CAMs.	  A,	  FMT	  assessment	  of	  protease	  (cathepsins	  and	  plasmin)	  activity	  
in	   vivo	   using	   ProSense	   750	   FASTTM	   indicated	   no	   difference	   between	   xenografts	  
containing	  CAM4	  cells	   compared	  with	   xenografts	   containing	  MKN45	  cells	   alone.	  B,	  
Tumour	  volume	  at	  the	  time	  of	  imaging	  was	  similar	  in	  the	  two	  groups.	  Mean	  results	  
from	  8	  animals	  are	  shown.	  	  








































Figure	  5.3.	  Cathepsin	  B	  activity	  is	  not	  significantly	  altered	  in	  xenografts	  containing	  
CAMs.	  A,	  Representative	  FMT	  images	  illustrating	  signal	  at	  750nm	  from	  mice	  bearing	  
xenografts	   composed	   of	   MKN45	   cells	   alone.	   B,	   Representative	   FMT	   images	  
illustrating	  signal	  at	  750nm	  from	  mice	  bearing	  xenografts	  composed	  of	  MKN45	  cells	  
+	   CAM4.	  B,	  Quantification	  of	   FMT	  assessment	   of	   cathepsin	  B	   activity	   in	   vivo	   using	  
CatB	  750	  FASTTM	  indicated	  no	  difference	  between	  MKN45	  cell	  xenografts	  containing	  
CAM4	  compared	  with	   those	  composed	  of	  MKN45	  cells	  alone.	  Mean	  results	   from	  5	  
animals	   are	   shown.	   Equivalent	   tumour	   volumes	   within	   4	   days	   of	   imaging	   are	  
illustrated	  in	  figure	  5.2B.	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5.3.3	  MMP	  activity	  is	  increased	  in	  xenografts	  containing	  CAMs.	  
To	  measure	  MMP	  activity	  in	  subcutaneous	  tumours	  in	  vivo,	  mice	  were	  injected	  with	  
MMPSense	  750	  FASTTM,	  a	  reagent	  which	  emits	  a	  fluorescence	  signal	  on	  cleavage	  by	  a	  
broad	   range	   of	  MMPs	   (e.g.	   2,	   3,	   7,	   9,	   12	   and	   13);	   the	   fluorescence	   in	   the	   tumour	  
measured	   24	   h	   later.	   MMP	   activity	   was	   significantly	   increased	   in	   xenografts	  
composed	   of	  MKN45	  with	   CAMs	   compared	   to	  MKN45	   cells	   alone	   or	   even	  MKN45	  
cells	  and	  NTMs	  (Figures	  5.4-­‐5).	  	  To	  eliminate	  differences	  in	  MMP	  activity	  arising	  from	  
differences	  in	  tumour	  size,	  the	  tumour	  volume	  at	  imaging	  was	  measured	  and	  found	  
to	  be	  similar	  in	  all	  groups	  (Figure	  5.5B).	  	  







Figure	   5.4.	   MMP	   activity	   is	   increased	   in	   xenografts	   containing	   CAMs.	   A,	  
Representative	  FMT	  images	  show	  low	  MMP	  activity	  measured	  with	  MMPSense	  750	  
FASTTM	  in	   tumours	  composed	  of	  MKN45	  cells	  alone.	  B,	  Representative	  FMT	   images	  
show	  elevated	  in	  vivo	  MMP	  activity	  in	  the	  presence	  of	  CAM8.	  C,	  Representative	  FMT	  
images	  show	  elevated	  in	  vivo	  MMP	  activity	  in	  the	  presence	  of	  CAM4.	  D,	  FMT	  images	  
showing	  low	  MMP	  activity	  in	  tumours	  with	  MKN45	  and	  NTMs.	  
	  





































































Figure	   5.5.	   MMP	   activity	   is	   increased	   in	   xenografts	   containing	   CAMs.	   A,	   FMT	  
assessment	   of	   MMP	   activity	   in	   vivo	   using	   MMPSense	   750	   FASTTM	   indicated	   an	  
increase	   in	   the	   presence	   of	   CAMs	   (mean	   ±	   SEM,	   0.22±0.21	   vs	   13.52±1.83	   pM	   for	  
CAM8	   and	   21.56±11.09	   for	   CAM4)	   when	   compared	   with	   MKN45	   cells	   alone.	   	   B,	  
Tumour	  volume	  at	  the	  time	  of	  imaging	  was	  similar	  in	  all	  groups.	  Mean	  results	  from	  
4-­‐5	  animals	  are	  shown;	  horizontal	  bars	  represent	  statistical	  significance	  by	  Kruskal-­‐
Wallis	  test	  with	  Dunn’s	  post-­‐hoc	  comparison.	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5.3.4	  Myofibroblasts	  enhance	  MKN45	  cell	  invasion	  in	  an	  organotypic	  model	  of	  cell	  
invasion.	  
In	   an	   attempt	   to	   dissect	   the	   contribution	   of	   myofibroblasts	   to	   MMP-­‐driven	  
tumorigenic	   processes,	   an	   organotypic	   co-­‐culture	   model	   of	   cell	   invasion	   was	  
developed.	   	  Myofibroblasts	  were	  seeded	   into	  a	  collagen/MatrigelTM	  gel	  and	  a	   layer	  
of	  MKN45	  cells	  was	  plated	  on	  top.	  After	  2	  weeks,	   the	  gels	  were	  examined	  and	  the	  
invasion	  of	  MKN45	  cells	   into	   the	  gel	  was	  examined.	   	  The	  projection	  of	   the	  MKN45	  
cell	  layer	  into	  the	  gel	  layer	  was	  quantified	  as	  detailed	  in	  figure	  3.10A	  such	  that	  higher	  
numbers	  of	  MKN45	  cells	   intruding	   into	   the	  gel	   resulted	   in	  a	  higher	  X/Y	   ratio.	   	  Gels	  
not	   seeded	   with	   myofibroblasts	   did	   not	   cause	   MKN45	   cell	   intrusion	   into	   the	   gel,	  
whereas	  those	  with	  myofibroblasts	  caused	  the	  MKN45	  cell	   layer	  to	  project	  into	  the	  
gels	  (Figure	  5.6A-­‐F).	   	   It	  was	  also	  noted	  that	   in	  gels	  seeded	  with	  myofibroblasts,	  the	  
MKN45	  cell	  layer	  appeared	  to	  be	  thicker.	  	  Staining	  of	  the	  gels	  with	  the	  marker	  of	  cell	  
proliferation	  Ki-­‐67	  did	  not	  reveal	  any	  difference	   in	  the	  proliferation	  rate	  of	  MKN45	  
cells	   (Figure	   5.7),	   suggesting	   that	   the	   difference	   observed	   is	   not	   due	   to	   increased	  
proliferation	  2	  weeks	  after	  the	  cells	  were	  seeded.	  































Figure	  5.6.	  Myofibroblasts	  enhance	  MKN45	  cell	  invasion	  in	  organotypic	  cultures.	  A-­‐
C,	   Representative	   images	   of	   organotypic	   cultures	   where	   the	   gel	   contains	   no	  
myofibroblasts.	   D-­‐F,	   Representative	   images	   of	   organotypic	   cultures	   with	  
myofibroblasts	   seeded	   in	   the	   Matrigel/collagen	   gel.	   G,	   Seeding	   of	   myofibroblasts	  
into	   the	   gel	   enhances	   MKN45	   cell	   invasion	   compared	   with	   a	   gel	   without	  
myofibroblasts,	  as	  shown	  by	  the	  higher	  X:Y	  ratio.	  	  








































Figure	   5.7.	   Proliferation	   in	   MKN45	   cells	   is	   unaffected	   by	   the	   presence	   of	  
myofibroblasts	   in	   the	  gel.	  A-­‐B,	  Representative	   images	  of	  organotypic	  cultures	  with	  
myofibroblasts	  stained	  for	  Ki-­‐67	  (A)	  and	  negative	  control	  (no	  primary	  antibody)	  (B).	  
C-­‐D,	  Representative	   images	  of	  organotypic	  cultures	  without	  myofibroblasts	  stained	  
for	   Ki-­‐67	   (C)	   and	   corresponding	   negative	   control	   (D).	   E,	   Quantification	   of	   Ki-­‐67	  
positive	   nuclei	   in	   the	   MKN45	   cell	   layer	   revealed	   no	   change	   in	   MKN45	   cell	  
proliferation	  in	  response	  to	  the	  myofibroblasts	  in	  the	  gel.	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5.3.5	  MMP-­‐2	  inhibition	  decreased	  cell	  invasion.	  
Addition	  of	   an	  MMP-­‐2	   inhibitor	   to	   the	  gels	  decreased	  MKN45	  cell	   invasion	   (Figure	  
5.8).	   	   This	   is	   in	   agreement	  with	   earlier	   data	   from	   our	   group	   showing	   that	  MMP-­‐2	  
activity	   is	   increased	   in	   the	   media	   of	   CAMs	   and	   its	   inhibition	   decreases	   AGS	   cell	  
migration	   in	   Boyden	   chamber	   assays	   (212)	   The	   effect	   of	  MMP-­‐2	   inhibition	   on	   cell	  
proliferation	  was	  again	  investigated	  using	  Ki-­‐67	  staining	  and	  no	  difference	  in	  MKN45	  
cell	  proliferation	  was	  noted	  (Figure	  5.9).	  	  Although	  in	  Boyden	  chamber	  assays	  MMP-­‐
3	  inhibition	  suppressed	  AGS	  cell	  migration,	  these	  findings	  were	  not	  replicated	  in	  the	  
organotypic	  model	  of	  MKN45	  cell	  invasion	  (Figure	  5.8H).	  
	  
5.3.6	  The	  presence	  of	  myofibroblasts	  in	  the	  gel	  does	  not	  affect	  the	  apoptotic	  rate	  of	  
MKN45	  cells.	  
Gels	  were	  stained	  for	  cleaved	  caspase-­‐3,	  a	  marker	  of	  apoptotic	  cells.	   	  This	  revealed	  
no	   evidence	   of	   apoptosis	   in	   the	   myofibroblasts	   seeded	   within	   the	   gel	   (data	   not	  
shown).	   	  The	  proportion	  of	  apoptotic	  MKN45	  cells	   in	   the	  gels	  was	  quantified	  using	  
the	  same	  fields	  as	  for	  Ki-­‐67	  quantification	  and	  no	  difference	  in	  apoptosis	  was	  found	  
between	  MKN45	  cells	  grown	  on	  a	  gel	  seeded	  with	  myofibroblasts,	  compared	  to	  one	  
without	  (Figure	  5.10D-­‐E).	   	  No	  difference	   in	  apoptosis	  was	  found	   in	  the	  presence	  of	  
the	  MMP-­‐2	  inhibitor	  (Figure	  5.10E-­‐F).	  	  In	  the	  gels	  seeded	  with	  myofibroblasts,	  these	  
could	   be	   identified	   using	   α-­‐SMA	   staining	   (Figure	   5.10K-­‐L,	   arrows).	   	   There	   was	   no	  
difference	   in	   their	   number	   or	   distribution	   in	   gels	   replenished	   with	   medium	  
containing	  MMP-­‐2	   inhibitor	   compared	   to	   those	   replenished	  with	   FM	   alone.	   	   In	   all	  
gels	  the	  MKN45	  layer	  did	  not	  exhibit	  any	  positive	  α-­‐SMA	  staining	  (Figure	  5.10G-­‐I).	  	  	  








































Figure	   5.8.	   Addition	   of	   an	   MMP-­‐2	   inhibitor	   suppressed	   MKN45	   cell	   invasion	   in	  
organotypic	   cultures.	   A-­‐C,	   Representative	   images	   of	   organotypic	   cultures	  without	  
MMP-­‐2	   inhibitor.	  D-­‐F,	  Representative	   images	  of	  organotypic	  cultures	  when	  MMP-­‐2	  
inhibitor	  has	  been	  added.	  G,	  The	  addition	  of	  an	  MMP-­‐2	  inhibitor	  to	  the	  gel	  and	  the	  
media	   suppresses	  MKN45	  cell	   invasion.	  H,	   The	  addition	  of	   an	  MMP-­‐3	   inhibitor	  did	  
not	  suppress	  MKN45	  cell	  invasion.	  




































Figure	   5.9.	   Proliferation	   in	  MKN45	   cells	   is	   unaffected	  by	   the	  presence	  of	  MMP-­‐2	  
Inhibitor.	   A-­‐B,	   Representative	   images	   of	   organotypic	   cultures	   without	   MMP-­‐2	  
inhibitor	   stained	   for	  Ki-­‐67	   (A)	   and	  negative	   control	   (no	  primary	  antibody)	   (B).	  C-­‐D,	  
Representative	   images	  of	  organotypic	  cultures	  with	  MMP-­‐2	  inhibitor	  stained	  for	  Ki-­‐
67	   (C)	   and	   corresponding	   negative	   control	   (D).	   E,	   Quantification	   of	   Ki-­‐67	   positive	  
nuclei	   in	   the	  MKN45	   cell	   layer	   revealed	   no	   change	   in	  MKN45	   cell	   proliferation	   in	  
response	  to	  MMP-­‐2	  inhibitor.	  
	  



































Figure	   5.10.	   Immunohistochemistry	   for	   α-­‐SMA	   and	   cleaved	   caspase-­‐3	  
demonstrates	   no	  difference	   in	   apoptosis	   and	   confirms	  myofibroblasts	  within	   the	  
gels	   A-­‐C,	   Negative	   control	   (no	   primary	   antibody)	   D-­‐F,	   Representative	   images	   of	  
cleaved	   caspase-­‐3	   staining	   showing	   no	   difference	   in	   apoptotic	   cells.	   G-­‐I,	   α-­‐SMA	  
staining	   in	   the	  MKN45	   layer	   is	   negative.	   J-­‐L,	  α-­‐SMA	   staining	   of	   the	  myofibroblasts	  
within	  the	  gels	  (arrows)	  seeded	  with	  these	  cells	  (K,L)	  




This	   study	   has	   shown	   that	   the	   in	   vitro	   observations	   of	   increased	  MMP	   activity	   in	  
CAMs	  are	  also	  reflected	  in	  vivo.	  	  Quantification	  of	  in	  vivo	  MMP	  activity	  in	  MKN45	  cell	  
xenografts	   revealed	   an	   increase	   in	   the	   presence	   of	   CAMs.	   	   In	   contrast,	   similar	  
experiments	   to	   determine	   the	   in	   vivo	   activity	   of	   other	   proteases,	   including	  
cathepsins	  and	  plasmin	  did	  not	  demonstrate	  any	  increase	  in	  the	  presence	  of	  CAMs.	  	  
Inhibition	   of	   MMP-­‐2	   activity	   led	   to	   a	   decrease	   in	   myofibroblast-­‐mediated	   cell	  
invasion	   assessed	   using	   an	   organotypic	   model.	   	   These	   data	   demonstrate	   that	   the	  
increased	   activation	   of	   stroma-­‐derived	   MMPs	   found	   in	   vitro	   results	   in	   increased	  
xenograft	  growth	  and	  increased	  cancer	  cell	  invasion.	  	  
	  
Imaging	  proteolytic	  processes	  in	  vivo	  is	  a	  fast-­‐growing	  field	  where	  the	  development	  
of	  newer	  imaging	  modalities	  and	  probes	  constantly	  widens	  the	  options	  for	  research.	  
Positron-­‐emission	  tomography	  (PET)	  is	  already	  in	  clinical	  use	  but	  attempts	  at	  imaging	  
MMPs	   using	   this	   technique	   have	   been	   restricted	   by	   unsuccessful	   attempts	   at	  
developing	   appropriate	   radiolabelled	   tracer	   molecules	   (262).	   	   The	   generation	   of	  
suitable	   contrast	   agents	   for	  MRI	   has	   shown	  more	   promise	   (263).	   	   Bioluminescent	  
techniques	   have	   the	   advantage	   of	   low	   background	   and	   a	   large	   signal	  window	   but	  
imaging	  MMP	  activity	  using	   this	   technique	  has	  proven	  difficult	  due	   to	  problems	   in	  
designing	  the	  recognition	  site	  of	  a	  bioluminescent	  substrate	  (264).	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Our	  assessment	  of	  in	  vivo	  MMP	  activity	  relied	  on	  the	  use	  of	  FMT,	  a	  technique	  which	  
utilizes	   the	   ability	   of	   far-­‐red	   light	   to	   propagate	   a	   few	   cm	  within	   animal	   tissue	   and	  
combines	  it	  with	  improvements	  in	  the	  mathematical	  modelling	  of	  photon	  scattering	  
behaviour.	   	  FMT	  is	  appealing	  because	  of	  the	  variety	  of	  fluorescent	  probes	  available	  
to	  measure	  different	  cellular	  processes.	   	  We	  have	  used	  MMPSense	  750	  FASTTM,	  a	  
reagent	   which	   produces	   fluorescence	   on	   cleavage	   by	   a	   broad	   range	   of	   MMPs.	  	  
Specific	  probes	  capable	  of	  assessing	  the	  activity	  of	  individual	  MMPs	  are	  not	  available	  
for	   in	   vivo	   work,	   and	   based	   on	   the	   present	   findings	   are	   now	   urgently	   needed.	  	  
Assessment	  of	  other	  protease	   systems	  was	  possible,	  however,	  and	  we	  utilised	   this	  
approach	  to	  examine	  the	  contributions	  of	  cathepsins	  and	  plasmin	  to	  in	  vivo	  protease	  
activity.	  	  
	  
The	  development	  of	   the	  organotypic	   co-­‐culture	   system	  allowed	  us	   to	  examine	   the	  
specific	   contribution	  of	  myofibroblast-­‐derived	  MMPs	   to	   cell	   invasion,	   as	   an	   in	   vivo	  
model	   incorporates	   contributions	   from	   other,	   mouse-­‐derived,	   stromal	   cell	   types	  
such	  as	   inflammatory	  cells,	  endothelial	  cells,	  MSCs	  and	  myofibroblasts.	   	  The	  use	  of	  
specific	  MMP	  inhibitors	   in	  this	  myofibroblast-­‐stimulated	  model	  of	  cell	   invasion	  also	  
allowed	   us	   to	   examine	   the	   contribution	   of	   individual	   MMPs.	   	   The	   patterns	   of	  
invasion	   observed	   in	   organotypic	   cultures	   mimic	   invasion	   in	   human	   cancers	   and	  
allow	  the	  incorporation	  of	  stromal	  cell	  types	  (258).	  	  
	  
Our	   previous	   study	   showed	   that	  myofibroblasts	   secrete	  MMPs	   (212)	   and	   this	   is	   in	  
agreement	  with	  existing	  evidence	  of	  high	  MMP	  expression	  by	  stromal	  cells	  (265).	  	  In	  
a	  xenograft	  model	  of	  cutaneous	  melanoma	  MMP-­‐13	  deficiency	  in	  the	  host	  mice	  led	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to	  decreased	  tumour	  growth	  and	  angiogenesis,	  showing	  that	  stromal-­‐derived	  MMPs	  
are	  important	  in	  these	  processes	  (266).	  	  Our	  findings	  show	  that	  CAMs	  contribute	  to	  
increased	  MMP	  activity	  in	  vivo.	  	  It	  is	  known	  that	  gastric	  epithelial	  cells	  express	  MMP-­‐
7	   (147)	  and	   it	   is	   likely	   that	   in	   vivo	   high	  protease	  activity	   in	   the	  extracellular	  milieu	  
arises	   as	   a	   result	   of	   reciprocal	   activation	   of	   stromal	   and	   epithelial-­‐derived	  MMPs.	  	  
The	   contributions	   to	  MMP	  activity	   by	   host-­‐derived	   stroma	  and	   gastric	   cancer	   cells	  
explain	   our	   finding	   that	   there	   is	   some	   MMP	   activity	   in	   xenografts	   injected	   with	  
MKN45	  cells	  alone.	   	  NTMs	  did	  not	  mediate	  an	  increase	  in	  MMP	  activity,	  suggesting	  
that	  MMP	  activation	   is	  part	  of	  an	  altered	  CAM	  phenotype.	   	  Our	  previous	  study	  did	  
not	  examine	  MMP	  activity	  in	  NTMs,	  but	  did	  show	  decreased	  activity	  in	  ATMs	  relative	  
to	  CAMs	  (212).	  
	  
Previous	  work	  has	  used	  a	   fluorescent	  probe	  activated	  by	  a	   variety	  of	  proteases	   to	  
track	   the	   development	   of	   orthotopic	   mesothelioma	   xenografts	   using	   FMT	   (267).	  	  
Another	  study	  used	  the	  activity	  of	  cathepsin,	  MMP	  and	  integrin	  activatable	  reagents	  
as	  a	   surrogate	  measure	  of	   tumour	  volume	  and	  applied	   this	   system	   to	  monitor	   the	  
response	  to	  therapy.	  	  Interestingly	  this	  group	  found	  that	  MMP	  activity	  in	  the	  tumour	  
was	   not	   an	   accurate	   predictor	   of	   tumour	   volume,	   suggesting	   that	   MMP	   activity	  
within	   the	   tumour	   was	   dependent	   on	   other	   factors	   (268).	   	   Our	   experiment	   was	  
designed	  such	  that	  the	  tumour	  volume	  was	  equivalent	  across	  groups	  at	  the	  time	  of	  
imaging,	   although	   this	   necessitated	   the	   injection	   of	   different	   amounts	   of	   MKN45	  
cells	  at	  the	  start.	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Our	   finding	   that	   the	   total	   activity	   of	   cathepsins	   and	   plasmin	   were	   unchanged	   in	  
xenografts	   containing	   CAMs	   may	   illustrate	   that	   MMPs	   represent	   particularly	  
important	   stroma-­‐derived	   proteases.	   	   Increased	   cleavage	   of	   cathepsin	   B	   in	   the	  
medium	  of	  CAMs	  compared	  to	  ATMs	  was	  noted	  in	  the	  proteomic	  investigation	  of	  the	  
myofibroblast	  secretome	  (212)	  but	  it	  is	  uncertain	  whether	  the	  cleavage	  identified	  led	  
to	  activation	  of	  the	  protease.	  	  Cathepsin	  B	  expression	  is	  known	  to	  be	  associated	  with	  
tumour	   invasion	  and	  metastasis	   in	   a	   variety	  of	   tumours	   	   (269).	   	   In	   vitro	  data	   from	  
breast	  cancer	  cells	  suggests	  that	  cathepsin	  B	  inhibition	  decreases	  cell	  invasion	  (270).	  	  
Cancers	  from	  different	  cells	  of	  origin	  may	  not	  share	  some	  characteristics;	  caution	  is	  
therefore	  required	  in	  extrapolating	  between	  cancer	  cell	  types.	  
	  
Although	  in	  our	  system,	  high	  MMP	  activity	  is	  associated	  with	  the	  presence	  of	  stromal	  
cells	   and	   increased	   tumour	   growth,	   there	   is	   increasing	   evidence	   that	   the	   role	   of	  
MMPs	  in	  cancer	  is	  more	  complex.	  	  Mice	  overexpressing	  MMP-­‐9	  developed	  a	  smaller	  
primary	  tumour	  but	  an	  increased	  rate	  of	  metastasis	  (271,272).	  	  It	  is	  well	  recognised	  
that	  MMPs	  are	  expressed	  in	  a	  variety	  of	  stromal	  cell	  types	  and	  that	  the	  interactions	  
between	   these	   in	   the	   extracellular	   environment	   determine	   overall	   activity	   (262).	  	  
The	   use	   of	   in	   vivo	   xenografts	   allowed	   us	   to	   identify	   increased	  MMP	   activity	   as	   a	  
result	  of	  the	  addition	  of	  myofibroblasts	  but	  the	  presence	  of	  other	  cell	   types	   in	  this	  
model	  does	  not	  permit	  us	  to	  examine	  whether	  MMPs	  from	  myofibroblasts	  directly	  
contribute	  to	  overall	  MMP	  activity,	  or	  whether	  they	  trigger	  the	  activation	  of	  MMPs	  
derived	  from	  other	  cells.	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In	   the	   organotypic	   co-­‐culture	   model,	   the	   interaction	   between	   cancer	   cells	   and	  
myofibroblasts	  is	  examined	  in	  a	  way	  that	  replicates	  the	  patterns	  of	  invasion	  seen	  in	  
vivo,	  without	  the	  influence	  of	  other	  cell	  types.	  	  The	  collagen/MatrigelTM	  gel	  simulates	  
extracellular	  matrix	  and	  the	  myofibroblasts	  seeded	  within	  secrete	  a	  range	  of	  factors	  
which	   promote	   the	   invasion	   of	   cancer	   cells.	   	   Our	   finding	   that	   fibroblasts	   enhance	  
cancer	  cell	  invasion	  is	  in	  agreement	  with	  previous	  data	  from	  3D	  co-­‐cultures	  in	  breast	  
cancer	   (273).	   	   This	   study	  also	   found	   that	  only	   cancer-­‐derived	   fibroblasts	   enhanced	  
invasion,	  whereas	  those	  from	  normal	  breast	  tissue	  did	  not.	  	  Another	  study	  in	  breast	  
cancer	  showed	  that	  increased	  invasion	  was	  associated	  with	  MMP-­‐2	  expression	  (274).	  	  
Our	   finding	   that	   MMP	   inhibition	   decreases	   invasion	   in	   an	   organotypic	   co-­‐culture	  
system	  is	  consistent	  with	  similar	  studies	  using	  organotypic	  cultures	  of	  skin	  fibroblasts	  
and	   skin	   cancer	   cells	   (275).	   	   Together	   the	  data	   indicate	   that	  myofibroblast-­‐derived	  
MMPs	  contribute	  to	  extracellular	  protease	  activity	  and	  this	  facilitates	  local	   invasion	  
by	  the	  cancer	  cells.	  
	  
Similar	  rates	  of	  proliferation	  and	  apoptosis	  were	  seen	  in	  organotypic	  cultures	  with	  or	  
without	  myofibroblasts,	   suggesting	   that	   at	   the	   end	   of	   the	   experiment	   the	   rate	   of	  
MKN45	  cell	   turnover	   is	   similar.	   	   It	   remains	  possible	   that	  differences	   in	   cell	   survival	  
and	  proliferation	  exist	  early	  in	  the	  experiment	  but	  are	  no	  longer	  evident	  at	  the	  end.	  	  
This	   might	   explain	   why	   the	   MKN45	   layer	   appeared	   thicker	   in	   gels	   seeded	   with	  
myofibroblasts,	   although	   the	   contractile	   properties	   of	   myofibroblasts	   cause	   gel	  
contraction,	  which	  may	  give	  the	  impression	  of	  a	  thicker	  gel.	  	  The	  addition	  of	  MMP-­‐2	  
inhibitor	   to	   the	   gel	   and	   the	   medium	   did	   not	   affect	   MKN45	   layer	   thickness,	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proliferation	   or	   apoptosis,	   suggesting	   that	   the	   decrease	   in	   invasion	   seen	   in	   the	  
presence	  of	  the	  MMP-­‐2	  inhibitor	  was	  not	  due	  to	  changes	  in	  cell	  turnover.	  
	  
We	  have	  examined	  the	  role	  of	  MMP	  activity	  and	  demonstrated	  that	  myofibroblast-­‐
stimulated	   xenografts	   show	   increased	   MMP	   activity	   in	   vivo	   and	   that	   MMP-­‐2	  
contributes	   to	  MKN45	  cell	   invasion	   in	  vitro.	   	  Our	   findings	  provide	   further	  evidence	  
for	  the	  important	  contribution	  of	  stroma-­‐derived	  MMPs	  in	  the	  promotion	  of	  tumour	  
growth	  and	  invasion.	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5.5	  Conclusions	  
	  
1. In	   vivo,	   MMP	   activity	   is	   increased	   in	   xenografts	   injected	   with	   CAMs,	  
compared	   to	   those	   injected	   with	   NTMs	   or	   with	   MKN45	   cell	   alone	   (Figure	  
5.11).	  
2. Myofibroblasts	   enhance	   cancer	   cell	   invasion	   in	   an	   organotypic	   co-­‐culture	  
model.	  
3. MMP-­‐2	  inhibition	  decreases	  myofibroblast-­‐stimulated	  cancer	  cell	   invasion	  in	  
organotypic	  cultures.	  










Figure	   5.11.	   The	   contribution	   of	   MMPs	   to	   tumour	   growth	   and	   invasion.	   	   	  MMP	  
activity	  is	  increased	  in	  tumours	  co-­‐injected	  with	  CAMs.	  	  MMPs	  also	  contribute	  to	  the	  
process	  of	  stroma-­‐stimulated	  invasion.	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CHAPTER	  6:	  THE	  ROLE	  OF	  CHEMERIN	  SIGNALLING	  IN	  THE	  RECRUITMENT	  OF	  




Oesophageal,	   like	   gastric,	   cancer	   presents	   at	   an	   advanced	   stage	   and	   has	   a	   poor	  
prognosis	  (276).	  	  	  Also	  like	  gastric	  cancer,	  oesophageal	  tumours	  rich	  in	  stroma	  have	  a	  
poor	  prognosis	  (277)	  and	  myofibroblasts	  form	  an	  important	  part	  of	  the	  oesophageal	  
cancer	   stroma	   (278).	   	   Oesophageal	  myofibroblasts	   are	   known	   to	   stimulate	   cancer	  
cell	   migration	   and	   invasion	   (J.	   D.	   Kumar,	   personal	   communication)	   and	   this	   work	  
investigates	  their	  role	  in	  subcutaneous	  xenografts.	  
	  
The	   recruitment	   of	   cells	   to	   tumours	   from	   the	   bone	   marrow	   has	   already	   been	  
demonstrated	   and	   it	   has	   been	   postulated	   that	   bone	   marrow-­‐derived	   cells	   may	  
become	   myofibroblasts	   or	   CAFs	   (41).	   	   The	   interaction	   between	   myofibroblasts	  
already	  in	  the	  tumour	  and	  bone	  marrow	  cells	  has	  not	  previously	  been	  studied.	  	  	  
	  
Work	   from	   this	   group	   has	   demonstrated	   that	   oesophageal	  myofibroblasts	   release	  
chemerin,	  which	   acts	   as	   a	   chemoattractant	   to	  MSCs,	  which	   express	   the	   ChemR23	  
receptor	   (J.	   D.	   Kumar,	   personal	   communication).	   	   Using	   labelled	   MSCs,	   this	   work	  
aims	   to	   extend	   the	   previous	   observation	   to	   an	   in	   vivo	   model	   of	   myofibroblast-­‐
stimulated	   oesophageal	   xenograft	   growth	   and	   to	   determine	   whether	   chemerin-­‐
chemR23	  signalling	  plays	  a	  role	  in	  the	  recruitment	  of	  MSCs	  to	  oesophageal	  tumours.	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CCX832	   is	   a	   chemR23	   antagonist	   developed	   by	   ChemoCentryx	   trialled	   in	   the	  
treatment	  of	  psoriasis	  but	  now	  withdrawn	  from	  progression	  (279).	  
	  
6.1.1	  Aims	  
1. To	   expand	   the	   in	   vivo	   model	   of	   stroma-­‐stimulated	   xenograft	   growth	   from	  
gastric	  cancer	  cells	  to	  oesophageal	  cells.	  
2. To	  model	  MSC	   homing	   to	   xenografts	   composed	   of	  MKN45	   cells	   and	   OE21	  
cells.	  	  	  
3. To	   ascertain	   the	   effect	   of	   antagonism	   of	   the	   ChemR23	   receptor	   on	   MSC	  
homing.	  




6.2.1	  Cell	  culture	  
MKN45	   cells	  were	   cultured	   as	   detailed	   in	   2.2.1-­‐2.	   	   J.	   Dinesh	   Kumar	   cultured	  OE21	  
cells,	  oesophageal	  CAMs	  and	  human	  MSC	  lines.	  
	  
6.2.2	  Subcutaneous	  xenografts	  
Cells	  were	  prepared	  as	  described	   in	   2.2.3.	   	  Where	  myofibroblasts	   and	   cancer	   cells	  
were	  co-­‐injected,	  they	  were	  mixed	  and	  re-­‐suspended	  in	  PBS	  such	  that	  one	  injection	  
corresponded	   to	   100μl.	   	   For	   the	   MKN45	   cell	   xenograft	   pilot	   experiment,	   1	   x	   105	  
MKN45	   cells	   were	   injected	   with	   or	   without	   5	   x	   104	   oesophageal	   CAMs.	   	   For	   the	  
oesophageal	   xenografts,	   1	   x	   106	  OE21	   cells	  were	   injected	  with	   or	  without	   5	   x	   105	  
CAMs.	  	  	  
	  
6.2.3	  IV	  injection	  of	  MSCs	  
MSCs	   for	   IV	   injection	  were	  prepared	  by	   J.	  Dinesh	  Kumar.	   	  First,	   they	  were	   labelled	  
using	  the	  cell	  membrane	  labels	  CellVue®	  Claret	  and	  PKH67.	  	  Labelling	  was	  evaluated	  
by	   flow	   cytometry	   (CellVue®	   Claret)	   or	   fluorescence	  microscopy	   (PKH67).	   	   For	   the	  
MKN45	  cell	  pilot	  experiment,	  1	  x	  106	  labelled	  MSCs	  (CellVue®	  Claret	  or	  PKH67)	  were	  
injected	  (IV	  tail	  vein)	  under	  GA	  24	  h	  prior	  to	  sacrifice.	  	  For	  the	  OE21	  xenografts,	  7.5	  x	  
105	  CellVue®	  Claret	  and	  7.5	  x	  105	  PKH67	  labelled	  cells	  were	  combined,	  suspended	  in	  
100μl	  PBS	  and	  injected	  (IV	  tail	  vein)	  under	  GA	  24	  h	  prior	  to	  sacrifice	  (Figure	  6.1).	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6.2.4	  CCX832	  
Animals	   received	   2	   subcutaneous	   doses	   of	   125μl	   of	   2mg/ml	   CCX832	   a	   ChemR23	  
antagonist	   (equivalent	   to	   10mg/kg	   dose)	   or	   125μl	   vehicle	   (corn	   oil),	   24	   h	   prior	   to	  
MSC	  injection	  and	  at	  the	  time	  of	  MSC	  injection	  (Figure	  6.1).	  	  	  	  
	  
6.2.5	  FMT	  imaging	  
FMT	  imaging	  was	  performed	  under	  GA	  as	  described	  in	  2.2.5b.	  	  Imaging	  for	  CellVue®	  
Claret	  labelled	  MSCs	  was	  performed	  at	  baseline	  and	  6	  and	  24	  h	  post	  MSC	  injection	  in	  
the	  680nm	  channel	  and	  quantification	  was	  performed	  using	  TrueQuant	  software.	  	  	  
	  
6.2.6	  Microscopy	  for	  PKH67	  labelled	  cells	  
Tumours	  were	  processed	  as	  described	  in	  2.2.4.	  	  Six	  sections	  per	  tumour	  were	  stained	  
with	  DAPI	  and	  PKH67	  positive	  cells	  counted	  in	  6	  fields	  by	  an	  independent	  observer.	  
	  













Figure	  6.1.	  Experimental	  design	  to	  investigate	  the	  effect	  of	  ChemR23	  inhibition	  on	  
in	   vivo	  MSC	   homing.	   Subcutaneous	   xenografts	   composed	   for	   OE21	   cells	   with	   or	  
without	  CAMs	  were	  established	   in	  BALB/c	  nu/nu	  mice.	   	   Prior	   to	   the	  mean	   tumour	  
diameter	  exceeding	  1.2	  cm	  the	  mice	  were	  given	  a	  dose	  of	  CCX832	  or	  vehicle.	  	  After	  
24	   h	   this	   dose	   was	   repeated,	   and	   MSCs	   were	   injected	   IV.	   	   FMT	   imaging	   was	  
performed	   6	   and	   24	   h	   post	   MSC	   injection.	   	   Frozen	   sections	   were	   examined	   for	  
evidence	  of	  labelled	  cells.	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6.3	  Results	  
	  
6.3.1	  The	  addition	  of	  CAMs	  to	  OE21	  xenografts	  stimulates	  tumour	  formation	  	  
In	   order	   to	   create	   an	   in	   vivo	   model	   of	   MSC	   tumour	   homing,	   OE21	   subcutaneous	  
xenografts	   were	   established.	   	   Co-­‐injection	   with	   oesophageal	   CAMs	   improved	   the	  
tumour	  yield	  from	  25%	  of	  animals	  (3/12)	  to	  58%	  (7/12).	  	  Where	  tumours	  appeared,	  
the	   rate	   of	   tumour	   growth	   was	   similar	   regardless	   of	   whether	   CAMs	   had	   been	  
injected	  (Figure	  6.2G).	  	  The	  histology	  of	  these	  tumours	  also	  appeared	  similar	  (Figure	  
6.2A-­‐F).	  	  OE21	  xenografts	  exhibited	  fewer	  areas	  of	  necrosis	  and	  no	  ulceration	  at	  the	  
skin	   surface	   compared	   with	  MKN45	   cell	   xenografts.	   	   The	  morphology	   of	   the	   cells	  
reflected	  the	  squamous	  origin	  of	  the	  OE21	  cells,	  with	  abundant	  mitotic	  cells.	  	  
	  
6.3.2	  MSCs	  labelled	  with	  CellVue®	  Claret	  membrane	  dye	  fluoresce	  at	  680nm	  
To	   validate	   the	   detection	   system	   for	   CellVue®-­‐labelled	   cells,	   initially	   droplets	  
containing	   varying	   concentrations	   of	   labelled	   MSCs	   were	   visualised	   using	   FMT	   at	  
680nm.	   	  The	   intensity	  of	   fluorescence	  was	  proportional	   to	   the	  cell	  number	   (Figure	  
6.3).	  	  Droplets	  containing	  PBS	  only	  did	  not	  exhibit	  fluorescence.	  	  


































Figure	  6.2.	  Histology	  and	  growth	  of	  OE21	  xenografts.	  	  A-­‐C,	  Representative	  images	  of	  
H&E	  stained	  sections	  of	  tumours	  composed	  of	  OE21	  alone.	  D-­‐F,	  H&E	  stained	  sections	  
of	   tumours	   containing	   OE21	   +	   CAM	   cells.	   G,	   OE21	   xenografts	   exhibit	   increased	  
tumour	  yield	  when	  CAMs	  are	  co-­‐injected	  compared	  to	  OE21	  alone.	  Fractions	  denote	  
the	   proportion	   of	   injections	  which	   yielded	   a	   tumour.	   	   	  Mean	   results	   from	   3	  OE21	  
animals	  and	  7	  OE21	  +	  CAM	  animals	  are	  shown.	  
	  









Figure	   6.3.	   MSCs	   labelled	   with	   CellVue®	   Claret	   can	   be	   visualised	   using	   FMT.	  
Representative	  images	  of	  droplets	  of	  MSCs	  suspended	  in	  PBS	  visualised	  using	  FMT	  at	  
680nm	  show	  increased	  fluorescence	  in	  droplets	  containing	  higher	  concentrations	  of	  
labelled	  MSCs.	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6.3.3	  Increased	  fluorescence	  in	  the	  tumour	  following	  MSC	  injection	  
A	  pilot	  experiment	  to	  examine	  the	  feasibility	  of	  imaging	  MSCs	  recruited	  to	  tumours	  
was	   conducted.	   	   This	   examined	   the	   fluorescence	   in	   xenografts	   0,	   6	   and	   24	   h	  
following	  IV	  MSC	  injection	  in	  xenografts	  composed	  of	  MKN45	  cells	  and	  oesophageal	  
CAMs.	   	   The	   fluorescence	   in	   the	   region	   of	   the	   tumour	   increased	   during	   the	   24	   h	  
period	  (Figure	  6.4A).	  	  	  
	  
Imaging	   of	   these	   mice	   also	   revealed	   increased	   fluorescence	   in	   the	   region	   of	   the	  
spleen	   following	   MSC	   injection	   (Figure	   6.4B).	   	   Although	   these	   mice	   are	  
immunosuppressed	   it	   is	   likely	   that	   the	   human	   MSCs	   are	   recognised	   as	   foreign	  
material	  by	  the	  mouse	  immune	  system	  and	  most	  are	  processed	  and	  broken	  down	  in	  
the	  spleen.	   	  The	  position	  of	   the	  mouse	  spleen	  beneath	  the	   left	   flank	  of	   the	  mouse	  
had	   the	   potential	   to	   confound	   future	   fluorescence	   readings	   taken	   from	   tumours	  
located	  immediately	  superficial	  to	  the	  spleen,	  so	  all	  further	  experiments	  injected	  the	  
subcutaneous	  xenografts	  on	  the	  right	  side	  in	  an	  attempt	  to	  remove	  this	  problem.	  
	  
Accumulation	   of	   fluorescently-­‐labelled	   cell	   debris	   in	   the	   spleen	   was	   confirmed	   in	  
mice	   injected	  with	  PKH67-­‐labelled	  MSCs,	  where	  microscopic	  examination	  of	   frozen	  
tumour	   sections	   revealed	   intense	   green	   staining	   in	   the	   spleen	   compare	   to	   mice	  
injected	  with	  CellVue®	  Claret	  labelled	  MSCs	  only	  (Figure	  6.5).	  	  	  






Figure	   6.4.	   Increased	   fluorescence	   in	   the	   tumour	   following	   injection	   of	   labelled	  
MSCs.	   A,	   Representative	   FMT	   images	   illustrating	   signal	   at	   680nm	   from	   a	   mouse	  
bearing	  a	  tumour	  composed	  of	  MKN45	  cells	  +	  oesophageal	  CAMs	  showing	  increased	  
fluorescence	   in	  the	  tumour	  6	  and	  24	  h	  post	   IV	   injection	  of	  CellVue®	  Claret	   labelled	  
MSCs.	  B,	  FMT	  image	  of	   fluorescence	  outside	  the	  tumour	  boundary	  (purple	  outline)	  
located	  in	  the	  region	  of	  the	  mouse	  spleen	  (arrow)	  6	  h	  post	  MSC	  injection.	  





Figure	   6.5	   Accumulation	   of	   PKH67-­‐labelled	   cell	   debris	   in	   mouse	   spleen.	  
Representative	   fluorescence	   microscopy	   images	   demonstrating	   fluorescent	   cell	  
debris	   (FITC	   filter)	   in	   the	   spleens	   of	   animals	   24	   h	   post	   injection	   of	   PKH67-­‐labelled	  
MSCs	  (top	  row).	  In	  mice	  injected	  with	  CellVue®	  Claret	  labelled	  MSCs	  (bottom	  row)	  no	  
green	  fluorescence	  accumulates	  in	  the	  spleen.	  From	  left	  to	  right:	  nuclear	  localisation	  
using	  DAPI,	  PKH67	  visualisation	  under	  FITC	  filter,	  merged	  images.	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6.3.4	  Xenografts	  containing	  myofibroblasts	  demonstrate	  increased	  fluorescence	  
following	  injection	  of	  labelled	  MSCs	  
In	  all	  cases	  the	  imaging	  performed	  immediately	  prior	  to	  MSC	  injection	  did	  not	  reveal	  
any	  fluorescence	  in	  the	  region	  of	  the	  tumour.	  	  When	  the	  tumour	  was	  composed	  of	  
OE21	   cells	   and	   CAMs,	   increased	   fluorescence	   24	   h	   post	  MSC	   injection	  was	   noted,	  
although	  this	  did	  not	  reach	  statistical	  significance	  (Figure	  6.6A).	   	  Treatment	  of	  mice	  
bearing	  OE21	  and	  CAM	  tumours	  with	  CCX832	  appeared	  to	  decrease	  the	  fluorescence	  
from	  tumours	  but	  this	  did	  not	  reach	  statistical	  significance	  (Figure	  6.6B).	  	  
	  
The	   same	   tumours	  were	   examined	  microscopically	   for	   evidence	   of	   PKH67-­‐labelled	  
MSCs	  and	  areas	  of	  fluorescent	  cells	  were	  identified	  (Figure	  6.7A).	  	  Quantification	  of	  
the	  number	  of	  green	  cells	  per	  section	  showed	  decreased	  green	  cells	  in	  mice	  injected	  
with	  CCX832	   compared	   to	   those	   injected	  with	   vehicle,	   demonstrating	   inhibition	  of	  
MSC	  homing	  by	  antagonism	  of	  ChemR23	  (Figure	  6.7B).	  











































Figure	  6.6.	  Effect	  of	  the	  addition	  of	  CAMs	  on	  MSC	  recruitment	  and	  its	  inhibition	  by	  
CCX832.	   A,	   FMT	   signal	   at	   680nm	  24	   h	   post	   injection	   of	   7.5	   x	   105	   CellVue®	   Claret-­‐
labelled	  MSCs	   is	  not	   significantly	  different	   in	  OE21	  +	  CAM	  xenografts	   compared	   to	  
OE21	  alone.	  B,	  FMT	  signal	  at	  680nm	  24	  h	  post	  injection	  of	  7.5	  x	  105	  CellVue®	  Claret-­‐
labelled	   MSCs	   in	   OE21	   +	   CAM	   xenografts	   is	   not	   significantly	   different	   when	   the	  
animals	  received	  2	  doses	  of	  CCX832	  prior	  to	  MSC	  injection	  compared	  to	  injections	  of	  
vehicle.	  Results	  from	  3-­‐5	  animals	  per	  group	  are	  shown.	  






























Figure	   6.7.	   CCX832	   administration	   suppresses	   MSC	   homing	   to	   OE21	   +	   CAM	  
tumours.	  A,	  Representative	  fluorescence	  microscopy	  images	  demonstrating	  areas	  of	  
fluorescent	   cells	   (FITC	   filter)	   in	   the	   OE21	   +	   CAM	   tumours	   (arrow).	   Top	   row:	   low	  
power	  view,	  bottom	   row:	  high	  power	  view.	   B,	  Tumours	  without	  CAMs	  have	   lower	  
overall	  MSC	  homing	  than	  those	  containing	  CAMs.	  CCX832	  administration	  suppresses	  
MSC	  homing	  to	  OE21	  +	  CAM	  tumours.	  Quantification	  of	  mean	  number	  of	  MSCs	  per	  
section	  per	  tumour,	  results	  from	  3-­‐6	  animals	  per	  group	  are	  shown.	  




We	   have	   created	   subcutaneous	   xenografts	   using	   OE21	   cells	   and	   shown	   that	   the	  
addition	  of	  CAMs	  increases	  tumour	  yield.	  	  The	  use	  of	  2	  membrane	  dyes	  has	  allowed	  
the	   identification	   of	   fluorescent	   MSCs	   in	   the	   tumour	   and	   in	   the	   spleen	   through	  
increased	  FMT	  signal	  and	  in	  frozen	  sections.	  	  The	  addition	  of	  CAMs	  to	  OE21	  tumours	  
increased	   fluorescence	   in	   the	   tumour	   following	  MSC	   injection.	   	   Treatment	   with	   a	  
ChemR23	   antagonist	   decreased	   both	   fluorescence	   detected	   by	   FMT	   and	   areas	   of	  
green	  fluorescence	  seen	  in	  frozen	  sections.	  	  
	  
FMT’s	  utilisation	  of	   the	   far-­‐red	  part	  of	   the	  electromagnetic	   spectrum	  enables	  non-­‐
invasive	  fluorescent	   imaging	  with	  minimal	   loss	  of	  signal	  from	  tissue	  absorption	  and	  
light	   scattering	   (280).	   	   FMT	   has	   been	   used	   to	   track	   fluorescently	   labelled	   cells	   in	  
order	   to	   calculate	   tumour	   volume.	   	   Breast	   cancer	   cells	   stably	   transfected	  with	   the	  
fluorescent	  protein	  dsRed	  have	  been	  used	   to	  monitor	   the	   response	  of	   the	  ensuing	  
subcutaneous	   xenografts	   to	   chemotherapy	   by	   using	   measurements	   of	   tumour	  
volume	  generated	  by	  FMT	  (281).	  	  FMT	  has	  also	  been	  used	  to	  study	  the	  migration	  of	  
macrophages	   labelled	   with	   a	   fluorescent	   dye	   to	   a	   subcutaneous	   inflammatory	  
stimulus	   (282).	   	  More	  recently,	   the	  recruitment	  of	  circulating	   fibrocytes	  to	  arthritic	  
joints	  was	  investigated	  using	  a	  CellVue®	  Claret	  membrane	  label	  and	  visualisation	  by	  
FMT	   (283).	   Alternative	   imaging	  methods	   have	   been	   used	   in	   tracking	   labelled	   cells	  
following	   injection.	   	   Thus	   the	   recruitment	  of	   fibroblasts	   labelled	  with	   the	   lipophilic	  
near	   infra-­‐red	   fluorochrome	   CellTrackerTM	   CM-­‐Dil	   injected	   intraperitoneally	   was	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followed	   in	   subcutaneous	   ovarian	   cancer	   xenografts	   using	   MRI	   (284).	   	   Iron	   oxide	  
labelled	  MSCs	  were	   shown	   to	   home	   to	   pulmonary	  metastases	   from	   breast	   cancer	  
xenografts	  using	  MRI	  (285).	   	  FMT	  is	  a	  safe,	  quick	  and	  non-­‐invasive	  imaging	  method	  
which	   is	   capable	   of	   detecting	   a	   variety	   of	   fluorescent	  molecular	   probes	   as	  well	   as	  
fluorescent	  cells,	  making	  it	  more	  versatile	  than	  other	  imaging	  modalities.	  	  In	  future,	  
FMT	  could	  provide	  a	  good	  method	  for	  examining	  cell	  migration	  or	  metastasis	  in	  vivo.	  	  
	  
Our	   finding	  that	  OE21	  cells	  established	  subcutaneous	  xenografts	   in	  nude	  mice	   is	   in	  
keeping	  with	  other	  xenograft	  studies	  using	  these	  cells	  (286,287).	  	  Like	  AGS	  cells,	  few	  
examples	  of	  xenografts	  using	  these	  cells	  exist	   in	  the	  literature,	  which	  might	  explain	  
the	   lower	   tumour	   yield	   and	   longer	   growth	   time	   than	   in	  MKN45	   cells,	  making	   this	  
model	   less	   efficient.	   	   The	   histology	   of	   these	   tumours	   reflected	   the	   origin	   of	   these	  
cells,	  showing	  a	  squamous	  cell	  carcinoma.	   	  The	   low	  tumour	  yield	  even	  when	  CAMs	  
were	   co-­‐injected	   suggests	   that	   future	   experiments	   should	   increase	   the	   number	   of	  
mice	   injected	   at	   the	   start	   of	   the	   experiment.	   	   Nevertheless,	   it	   is	   clear	   that	   the	  
addition	  of	  CAMs	  increased	  tumour	  yield	  substantially.	  
	  
We	  have	  shown	  that	  systemically	  administered	  MSCs	  are	  capable	  of	  homing	  to	  OE21	  
xenografts,	   both	   through	   increased	   far	   red	   fluorescence	  measured	  by	   FMT	  and	  by	  
examination	  of	  frozen	  tumour	  tissue	  sections	  for	  labelled	  MSCs.	  	  It	  has	  already	  been	  
shown	   that	   MSCs,	   either	   from	   the	   bone	   marrow	   or	   injected	   into	   the	   circulation,	  
home	   to	   tumours.	   	   GFP-­‐labelled	   MSCs	   injected	   IV	   can	   later	   be	   identified	   in	   the	  
subcutaneous	   breast	   cancer	   xenografts	   of	   those	   mice	   ( 288 ).	   	   Subcutaneously	  
implanted	   human	   bone	   marrow-­‐derived	   MSCs	   home	   to	   distant	   subcutaneous	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xenografts,	   demonstrating	   that	   human	   MSCs	   can	   free	   themselves	   from	   local	  
attachments,	  enter	  the	  circulation	  and	  establish	  themselves	  elsewhere	  (289).	  	  
	  
A	  mechanism	   for	   the	  homing	  of	  MSCs	   remains	  uncertain.	   	  Unlike	  when	   leucocytes	  
are	   recruited	   to	   tissues	   and	   the	   well-­‐defined	   leucocyte	   adhesion	   cascade	   is	  
activated,	  there	   is	  no	  consensus	  for	  a	  molecular	  mechanism	  of	  MSC	  homing.	   It	  has	  
been	  speculated	  that	  specific	  recruitment	  to	  an	  organ	  is	  not	  occurring,	  but	  rather	  the	  
cells	   are	   becoming	   trapped	   in	   the	   vasculature,	   a	   process	   known	   as	   ‘passive	  
engraftment’	   (290).	   	   This	  may	   explain	  why	   some	   studies	   show	   that	  MSCs	   become	  
part	  of	  a	  tumour	  only	  when	  injected	  arterially	  into	  a	  vessel	  anatomically	  close	  to	  the	  
tumour,	  but	  not	  when	  injected	  at	  a	  distant	  site	  or	   IV	  (291).	   	  However,	  there	  is	  also	  
evidence	   that	   MSC	   recruitment	   occurs	   preferentially	   to	   sites	   of	   tumour	   or	  
inflammation,	  suggesting	  specific	  molecular	  mechanisms	  are	  responsible.	  	  Moreover,	  
MSC	  recruitment	  to	  ischaemic	  myocardium	  is	  dependent	  on	  integrin	  β1	  (292).	  	  While	  
in	  gastric	  cancer,	  bone	  marrow-­‐derived	  MSCs	  contribute	  to	  the	  CAM	  population	  and	  
recruitment	   of	  MSCs	   to	   the	   tumour	   is	   dependent	   on	   CXCR4/SDF-­‐1	   signalling	   (41).	  	  
This	  pathway	  was	  previously	  identified	  as	  playing	  an	  important	  role	  in	  the	  promotion	  
of	  an	  ‘activated’	  myofibroblast	  state	  via	  autocrine	  signalling	  (33).	  	  	  
	  
Our	  findings	  that	  successful	  in	  vivo	  MSC	  homing	  may	  require	  the	  ChemR23	  receptor	  
identify	   a	   novel	   signalling	   pathway	  which	   has	   not	   previously	   been	   associated	  with	  
MSC	   recruitment.	   	   Proteomic	   data	   from	   our	   group	   identified	   chemerin	   as	   being	  
expressed	   by	   oesophageal	   myofibroblasts	   (293).	   	   Further	   in	   vitro	   validation	   has	  
confirmed	   this,	   and	   shown	   that	   MSCs	   express	   ChemR23.	   	   In	   Boyden	   chamber	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migration	  assays,	  both	  chemerin	  and	  myofibroblast	  CM	  enhance	  MSC	  migration	  and	  
both	  are	  suppressed	  by	  the	  addition	  of	  a	  chemerin	  neutralizing	  antibody	  or	  CCX832	  
(J.	   Dinesh	   Kumar,	   unpublished	   data).	   	   Taken	   together,	   these	   findings	   indicate	   that	  
chemerin	  released	  by	  oesophageal	  CAMs	  acts	  as	  a	  chemoattractant	  to	  MSCs	  via	  the	  
ChemR23	  receptor.	  	  
	  
In	  summary	  we	  have	  demonstrated	  homing	  of	  MSCs	  to	  oesophageal	  xenografts	  and	  
examined	  the	  effect	  of	  a	  ChemR23	  antagonist	  on	  this	  phenomenon.	  	  This	  novel	  use	  
of	  FMT	  will	  permit	  future	  studies	  involving	  cell	  tracking.	  	  Further	  investigation	  of	  the	  
mechanism	  of	  MSC	  homing	  will	  reveal	  precisely	  how	  chemerin-­‐ChemR23	  interaction	  
leads	  to	  the	  recruitment	  of	  MSCs	  to	  tumours.	  	  




1. The	  addition	  of	  CAMs	   to	  OE21	   cells	   increases	   the	   likelihood	  of	  producing	  a	  
subcutaneous	  xenograft.	  
2. MSCs	  injected	  IV	  home	  to	  subcutaneous	  tumours	  (Figure	  6.8).	  
3. Antagonism	   at	   the	   ChemR23	   receptor	   inhibits	   MSC	   homing	   to	   OE21	  
xenografts	  containing	  CAMs.	  	  	  










Figure	  6.8.	  MSC	  homing	  requires	  chemerin	  signalling.	  	  Antagonism	  at	  the	  ChemR23	  
receptor	   suppresses	  MSC	   recruitment	   from	   the	   bone	  marrow,	   demonstrating	   that	  
chemerin-­‐ChemR23	  signalling	  is	  necessary	  for	  MSC	  homing.	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CHAPTER	  7:	  GENERAL	  DISCUSSION	  
	  
7.1	  Main	  findings	  
	  
This	   study	   has	   extended	   present	   understanding	   of	   the	   role	   of	   stroma-­‐derived	  
protease	   systems	   in	   tumour	   growth.	   	   PAI-­‐1	   overexpression	   in	   gastric	   cancer	   cells	  
results	  in	  decreased	  in	  vitro	  cell	  adhesion	  and	  exerts	  a	  suppressive	  effect	  on	  tumour	  
growth	   in	   vivo.	   	   Stromal	   myofibroblasts	   stimulate	   gastric	   tumour	   growth	   in	   a	  
xenograft	  model	   and	   exert	   a	   systemic	   effect	   capable	   of	   affecting	   the	   growth	   of	   a	  
distant	  tumour.	  	  Tumours	  seeded	  with	  myofibroblasts	  have	  increased	  MMP	  activity	  
and	  MMP	  inhibition	  results	   in	  decreased	  tumour	   invasion	  in	  an	  organotypic	  model.	  	  
Myofibroblasts	   play	   a	   role	   in	   the	   recruitment	   of	   MSCs	   from	   the	   bone	   marrow,	   a	  
process	   which	   relies	   on	   chemerin	   signalling.	   	   FMT	   is	   a	   promising	   in	   vivo	   imaging	  
technique,	  which	  is	  versatile,	  non-­‐invasive	  and	  has	  the	  potential	  for	  imaging	  a	  wide	  




The	   present	   study	   relies	   on	   the	   use	   of	   cell	   lines,	   which	   are	   derived	   from	   a	   single	  
population	   of	   cells	   and	   may	   not,	   therefore,	   reflect	   the	   heterogeneity	   of	   human	  
gastric	  cancer.	   	  Having	  been	  maintained	   in	  culture	   for	  many	  years,	   these	  cells	  may	  
acquire	   or	   lose	   characteristics	   through	   phenotypic	   drift	   (294).	   	   The	   use	   of	   early	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passage	   primary	   cells,	   such	   as	   the	   gastric	   CAMs	   utilised	   in	   the	   present	   study,	  
attempts	  to	  ensure	  that	  the	  characteristics	  of	  the	  cells	  still	  closely	  resemble	  those	  of	  
the	  tissue	  of	  origin.	  	  
	  
An	   insight	   into	   the	   role	   of	   stroma-­‐derived	  PAI-­‐1	   in	   gastric	   cancer	  was	   provided	  by	  
studying	  the	  effect	  of	  PAI-­‐1	  overexpression	  in	  cancer	  cells.	  	  This	  approach	  could	  have	  
been	  complemented	  by	  the	  use	  of	  a	  knockdown	  system	  to	  decrease	  PAI-­‐1	  secreted	  
by	   cancer	   cells	   and	   by	  myofibroblasts	   (295).	   	   For	   instance,	   siRNAs	   targeting	   PAI-­‐1	  
mRNA	  could	  have	  been	  utilised	  to	  decrease	  PAI-­‐1	  expression.	  	  The	  growth	  of	  gastric	  
cancer	  xenografts	  could	  have	  been	  studied	  in	  immunocompromised	  mice	  lacking	  the	  
PAI-­‐1	  gene.	  	  The	  use	  of	  new	  PAI-­‐1	  inhibitors	  could	  also	  have	  provided	  insight	  into	  the	  
effect	  of	  reducing	  extracellular	  PAI-­‐1	  (296).	  
	  
The	  use	  of	  subcutaneous	  xenografts	   in	   immunosuppressed	  mice	  has	  the	  advantage	  
of	   being	   simple	   and	   minimally	   invasive,	   and	   using	   cells	   of	   human	   origin.	   	   In	   the	  
present	   study,	   this	   model	   permitted	   the	   manipulation	   of	   the	   myofibroblast	  
component	  of	  the	  stroma,	  which	  was	  crucial	  to	  the	  investigation.	  	  However,	  the	  lack	  
of	  a	  normal	  immune	  response	  to	  the	  tumour	  may	  compromise	  the	  accuracy	  of	  such	  
models.	  	  In	  addition,	  subcutaneous	  xenografts	  have	  not	  proved	  to	  be	  reliable	  models	  
of	   a	   tumour’s	   response	   to	   treatment	   (297).	   	   Genetically	   modified	   mice	   prone	   to	  
developing	   a	   tumour	   of	   interest	   can	   be	   useful	   in	   replicating	   the	   progression	   of	  
human	   disease	   and	   have	   the	   advantage	   of	   a	   functioning	   immune	   component,	   but	  
manipulation	  of	  the	  stromal	  component	  in	  these	  models	  is	  more	  difficult	  (298).	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Organotypic	  cultures	  attempt	  to	  recreate	  the	  architectural	  arrangement	  of	  cells	  in	  a	  
tumour	  and	  the	  resulting	   invasion	  pattern	  resembles	   those	  seen	   in	  human	  cancers	  
(299).	   	   This	   approach	   enabled	   the	   use	   of	   specific	   MMP	   inhibitors	   and	   specifically	  
examined	  the	  contribution	  of	  myofibroblasts.	  	  The	  in	  vivo	  xenograft	  system,	  although	  
a	   good	  model	   incorporating	  most	   of	   the	   stromal	   features	   of	   a	   tumour,	   could	   not	  
examine	  the	  specific	  contribution	  of	  CAMs	  to	  MMP	  activity.	  
	  
The	   use	   of	   FMT,	   a	   novel	   imaging	   modality	   capable	   of	   visualising	   a	   variety	   of	  
processes	   and	   molecules,	   enabled	   the	   tracking	   of	   cancer	   cells	   and	  MSCs	   and	   the	  
assessment	  of	   protease	   activity	   in	   vivo.	   	   Alternative	   approaches	   to	   in	   vivo	   imaging	  
include	  MRI,	  which	  has	  the	  advantage	  of	  giving	  simultaneous	  anatomical	  information	  
(300).	   	   The	   identification	  of	  myofibroblasts	   in	   subcutaneous	   xenografts	   could	  have	  
been	   improved	  using	   fluorescent	   tagging	  of	  primary	  myofibroblasts	   in	  combination	  
with	  FMT.	  
	  
7.3	  Stromal	  PAI-­‐1	  in	  gastric	  cancer	  
	  
This	  work	  has	  shown	  that	  in	  gastric	  cancer	  the	  myofibroblast	  is	  a	  rich	  source	  of	  PAI-­‐1.	  	  
This	   is	   in	   agreement	  with	   data	   from	  other	   cancers,	  where	   stromal	   contribution	   of	  
PAI-­‐1	   has	   been	   characterised	   (211).	   	   In	   a	   recent	   study	   in	   colorectal	   cancer,	  MSCs	  
were	   shown	   to	   produce	   PAI-­‐1,	   with	   effects	   on	   cancer	   cell	   migration	   (301).	   	   In	  
xenograft	  studies,	  PAI-­‐1	  secretion	  by	  host	  cells	  stimulates	  tumour	  growth	  and	  PAI-­‐1	  
overexpression	  by	   cancer	   cells	   cannot	  overcome	   the	   absence	  of	   PAI-­‐1	   in	   the	  host,	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emphasising	  the	  importance	  of	  the	  cellular	  origin	  of	  PAI-­‐1	  (302).	  	  It	  is	  clear	  that	  PAI-­‐1	  
secretion	  by	   stromal	   cells	   forms	  an	   important	   component	  of	   the	   stromal-­‐epithelial	  
interactions	  in	  cancer.	  
	  
The	  PAI-­‐1	   ‘paradox’	   in	  cancer	  refers	  to	  the	  ability	  of	  PAI-­‐1	  to	  stimulate	  tumour	  cell	  
migration	   and	   invasion	   when	   its	   physiological	   function	   would	   suggest	   that	   by	  
suppressing	  proteolysis	  it	  might	  suppress	  these	  processes	  and	  act	  to	  inhibit	  tumour	  
growth.	   	   The	   present	   work	   has	   shown	   that	   in	   gastric	   cancer,	   PAI-­‐1	   can	   also	   have	  
conflicting	  effects,	  as	  demonstrated	  by	  the	  finding	  that	  PAI-­‐1	  decreases	  cell	  adhesion	  
in	   vitro	   but	   decreases	   in	   vivo	   xenograft	   growth.	   	   The	   ‘paradox’	   of	   PAI-­‐1	   has	   been	  
extended	   to	   other	   systems,	   as	   it	   seems	   that	   its	   role	   in	   the	   fibronolytic	   system	  
extends	  wider	  than	  its	  ability	  to	  inhibit	  plasmin	  (303).	  	  
	  
In	   gastric	   cancer,	   high	   PAI-­‐1	   expression	   is	   a	   marker	   of	   advanced	   stage	   and	  
consequently	  of	  poor	  prognosis.	   	   In	  breast	  cancer,	  PAI-­‐1	  expression	  also	  denotes	  a	  
poor	  prognosis	  and	  this	  has	   recently	  been	  used	  to	   identify	  patients	  most	  at	   risk	  of	  
recurrence	  after	  surgery	  (304).	  	  Patients	  with	  tumours	  expressing	  PAI-­‐1	  are	  selected	  
for	   chemotherapy	   and	   those	   negative	   for	   PAI-­‐1	   can	   avoid	   chemotherapy	   (and	   its	  
toxic	  side	  effects)	  on	  the	  basis	  that	  they	  are	  at	  low	  risk	  of	  recurrence	  (305).	  	  Perhaps	  
in	   future	   PAI-­‐1	   expression	   in	   gastric	   cancer	   might	   also	   provide	   a	   method	   for	   risk	  
stratification	  in	  patients	  post	  gastrectomy.	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7.4	  The	  contribution	  of	  myofibroblasts	  to	  tumour	  growth	  
	  
The	   present	   study	   has	   shown	   that	   primary	   gastric	   myofibroblasts	   stimulate	   the	  
growth	  of	  gastric	  cancer	  subcutaneous	  xenografts.	   	  CAMs	  are	  known	  to	  differ	  from	  
NTMs	   in	   the	  proteins	   they	   release	   and	   in	   their	   proliferation	  and	  migration	   in	   vitro	  
(43).	   	   In	   vivo,	   however,	   this	   work	   has	   demonstrated	   that	   both	   CAMs	   and	   NTMs	  
stimulate	  xenograft	  growth.	  	  This	  contrasts	  with	  data	  from	  other	  cancers	  where	  only	  
CAMs	  stimulate	  xenograft	  growth	  (47).	  Future	  cancer	  therapies	  could	  be	  directed	  at	  
myofibroblast-­‐derived	   stimulators	   of	   tumour	   growth.	   	   Few	  molecular	  mechanisms	  
promoting	   the	   recruitment	   of	   or	   activation	  of	  myofibroblasts	   have	  been	   identified	  
although	   TGFβ	   is	   widely	   used	   to	   stimulate	   differentiation	   of	   fibroblasts	   into	  
“activated	  fibroblasts”	  ie	  myofibroblasts	  (33).	  	  	  
	  
Work	   from	   this	   group	  has	   identified	  TGFβIgh3	  as	  a	  potential	  modulator	  of	   tumour	  
growth.	   	   This	   protein	   is	   released	   by	  myofibroblasts	   and	   inhibits	   gastric	   cancer	   cell	  
migration.	   	   Secretion	   of	   TGFβIgh3	   is	   decreased	   in	   myofibroblasts	   from	   advanced	  
cancer.	  	  Parenteral	  administration	  of	  TGFβIgh3	  resulted	  in	  decreased	  tumour	  growth	  
(43).	   	   The	   CXCR4-­‐SDF-­‐1	   signalling	   pathway	   plays	   a	   role	   in	   the	   activation	   of	  
myofibroblasts	   in	  breast	   cancer,	   and	  blockade	  of	   this	  pathway	  using	  a	  neutralising	  
antibody	   suppressed	   tumour	   growth	   (48).	   	   These	   have	   not	   yet	   resulted	   in	   the	  
development	   of	   any	  molecule	   suitable	   for	   use	   in	   the	   clinic.	   	   Inhibition	   of	   platelet-­‐
derived	   growth	   factor	   is	   also	   thought	   to	   inhibit	   tumour	   growth	   by	   affecting	   both	  
cancer	   cells	   and	   stromal	   cells,	   but	   in	   spite	   of	   promising	   results	   in	   mouse	   models	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(306),	  use	  of	  these	  compounds	  in	  the	  clinic	  has,	  again,	  not	  yet	  produced	  any	  survival	  
benefit	  (307).	  
	  	  
The	  addition	  of	  myofibroblasts	  to	  a	  xenograft	  resulted	  in	  the	  inhibition	  of	  the	  growth	  
of	  a	  distant	  xenograft.	  	  Although	  it	  has	  long	  been	  known	  that	  tumours	  exert	  systemic	  
effects,	   resulting	   in	   paraneoplastic	   syndromes	   (308),	   the	  mechanism	   for	   these	   has	  
not	  been	  characterised.	   	  Using	  breast	  cancer	  cells,	  another	  group	  have	  shown	  that	  
the	  growth	  of	  one	  xenograft	  can	  be	  potentiated	  by	  a	  distant	  xenograft	  composed	  of	  
a	  more	  aggressive	  cell	   line.	   	   This	   is	  mediated	  by	   the	   release	  of	  osteopontin,	  which	  
stimulates	  the	  recruitment	  of	  bone	  marrow	  cells	  (255).	  	  The	  present	  data	  add	  to	  this,	  
as	   they	   demonstrate	   that	   a	   xenograft	   seeded	   with	   myofibroblasts	   is	   capable	   of	  
affecting	   the	   growth	   of	   a	   distant	   xenograft	  without	  myofibroblasts.	   	   This	   confirms	  
the	  existence	  of	   long-­‐range	  signalling	  and	   implicates	   stromal-­‐epithelial	   interactions	  
in	   this	  process	  but	   further	  work	   is	  needed	  to	  elucidate	  a	  molecular	  mechanism	  for	  
this	  not	  least	  because	  it	  might	  lead	  to	  a	  novel	  type	  of	  anti-­‐cancer	  therapy.	  
	  
7.5	  Stroma-­‐derived	  MMPs	  
	  
MMP	  activation	  in	  a	  variety	  of	  cancers	  became	  a	  subject	  of	  interest	  some	  years	  ago	  
and	  a	  number	  of	  MMP	  inhibitors	  were	  trialled.	  	  These	  did	  not,	  however,	  result	  in	  any	  
clinically	   useful	   treatments	   for	   cancer	   and	   the	   reasons	   for	   this	   are	   complex	   (309).	  	  
The	   trials	   only	   included	  patients	  with	   late	   stage	  disease	  and	   the	  measurements	  of	  
the	  effect	  of	  MMP	  inhibitors	  may	  have	  been	  too	  simple.	   	   In	  addition,	  the	  inhibitors	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used	  were	  not	  specific	  and	  there	  is	  growing	  evidence	  that	  different	  MMPs	  may	  have	  
different	   roles	   in	  different	   cancers	   (257).	   	   The	   contribution	  of	   the	   stroma	   to	  MMP	  
activity	  was	  not	  considered.	  
	  
The	  present	  work	  has	  shown	  that	  MMP	  activity	  is	  increased	  in	  xenografts	  containing	  
CAMs	  compared	  to	  those	  containing	  NTMs	  or	  no	  myofibroblasts.	  	  The	  identification	  
of	  MMP-­‐1,	  -­‐1	  and	  -­‐3	  as	  myofibroblast-­‐derived	  stimulators	  of	  gastric	  cancer	  growth	  is	  
encouraging	   for	   the	  development	  of	   specific	  MMP	   inhibitors	   (310).	   	   The	   increased	  
MMP	  activity	  demonstrated	   in	  CAM-­‐stimulated	   tumours	  may	  also	  be	  harnessed	   to	  
activate	  drug	  molecules	  at	  the	  site	  of	  the	  cancer	  (311).	  
	  
MMPs	   may	   also	   provide	   a	   source	   of	   biomarkers	   in	   gastric	   cancer.	   	   The	   elevated	  
activation	   of	   MMPs	   demonstrated	   in	   gastric	   cancer	   is	   reflected	   in	   serum	   MMP	  
concentrations	  and	  detection	  of	   these	  proteases	  could	  provide	  a	  useful	  marker	   for	  
the	  diagnosis	  or	  monitoring	  of	  treatment	  response	  (312).	  	  	  
	  
7.6	  Recruitment	  of	  MSCs	  to	  oesophageal	  xenografts	  
	  
Although	   the	   recruitment	   of	   MSCs	   to	   gastric	   tumours	   has	   previously	   been	  
characterised	   (313),	   the	   finding	   that	   in	  oesophageal	   cancer,	  MSCs	   are	   recruited	   to	  
the	  tumour	  is	  new.	  	  The	  data	  demonstrate	  that	  the	  presence	  of	  CAMs	  stimulates	  the	  
recruitment	  of	  MSCs.	  	  In	  gastric	  cancer,	  MSC	  recruitment	  occurs	  through	  SDF-­‐1	  and	  
hedgehog	   signalling	   (41,314).	   	   In	   oesophageal	   cancer,	   it	   seems	   that	   chemerin,	   a	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novel	   chemoattractant,	   is	   important	   in	   recruiting	  MSCs	   (J.	  Dinesh	  Kumar,	   personal	  
communication),	   as	   the	   administration	   of	   an	   antagonist	   to	   the	   chemerin	   receptor	  
prevents	  MSC	  homing	  to	  an	  oesophageal	  subcutaneous	  xenograft.	  	  	  	  
	  
A	  recent	  immunohistochemical	  study	  of	  samples	  of	  oesophageal	  mucosa	  taken	  from	  
Barretts	   oesophagus	   and	   oesophageal	   cancer	   has	   shown	   increased	   chemerin	  
expression	  in	  cancer	  (315).	  	  The	  pattern	  of	  staining	  was	  noted	  to	  include	  the	  stroma,	  
which	   is	   consistent	   with	   the	   finding	   that	   oesophageal	   CAMs	   express	   chemerin,	  
although	  epithelial	  expression	  of	  chemerin	  was	  also	  noted	   in	  this	  study.	   	  This	  work	  
also	   postulated	   that	   chemerin	   expression	   stimulated	   the	   recruitment	   of	   dendritic	  
cells;	  again	  this	  parallels	   the	  finding	  that	  chemerin	  release	  by	  CAMs	  results	   in	  MSC	  
recruitment.	  	  	  
	  
Further	   characterisation	   of	   this	   system	   may	   provide	   a	   novel	   approach	   to	   the	  
development	  of	  cancer	  therapies	  directed	  at	  the	  stroma	  –	  rather	  than	  targeting	  the	  
cells	  already	  within	  the	  tumour	  perhaps	  they	  could	  aim	  to	  prevent	  the	  recruitment	  
of	  bone	  marrow-­‐derived	  cells.	  	  CCX832	  has	  been	  in	  a	  phase	  1	  trial	  for	  the	  treatment	  
of	  psoriasis	  but	  its	  efficacy	  in	  human	  cancer	  has	  never	  been	  assessed.	  
	  
This	   work	   emphasises	   the	   importance	   of	   assessing	   the	   contribution	   of	   specific	  
proteases	   and	   their	   inhibitors	   in	   gastric	   cancer.	   The	   stroma	   is	   an	   important	  
contributor	   to	   extracellular	   protease	   activity	   and	   myofibroblasts	   contribute	   both	  
proteases	   and	   their	   inhibitors	   to	   the	   tumour	   microenvironment,	   resulting	   in	   the	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modulation	  of	  tumour	  growth	  and	  cell	  adhesion.	  	  MSCs	  are	  recruited	  to	  oesophageal	  
tumours	  via	  a	  novel	  signalling	  pathway	  (Figure	  7.1).	  

















Figure	   7.1	   Short-­‐	   and	   long-­‐	   range	   signalling	   in	   upper	   gastrointestinal	   cancers.	  	  
Within	   a	   solid	   tumour,	   signals	   between	   cell	   types	   modulate	   tumour	   growth	   and	  
invasion.	   	   In	  gastric	  cancer,	  proteins	  from	  the	  uPA	  system	  and	  MMPs	  contribute	  to	  
these	   signals.	   	   The	   addition	   of	   CAMs	   to	   gastric	   cancer	   cells	   potentiates	   tumour	  
growth.	   	   Long-­‐range	   signals	   occurring	   as	   a	   result	   of	   stromal-­‐epithelial	   cell	  
interactions	   are	   capable	   of	   modulating	   the	   growth	   of	   a	   distant	   tumour.	   	   In	  
oesophageal	   cancer	   MSC	   recruitment	   is	   dependent	   on	   chemerin-­‐ChemR23	  
signalling,	  a	  novel	  pathway	  involved	  in	  long-­‐range	  signalling	  in	  cancer.	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